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ABSTRACT 

There are 4 isoforms of p38 MAP kinase: , , , and . p38 signaling has been 
implicated in fibrosis and apoptosis during cardiac hypertrophy. MK5, originally 
identified as a p38 Regulated/Activated Protein Kinase (PRAK), is known to be 
downstream of p38 mitogen activated protein kinase (MAPK). Although highly 
expressed in the heart, the physiological roles of MK5 remain unknown. To determine if 
MK5 plays a role in mediating detrimental effects downstream of p38, we studied the 
effect of transverse aortic constriction (TAC)-induced chronic pressure overload in mice 
heterozygous for a knockout of MK5 (MK5+/-). Moreover, as MK5 is also activated by 
the atypical MAPKs, ERK3 and ERK4, the effects of TAC were also studied in ERK3+/- 
mice. Wild-type (MK5+/+; ERK3+/+) littermates were used as controls.  
Two wks post-TAC, heart weight/body weight ratios were significantly and 
similarly increased in both MK5+/- and MK5+/+ hearts. Trans-thoracic echocardiography 
revealed that pressure overload impaired left ventricular diastolic function in MK5+/+, 
but not in MK5+/- hearts. In addition, less collagen deposition, assessed by Masson 
trichrome staining, was observed in MK5+/- hearts 2 and 3 wks post-TAC. Furthermore, 
TAC-induced increases in collagen alpha1 type1 mRNA levels were significantly lower 
in MK5+/- hearts at both 2 and 3 wks post-TAC. Immunoprecipitation of MK5 resulted 
in co-immunoprecipitation of ERK3 but not ERK4 or p38 in either acute or chronic 
sham-operated and TAC hearts. In contrast, exogenous GST-MK5 pulled down 
endogenous ERK4 and p38, but not ERK3, from mouse heart lysates. Neither 
exogenous GST-ERK3 nor GST-p38 pulled down MK5. These results suggest that 
MK5 associates with, and is regulated by ERK3, but not ERK4 or p38 in heart. At 
physiological expressional levels, all MK5 was bound to ERK3 and hence not available 
to bind exogenous protein. Along similar lines, mice heterozygous for an ERK3 
knockout (ERK3+/-) also showed reduced or absent collagen deposition and lower 
collagen alpha1 type1 mRNA levels 3 wks post-TAC. This data suggests an important 
pro-fibrotic role of MK5-ERK3 signaling during chronic pressure overload. 
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We also demonstrated the existence of 5 splice variants of (MK5.1-5), including 
the originally published form (MK5.1). MK5.2 and MK5.5 had a 6 base pair deletion in 
exon 12: MK5.3 lacked exon 12: and MK5.4 and MK5.5 lacked exons 2-6. 
Subsequently, expression of the splice variants at the mRNA level was quantified by 
real time qPCR. Although ubiquitously expressed, the relative abundance of each 
variant was tissue-specific (heart, kidney, pancreas, skeletal muscle, lung, liver, and 
brain). Additionally, the relative abundance of MK5 splice variants changed in the heart 
during pressure overload and post-natal development. Furthermore, 
immunofluorescence revealed MK5.1-5.3 localized to the nucleus and MK5.4-5.5 to the 
cytoplasm in unstimulated HEK 293 cells. Upon stimulation with anisomycin, which 
activates p38 MAPK, MK5.1-5.3 translocated from the nucleus to the cytoplasm and 
small amounts of MK5.4-5.5 relocated to the nucleus. These splice variants may further 
diversify MK5-ERK3 signaling in the heart, but their exact role awaits further 
investigation.  
With the exception of p38, all p38 isoforms are expressed in the heart and  is 
considered to be the prominent isoform in this tissue. qPCR and western blot analysis 
revealed p38 and p38 to be the predominant isoforms and p38 and p38 are 
expressed at comparable levels in the adult heart. Confocal immunofluorescence studies 
revealed p38 and p38 in both the cytoplasm and nucleus. However, in response to 
TAC, p38 accumulated in the nucleus whereas the distribution of p38 remained 
unaffected. The high abundance of p38 and its nuclear accumulation during chronic 
pressure overload suggest that this isoform may play a role in gene expression during 
pathological cardiac remodeling.  
In conclusion, we have shown for the first time a pro-fibrotic role for MK5-ERK3 
signaling during chronic pressure overload. Moreover, comparable expression levels of 
p38 with p38, and differential localization of p38 during acute or chronic pressure 
overload, suggest these isoforms play different roles during cardiac remodeling.  
 
                                                                     
RÉSUMÉ 
 
Il y a 4 isoforme de p38 : , , , and . MK5, à l'origine identifié comme étant un 
régulateur de PRAK (Regulated/Activated Protein Kinase), est maintenant connu pour 
être activée par la protéine kinase p38 (qui est un mitogène activé par la protéine kinase, 
MAPK). Cette dernière est impliquée dans les mécanismes de fibrose et d'apoptose 
pendant l'hypertrophie cardiaque. De plus, MK5 est également activée par les MAPKs 
atypiques; ERK3 et ERK4. Bien qu’elles soient fortement exprimées dans le cœur, le 
rôle physiologique de MK5 et ERK3 demeure inconnu. Par conséquent, nous avons 
étudié l'effet de la constriction aortique transversale (TAC) – induisant un surcharge 
chronique de pression chez les souris hétèrozygotes knockout pour MK5 (MK5+/-) ou 
ERK3 (ERK3+/-) et pour leurs types sauvages (MK5+/+ et ERK3+/+). 
Deux sem post-TAC; le ratio de poids du cœur/poids corporel a été augmenté chez 
les 2 souris MK5+/- et MK5+/+. L'échocardiographie de la trans-thoracique démontre que 
la surcharge de pression a altéré la fonction diastolique du ventricule gauche chez 
MK5+/+, mais pas chez la souris MK5+/-. De plus, nous avons observé moins de dépôt 
de collagène, évalué par une coloration au trichrome de Masson, 2 et 3 sem post-TAC 
chez les souris MK5+/-. Parallèlement, le niveau de l’ARNm de collagène type1 alpha-1 
a été significativement diminué dans les cœurs des souris MK5+/-, 2 et 3 sem post-TAC. 
De même, ERK3, mais pas ERK5 ni p38, co-IP avec MK5 dans les 2 modèles des 
cœurs TAC; aigus ou chroniques. En revanche, l’ajout exogénique de GST-MK5 a 
abaissé ERK4 et p38, mais pas ERK3 dans les lysâtes de cœur de souris. Par contre, 
GST-ERK3 et GST-p38 ne démontrent aucune co-IP avec MK5. Ces données 
suggèrent que dans le cœur seul ERK3, et non ERK4 ou p38, est capable d’interagir 
avec, et réguler MK5. A niveau physiologique MK5 interagit entièrement avec ERK3 et 
par conséquent MK5 n’est pas disponible pour lier les protéines exogéniques. Les souris 
hétérozygotes pour ERK3 (ERK3+/-) ont également démontré une réduction ou une 
absence de collagène et une faible expression d’ARNm du collagène type1 alpha1, 3 
sem post-TAC. Ces résultats démontrent un important rôle pro-fibrotique de la 
signalisation MK5-ERK3 pendant une surcharge chronique de pression. 
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Nous avons également démontré 5 variant d'épissage de (MK5.1-5), y compris la 
forme originale (MK5.1). MK5.2 et MK5.5 subissent une délétion de 6 paires de base 
dans l’exon 12 : MK5.3 manque l'exon 12 : MK5.4 et MK5.5 manquent les exons 2-6. 
L'expression des ARNm des différents variant d'épissage a été vérifiée par PCR en 
temps réel (qPCR). Bien que l’expression est ubiquitaire, l'abondance relative de chaque 
variant était tissu-spécifique (cœur, rein, pancréas, muscle squelettique, poumon, foie, et 
cerveau). En plus, l'abondance relative des variant d’épissage varie pendant la surcharge 
de pression et le développement postnatal du cœur. En outre, l'immunofluorescence a 
indiqué que MK5.1-5.3 se localise au noyau alors que MK5.4-5.5 est situé au niveau 
cytoplasmic dans les cellules HEK 293 non stimulées. Suite à une  stimulation avec 
l'anisomycin, un activateur de p38 MAPK, MK5.1-5.3 se translocalise du noyau au 
cytoplasme alors qu’une petite fraction de MK5.4-5.5 translocalise vers le noyau. Ces 
variant d'épissage peuvent diversifier la signalisation de MK5-ERK3 dans cœur, mais 
leur rôle exact oblige des recherches supplémentaires. 
Excepté l’isoforme , toutes les isoformes de p38 sont exprimées dans le cœur et la 
forme  est considérée comme étant l'isoforme dominante. L’analyse par qPCR et 
immunobuvardage de type western ont démontré que p38 et p38 sont les deux 
isoformes prédominantes alors que p38 et p38 sont exprimées aux mêmes niveaux 
dans le cœur de rat adulte. L'immunofluorescence a démontré que p38 et p38 se 
trouvent dans le cytoplasme et le noyau. Cependant, suite à la surcharge par TAC, p38 
s'est accumulé dans noyau tandis que la distribution de p38 est demeurée inchangée. 
Ainsi, l'abondance de p38 et sa translocalisation nucléaire suite à la surcharge de 
pression indique un rôle potentiel dans l'expression génique pendant le remodelage 
cardiaque.  
 En conclusion, nous avons mis en évidence pour la première fois un rôle pro-
fibrotique pour la signalisation MK5-ERK3 pendant une surcharge chronique de 
pression. D'ailleurs, les niveaux comparables d'expression de p38 avec p38, et la 
localisation différentielle de p38 pendant la surcharge aiguë ou chronique de pression 
suggèrent différents rôles possibles pour ces isoformes pendant le remodelage 
hypertrophique cardiaque. 
                                                                     
TABLE OF CONTENTS 
 
Section                                                                                                                          Page 
 
ABSTRACT ..................................................................................................................... iii 
RÉSUMÉ .......................................................................................................................... v 
TABLE OF CONTENTS ................................................................................................ vii 
LIST OF TABLES .......................................................................................................... xii 
LIST OF FIGURES ....................................................................................................... xiii 
LIST OF ABBREVIATIONS ......................................................................................... xv 
ACKNOWLEDGEMENTS .......................................................................................... xvii 
DEDICATION ............................................................................................................. xviii 
INTRODUCTION ............................................................................................................ 1 
I) Cardiac hypertrophy .................................................................................................. 1 
II) Physiological and pathological remodelling of the heart ....................................... 3 
III) Cardiac cells and the extracellular matrix .............................................................. 4 
IV) Cellular signaling ................................................................................................... 6 
a) Sensing biomechanical signaling ........................................................................... 6 
b) Sensing secreted molecules at the cell surface by receptors .................................. 8 
MAPK signaling in the heart ......................................................................................... 9 
i) ERK1/2 ............................................................................................................... 9 
ii) p38 MAPK ........................................................................................................ 10 
vii

Table of Contents 
                       
iii) Atypical MAPKs: ERK3/ERK4 ......................................................................... 14 
iv) JNK ................................................................................................................... 17 
v) ERK5/big MAPK (BMK) 1 ............................................................................... 18 
MAPK downstream signaling .................................................................................. 19 
(a) MK5/MAPKAPK5/PRAK .......................................................................... 19 
(i) Regulation of MK5 by p38 ........................................................................ 19 
(ii) Regulation of MK5 by PKA ................................................................... 23 
(iii) Regulation of MK5 by ERK3/ERK4 ...................................................... 26 
(iv) Pharmacological inhibitors of MK5 ...................................................... 32 
(v) MK5 in the heart .................................................................................... 33 
(b) MK2/MAPKAPK2 ..................................................................................... 33 
(c) MK3/3pK/MAPKAPK3 ............................................................................. 35 
V) Extracellular matrix (ECM) regulation during cardiac hypertrophy .................... 35 
a) ECM synthesis during cardiac hypertrophy ......................................................... 35 
b) ECM degradation during cardiac hypertrophy ..................................................... 37 
c) Regulation of ECM by microRNA ...................................................................... 38 
MATERIALS AND METHODS .................................................................................... 40 
I) Materials ............................................................................................................... 40 
II) Methods ................................................................................................................ 41 
1) Total RNA isolation from mouse heart ............................................................. 41 
2) Total RNA isolation from heart tissue sections ................................................ 42 
3) cDNA synthesis ................................................................................................. 43 
4) Quantitative real-time PCR (qPCR) ................................................................. 43 
5) DH5 chemical competent cells ....................................................................... 44 
viii

Table of Contents 
                       
6) Transformation of BL-21 or DH5 competent cells ......................................... 44 
7) Cloning of p38 MAPK isoforms ....................................................................... 45 
i) Cloning of p38 ............................................................................................ 45 
ii) Cloning of p38 ............................................................................................ 47 
iii) Cloning of p38 ............................................................................................ 49 
8) Coomassie Brilliant Blue (R250) staining and destaining ............................... 50 
9) Expression and purification of GST-fusion proteins ........................................ 50 
10) Immunocytofluorescence .............................................................................. 51 
11) Detection of p38 and p38 subcellular localization by confocal microscopy
 52 
12) Preparation of murine cardiac lysates ......................................................... 53 
13) Immunoprecipitation of endogenous MK5 ................................................... 53 
14) GST-pull down assay .................................................................................... 54 
15) Genotyping .................................................................................................... 54 
16) Activation of p38 MAPK and determining its specific activity ..................... 55 
17) In vitro protein kinase assay ......................................................................... 56 
18) Miscellaneous methods ................................................................................. 57 
19) Immunoblotting ............................................................................................. 57 
20) Statistical Analysis ........................................................................................ 57 
HYPOTHESIS AND OBJECTIVES .............................................................................. 59 
Hypothesis ................................................................................................................... 59 
Objectives .................................................................................................................... 59 
ARTICLE-1 .................................................................................................................... 61 
ABSTRACT ................................................................................................................ 63 
ix

Table of Contents 
                       
1. Introduction .......................................................................................................... 64 
2. Materials and methods ......................................................................................... 66 
3. Results .................................................................................................................. 72 
4. Discussion ............................................................................................................ 80 
5. Conclusion ........................................................................................................... 85 
References ................................................................................................................... 87 
Figure Legends ............................................................................................................ 90 
Figures ......................................................................................................................... 94 
Tables ........................................................................................................................ 105 
ARTICLE-2 .................................................................................................................. 106 
ABSTRACT .............................................................................................................. 108 
1. Introduction ........................................................................................................ 109 
2. Materials and methods ....................................................................................... 111 
3. Results ................................................................................................................ 116 
4. Discussion .......................................................................................................... 121 
5. Conclusions ........................................................................................................ 125 
References ................................................................................................................. 126 
Figure Legends .......................................................................................................... 130 
Figures ....................................................................................................................... 132 
Tables ........................................................................................................................ 138 
ARTICLE-3 .................................................................................................................. 139 
ABSTRACT .............................................................................................................. 141 
1. Introduction ........................................................................................................ 142 
2. Materials and methods ....................................................................................... 145 
x

Table of Contents 
                       
xi

3. Results ................................................................................................................ 149 
4. Discussion .......................................................................................................... 156 
5. Conclusions ........................................................................................................ 161 
References ................................................................................................................. 162 
Figure Legends .......................................................................................................... 169 
Figure ......................................................................................................................... 172 
Tables ........................................................................................................................ 180 
UNPUBLISHED RESULTS ......................................................................................... 199 
DISCUSSION ............................................................................................................... 201 
CONCLUSIONS ........................................................................................................... 210 
ORIGINAL CONTRIBUTION TO THE LITERATURE ............................................ 211 
REFERENCES .............................................................................................................. 212 
 
 
                                                                      
LIST OF TABLES 

Table                                                                                                                             Page 
 
1. Primers used during cloning…………………………………………………....58 
Article-1 
1. Primers used during real-time qPCR………………………………………….105 
Article-2 
1. Primers used during real-time qPCR………………………………………….138 
Article-3 
1. Hemodynamic parameters for MK5+/+ and MK5+/- mice after 2 wk of  
pressure overload……………………………….……………………………..180 
2. Echocardiographic parameters of MK5+/+ and MK5+/- mice after 2 wk of 
pressure overload……………………………………………………………...181 
3. Structural and functional assessment of ERK3+/+ and ERK3+/- mice by 
echocardiography……………………………………………………………...184 
4. Hemodynamic parameters for ERK3+/+ and ERK3+/- mice after 3 wk of     
pressure overload…….………………………………………………………..187 
5. Echocardiographic parameters of ERK3+/+ and ERK3+/- mice after 3 wk of 
pressure overload……………………………………………………………...188 
S1. The primers used for qPCR…………………………………………………...191 
S2. Structural and functional assessment of MK5+/+ and MK5+/- mice by  
      echocardiography……………………………………………………………...192 
S3. Hemodynamic parameters for MK5+/+ and MK5+/- mice after 3 wk of  
      pressure  overload………….………………………………………………….195 
S4. Structural and functional assessment of ERK3 and MK5 mice by   
      echocardiography……………………………………………………………...196
xii

                                                                      
LIST OF FIGURES 

Figure                                                                                                                           Page 
 
1. Architectural patterns of cardiac hypertrophy……………………………………2 
2. Integrins’ interaction with the extracellular matrix and a number of  
intracellular signaling pathways………………………………………………….5 
3. Cytoskeletal proteins of sarcomeres……………………………………………..7 
4. MAPK and other signaling pathways involved in cardiac hypertrophic 
response…………………………………………………………………………10 
5. Model for the regulation of MK5’s subcellular distribution……………………21 
6. A model of the activation of ERK3/ERK4-MK5 complexes…………………..31 
7. Screening for MK5 substrates in heart………………………………………...200 
Article-1 
1. Sequence comparison of murine MK5 splice variants. Figure shows the 
predicted amino acid sequences………………………………………………...94 
2. Detection of MK5 variants in murine tissues…………………………………...95 
3. Expression of recombinant MK5 splice variants……………………………….96 
4. Activation of p38 MAPK induces translocation of endogenous MK5 in  
HEK293 cells…………………………………………………………………...97 
5. p38MAPK activation alters the subcellular localization ofMK5-V5 variants….98 
6. Pressure overload-induced hypertrophy alters MK5 splicing…………………..99 
7. Regulation ofMK5 splicing in heart during postnatal maturation…………….100 
8. MK5 interacts with ERK3 in heart……………………………………………101 
S1. Genomic alignment of cDNA sequence of MK5 variants cloned from murine                               
heart……………………………………………………………………………102 
S2. Schematic representation of MK5 variants……………………………………104 
Article-2 
1. Cardiac expression of p38 in murine heart……………………………………132 
2. Effect of pressure-overload hypertrophy on p38 expression………………….133 
xiii

                                                                                                                 List of Figures                              
xiv

3. Changes of p38 mRNA during post-natal heart development………………...134 
4. Specific activity of p38 isoforms……………………………………………...135 
5. Subcellular localization of p38 and p38 during chronic pressure overload..136 
Article-3 
1. Hypertrophic response of MK5+/- hearts to pressure overload………………..172 
2. Expression of molecular markers of hypertrophy in the ventricular  
myocardium of MK5+/+ and MK5+/- mice after 2 weeks of pressure overload..173 
3. Assessment of cardiac fibrosis in MK5+/+ and MK5+/- mice after pressure 
overload………………………………………………………………………..174 
4. ERK3 co-immunoprecipitates with MK5……………………………………..175 
5. Hypertrophic response of ERK3+/- mice to pressure overload………………...176 
6. Assessment of cardiac fibrosis in ERK3+/+ and ERK3+/- mice after 3 weeks  
of pressure overload…………………………………………………………...177 
7. Quantification of TGF1 and TGF3 mRNA…………………………………178 
S1.   Response of MK5+/- hearts to 3 weeks of pressure overload………………...179 


 

 
                                                                      
LIST OF ABBREVIATIONS 

%EF  Percentage ejection fraction 
%FS  Percentage fractional shortening 
ANP  Atrial natriuretic peptide 
AS  Anti-sense 
BW  Body weight 
COL1 1 Collagen type 1 alpha 1 
DMSO  Dimethylsulfoxide 
DNA  Deoxyribonucleic acid 
DTT  Dithiothreitol 
E  Early mitral filling E-wave velocity 
Em  Early mitral annular velocity 
ERK1/2 Extracellular signal-regulated kinase 1/2 
ERK3  Extra-cellular regulated kinase 3 
ERK4  Extra-cellular regulated kinase 4 
ERK5  Extra-cellular regulated kinase 5 
FPLC  Fast protein liquid chromatography 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GPCR  G protein coupled-receptor 
GSK-3 glycogen synthase kinase-3 
GST  Glutathione S-transferase 
HEK293  Human embryonic kidney 293  
IGF-2  Insulin like growth factor-2 
IP  Immunoprecipitation  
IVRT  Isovolumic relaxation time 
IVRTc  Heart rate corrected IVRT 
JNK  c-jun amino-terminal kinase 
LV  Left ventricle  
MAPK  Mitogen-activated protein kinase 
xv

                                                                                                            List of Abbreviations                        
xvi

MAPKAPK5 MAP kinase-activated protein kinase 5 
MBP  Myelin basic protein 
MK  MAPK-activated protein kinase 
MK2  MAP kinase-activated protein kinase-2 
MK3  MAP kinase-activated protein kinase-3 
MK5  MAP kinase-activated protein kinase-5 
MPI  Myocardial performance index 
mRNA  Messenger RNA 
NES  Nuclear export signal 
NLS  Nuclear localization signal  
PAGE  Polyacrylamide gel electrophoresis 
PKI  Cyclic AMP-dependent protein kinase inhibitory peptide 
PMSF  Phenylmethylsulfonyl fluoride 
PRAK  p38 Regulated/Activated Protein Kinase 
qPCR  Quantitative polymer chain reaction 
RNA  Ribonucleic acid  
S  Sense 
TAC  Transverse aortic constriction 
TGF-1 Transforming growth factor beta 1 
TGF-3 Transforming growth factor beta 3 
TRAF6 TNF receptor associated factor 6 
TTE  Transthorasic echocardiogram 
TX-100 Triton X-100 
-MHC  -myosin heavy chain
                                                                      
ACKNOWLEDGEMENTS 

 I express my gratitude to my PhD supervisor Dr. Bruce Allen, without him it 
would have been not possible to complete this task. He has provided good support and 
guidance throughout my doctoral work. Under his guidance, I learned a lot about 
signaling mechanisms in the heart during both normal and pathological conditions. 
Working with Dr. Allen equipped me with various scientific techniques and taught how 
to ask the right questions and how to address those questions using the correct scientific 
tools. I would also like to thanks members of thesis committee; Dr. Sylvain Meloche 
and Dr. Benoit Coulombe, for their valuable research input.     
 I also wish to thanks Dr. Matthias Gaestel and Dr. Sylvain Meloche for 
providing us with MK5 and ERK3 knockout mice as well as Dr. Jean-Claude Tardif and 
Dr. Yanfen Shi for echocardiography support. 
 I acknowledge technical help from Mr. Marc-Antoine Gillis, Mr. Louis R. 
Villeneuve, Ms. Karine Bouthillier, and Ms. Maya Mamarbachi.  
 I also would like to thanks Canadian Institutes of Health Research (CIHR) for 
providing funds to do my research project as well as to those mice who sacrificed their 
life for the greater cause of science and betterment of human health.  
 Finally, I appreciate all the help I got during my doctoral work from my 
colleagues; George Vaniotis, Nadege Moise, Nada Farhat, Dr. Clemence Merlen, Dr. 
Maya Khairallah, and Catherine Lavoie.  
   
 
 
 
 
 
 
  
xvii

                                                                                                                                                                       
xviii

DEDICATION 
 
 
 
 
 
 
 
 
To my mother and late father.
                                                                      
INTRODUCTION 

I) Cardiac hypertrophy 
Hypertrophy of an organ is described as an increase in the size of its cells. The 
central characteristics of cardiac hypertrophy are an increase in cardiomyocyte size, 
increased organisation of the sarcomere, and enhanced protein synthesis. This can 
generate different architectural patterns, which are generally described as being either 
eccentric or concentric hypertrophy. In eccentric hypertrophy, there is an increase in 
cardiac mass and chamber volume while relative wall thickness may be unchanged, 
decreased, or increased. Concentric hypertrophy refers to an increase in cardiac mass 
and relative wall thickness with reduced or unchanged chamber volume (Fig. 1). During 
eccentric hypertrophy heart enlargement is the result of the addition of new sarcomeres 
in series, to lengthen the cardiomyocyte. During concentric hypertrophy, the reduction 
in chamber volume is the result of the addition of new sarcomeres in parallel, to increase 
the width of cardiomyocytes. Hypertrophy can be further classified as: 1) developmental 
hypertrophy, which is linked to the normal post-natal growth of the heart, 2) 
pathological hypertrophy, which is linked to disease-inducing stimuli such as pressure or 
volume overload, and 3) physiological hypertrophy, often seen in athletes and is linked 
to exercise or pregnancy. Physiological and developmental hypertrophy are 
characterised by a uniform profile of ventricular wall and septal growth that is matched 
by an increase in chamber dimension, while pathological cardiac hypertrophy is 
characterised by a thickened ventricular wall and septum with a net change in 
ventricular chamber dimensions [1, 2]. 
 Pathologic cardiac hypertrophy is a compensatory response to stress and occurs 
when the heart is continuously exposed to increased external stimuli such as stretch, 
hemodynamic overload and/or increased neurohormonal factors. These stimuli are 
associated with the release of hormones, cytokines, chemokines, and peptide growth 
factors [1]. The mechanisms where biomechanical signals are transmitted across the 
plasma membrane remains unclear, although they probably involve stretch-sensitive ion 
channels, integrins, and other structural proteins in a complex network that links the 
1

                                                                                                                          Introduction                         
extracellular matrix, cytoskeleton, sarcomere, Ca2+-handling proteins, and nucleus [3]. 
The general understanding of hypertensive heart disease is development of concentric 
left ventricular hypertrophy with diastolic dysfunction, which is followed by ventricular 
dilatation with impaired contractility. 
 
 
 
Fig. 1. Architectural patterns of cardiac hypertrophy. After myocardial infarction, 
eccentric hypertrophy in the non-infarcted region cause regional wall motion 
abnormalities. Ejection fraction is decreased in dilated cardiomyopathy and increased in 
volume overload-induced eccentric hypertrophy. In the case of pressure overload-
induced hypertrophy, diastolic function is reduced due to increased stiffness of the 
ventricle (taken from [2]). 

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II) Physiological and pathological remodelling of the heart 
 Apart from the differences in morphology observed in physiological and 
pathological hypertrophy, there are also differences at the molecular level. In 
physiological hypertrophy cardiac function remains normal or is enhanced whereas in 
pathological hypertrophy cardiac function is reduced over time. In addition, 
physiological hypertrophy is generally reversible whereas pathological hypertrophy is 
not [4]. Furthermore, hypertrophy induced by exercise is usually not accompanied by 
interstitial collagen deposition [5] while hypertrophy induced by pressure- or volume-
overload has collagen deposition [6]. In addition, contrary to physiological hypertrophy, 
pathological hypertrophy is associated with the re-expression of fetal genes such as 
atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and the fetal isoforms 
of contractile proteins such as -actin and -myosin heavy chain (-MHC), as well as 
the down-regulation of -MHC and sarcoplasmic reticulum Ca2+-ATPase expression 
[4]. Furthermore, differential regulation in -MHC and -MHC is observed in 
hypertrophy induced by exercise versus pressure overload [7]. The shift in expression of 
myosin heavy chain isoform (exchange “low” and “high”) that accompanies a reversion 
to the fetal phenotype weakens the heart by reducing shortening velocity while at the 
same time helping the heart adapt to the greater energy requirements associated with 
increased wall stress, as -MHC (low ATPase activity) develops tension with greater 
efficiency than -MHC (high ATPase activity). Another important consequence of the 
reversion to the fetal phenotype is the reduction of expression of sarco (endo) plasmic 
reticulum calcium pump ATPase (SERCA) that contributes to arrhythmias and sudden 
death as seen in end stage heart failure. SERCA participate in intracellular calcium cycle 
by transporting Ca2+ back into the SR in order to allow the myocardium to relax after 
each contraction [2]. Remodelling caused by hypertension is a major risk factor for heart 
failure. The stiffening of the heart, caused by excessive collagen accumulation, together 
with the loss of contractility, as a result of myocyte apoptosis or necrosis, are major 
undesirable consequences of pathological remodelling [8]. From this point onward the 
term cardiac hypertrophy or hypertrophy is used to describe pathological hypertrophy. 
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III) Cardiac cells and the extracellular matrix   
Cardiac myocytes make up the majority of the heart’s mass, however 
numerically-speaking approximately 70% of the cells in the heart are smaller non-
myocytes. The heart is made up of myocytes, vascular smooth muscle cells, endothelial 
cells, and fibroblasts. The fibroblast secretes extracellular matrix proteins (connective 
tissue) that contributes to heart’s tensile strength and stiffness. The extracellular matrix 
(ECM) consists mainly of fibrillar and network collagens, elastic fibres formed by 
elastin, hydrated proteoglycans and adhesive proteins such as fibronectin and laminin, 
which couple myocytes to the collagen networks. The ECM provides a scaffold for both 
myocytes and non-myocytes and hence distributes mechanical forces throughout the 
myocardium, and transmits mechanical signals to individual cells via surface receptors 
[9, 10]. Furthermore, the cells’ cell surface or adhesion proteins connect its actin 
microfilaments to extracellular matrix proteins, which include the dystrophin 
glycoprotein complex and integrins. Dystroglycans bind to many ECM proteins 
including fibronectin and laminin, while integrins bind to fibronectin, laminin, and 
vitronectin, which along with heparans and other proteoglycans link the integrins to 
collagen. Integrins lack enzymatic activity but they do allow mechanical stresses to 
activate a number of signal transduction pathways by modifying the activity of small G-
proteins such as Rho, Rac, and Ras; focal adhesion associated kinases (FAKs); and a 
variety of protein kinases including Akt, Raf, MEK, and ERK [2].  The ECM’s 
connections to the intracellular cytoskeletal and signaling proteins through cell surface 
proteins are shown in Figure 2.  
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Fig. 2. Integrins’ interaction with the extracellular matrix and a number of 
intracellular signaling pathways. See explanation in the text (modified from [2]).  
 
The connective tissue within the myocardium or the network of fibrillar collagen 
based on morphology are divided into: 1) endomysium, which surrounds individual 
cardiomyocytes and function as the sites for connections to cardiomyocyte cytoskeletal 
proteins across the plasma membrane, 2) perimycium, which supports groups of 
myocytes or surrounds muscle fibres, and 3) epimycium, which encases the entire 
muscle [2]. The endomycium is also the source of ECM scaffolding for blood vessels. 
Pathological cardiac remodelling’s fundamental characteristic is myocardial stiffness, 
which is associated with fibrosis, systolic and diastolic dysfunction, and changes in 
cardiac cellularity. An increase in collagen (fibrosis or accumulated perimycium) during 
hypertrophy is coupled with diastolic heart failure, whereas the degradation of collagen 
(endomysial and perimysial) is associated with ventricular dilatation and systolic heart 
failure [6]. Therefore, the right proportion of ECM is critical for the heart’s normal 
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physiological function and any anomaly in synthesis or degradation can have 
devastating consequences.  
 
IV)   Cellular signaling 
  Cardiomyocyte function is influenced by interactions with the ECM, autocrine 
and paracrine secreted molecules, and circulating hormones. Therefore, it is important to 
understand cellular events at the molecular level. Membrane receptors and/or 
mechanical sensors permit cardiomyocytes to sense stress caused by pressure- or 
volume-overload. This is then transmitted through numerous signaling cascades, which 
results in alteration in gene expression and subsequently changes in physiology of the 
heart.  
 
a) Sensing biomechanical signaling 
 In cardiomyocyte, the cytoskeletal proteins transmit tension developed by the 
contractile proteins from one sarcomere to another and to the cell surface. Interactions of 
these proteins are shown in figure 3. Apart from participating in this mechanical 
function, many cytoskeletal proteins also participate in signaling. Therefore, 
cardiomyocytes can directly sense deformation or stretch through an internal sensory 
apparatus, which includes integrins and MLPs (muscle LIM protein), and translate it 
into internal biochemical changes. Melusin, which interacts with the integrin beta 1 
cytoplasmic domain, senses pressure-overload stress in cardiomyocytes and, in turn, 
regulates the inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3). 
Melusin knockout mice develop dilated cardiomyopathy and contractile dysfunction in 
response to chronic pressure overload; however, they respond similarly to wild type 
mice when treated with angiotensin II and phenylephrine [11]. Additionally, cardiac-
selective inactivation of integrin or integrin effector molecules, such as focal adhesion 
kinase (FAK), in mice leads to dilated cardiomyopathy [12]. Another stretch-sensing 
apparatus is the sarcomere’s Z-disc, specifically the MLP, which is anchored at the Z 
disc, to telethonin (T-cap), a titin-interacting protein (Fig. 3). MLP is considered to 
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sense stretch through a complex of transducing proteins and then signal through the 
calcineurin-NFAT pathway [13, 14]. 
 
 
 
 
Fig. 3. Cytoskeletal proteins of sarcomere.  Titin, a huge protein of molecular weight 
3,000,000, and t-cap (telethonin) both link Z lines to the thick filament. On the thick 
filament titin is connected to myosin by myosin-binding protein C. Sarcomere’s signal 
transduction active regions are labeled as Z-line base signaling, M-band base signaling, 
and central I-band-based signaling (adopted from [2]). 
 
 Angiotensin II type 1 (AT1) receptors have been well characterized for 
mediating angiotensin II signaling during cardiac hypertrophy. Zou et al show that AT1 
receptors sense stretch and activate downstream signaling in an angiotensin II (Ang II) 
independent manner. Angiotensin knock out mice develop hypertrophy after the aortic 
banding [15].  This peculiar signaling was later shown as an emerging phenomenon, 
now know as biased agonism, wherein ligands are able to induce conformational change 
of receptor that preferentially activate specific downstream signaling pathways. Stretch 
activates AT1 receptor--arrestin signaling which is independent of the classical 
paradigm of Ang II-mediated G-protein activation [16].   
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b) Sensing secreted molecules at the cell surface by receptors 
 When the heart is subjected to hemodynamic stress, the body responds by 
producing endogenous signals, which can be systemic or local and can lead to a variety 
of changes in the heart. The cell’s cytosol and extracellular space are separated by the 
plasma membrane, which act a as barrier, but also allows signal transduction through 
cell-surface receptor proteins. There are three known classes of cell-surface receptor 
proteins: ion channel-linked, G protein-linked, and enzyme-linked [17].  Ion channel-
linked receptors are transiently opened or closed by ligands, briefly changing the ion 
permeability of the plasma membrane. G protein-coupled receptors  (GPCRs) belong to 
a large superfamily of homologous, seven transmembrane proteins that regulate the 
activity of separate plasma membrane-bound proteins (enzyme or ion channel) through 
trimeric GTP-binding regulatory proteins (G protein).  Enzyme-linked receptors, most of 
which are single transmembrane proteins, when activated, either function directly as 
enzymes or are associated with enzymes [17]. In the heart, GPCRs are the most widely 
studied, and include catecholamines signaling through -/-adrenergic receptors, 
endothelin acting on the ETA and ETB receptors, Ang II signaling through AT1 and AT2 
receptors, adenosine signaling through A1 and A2 receptors, and acetylcholine signaling 
through muscarinic receptors [18]. Ang II and endothelin 1 (ET-1), which binds to 
GPCRs associated with Gq and G11, and -adrenergic stimulation, which binds to 
GPCRs associated with Gs, cause cardiac hypertrophy and fibrosis, as well as 
cardiomyocyte apoptosis [8]. There is more interest in signaling mediated by Gq/G11, 
which are required for the development of pathological hypertrophy. Double knockout 
of Gq/G11 showed no detectable hypertrophy, but showed myocardial fibrosis and 
apoptosis post-transverse aortic constriction [19]. Over expression of the activated or 
wild type form of Gq resulted in development of cardiac hypertrophy that lead into 
progression towards apoptosis and heart failure [20, 21]. These receptors regulate 
several different intracellular signaling cascades. Here we will focus more specifically 
on the MAPK signaling cascades.   
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MAPK signaling in the heart 
 Five distinct MAPK pathways have been identified in mammals: the 
extracellular signal-regulated kinases (ERKs) ERK1/2, ERK3/4, ERK5, c-jun amino-
terminal kinases (JNKs) (1-3), and p38 MAPKs (, , , and ) [22]. Each pathway, 
except for ERK3/4, displays a characteristic hierarchical organization wherein MAPK 
kinase kinases (MAPKKK) phosphorylate and activate MAPK kinases (MAPKK), 
which in turn activate their respective MAPKs. In the cardiac myocyte MAPK signaling 
is initiated by GPCRs, receptor serine/threonine kinases (e.g., transforming growth 
factor-  (TGF)), receptor tyrosine kinases (e.g., IGF-1 and fibroblast growth factor 
receptors), cardiotrophin-1 (gp130 receptor), and by mechanical stress such as stretch 
(Fig. 4) [1]. 
 
i) ERK1/2 
 The ERK1/2 module consists of MAPKKKs, A-Raf, B-Raf, and Raf-1, the 
MAPKKs MEK1 and MEK2, and MAPKs ERK1 and ERK2. MEK1 and MEK2 
catalyze a dual phosphorylation (T-E-Y) within the activation loop of ERK1/2, resulting 
in a conformational change that removes steric blocking of the activation loop, which in 
turn facilitates substrate binding [23].  In the heart, MEK1-ERK1/2 activation is 
required for hypertrophic growth. Cardiac specific over-expression of activated MEK1 
results in the development of concentric hypertrophy without any signs of 
cardiomyopathy or interstitial fibrosis [24]. In contrast, cardiac-specific over-expression 
of an activated form of Ras, an upstream kinase of Raf, promoted a cardiomyopathy that 
was characterized by pathological cardiac remodeling and premature death [25]. In 
contrast, mice having cardiac-specific expression of dominant negative Raf showed 
marked resistance to hypertrophy along with inhibition of ERK, but not p38 or JNK, 
activation following pressure overload [26]. These data suggest that ERK1/2 activity is 
required for growth and is beneficial whereas upstream Ras regulates multiple 
downstream signaling targets which are both beneficial and detrimental to the heart. 
Recent evidence suggests that ERK1/2 may specifically be required for concentric 
hypertrophy. ERK1/2 knock out mice develop eccentric hypertrophy whereas mice 
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having myocyte-targeted expression of constitutively active MEK1 develop concentric 
hypertrophy after pathological insult [27]. This shows the importance of ERK1/2 in 
directing the heart towards concentric versus eccentric growth.   
 
 
 
Fig. 4. MAPK and other signaling pathways involved in cardiac hypertrophic 
reposne (taken from [1])  
 
ii) p38 MAPK 
 The p38 MAPK module consists of MAPKKKs MEKKs 1-4, MLK-2 and -3, 
DLK, ASK-1, Cot (Tpl2), and Tak1, the MAPKKs MKK3 and MKK6, and four known 
p38 isoforms (p38, p38, p38, and p38) [23]. MKK3 and MKK6 phosphorylate the 
dual phosphorylation site (T-G-Y) in the activation loop of p38 MAPKs. p38 and p38 
are ubiquitously expressed, while p38 is primarily expressed in striated muscle and 
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p38 is expressed in lung, kidney, testis, pancreas, and small intestine [28, 29]. To date, 
except for p38, all isoforms (p38, p38, and p38) have been detected in the heart 
[30]. All four p38 isoforms have been knocked out in mice: p38-deficient mice show 
embryonic lethality due to placental defects, while p38-, p38-, and p38-null mice 
appear to have normal phenotypes [31]. 
 To determine if p38 MAPK plays a role in pathologic cardiac remodeling, 
transgenic mice over-expressing dominant negative forms of p38 (DN-p38) or p38 
(DN-p38) were examined [32, 33]. Transgenic mice expressing DN-p38 or DN-p38 
developed cardiac hypertrophy but were resistant to cardiac fibrosis after transverse 
aortic constriction [32]. In another study, Wang et al. dissected the functions of the p38 
and p38 isoforms in neonatal cardiomyocytes infected with adenoviral vectors 
expressing activated mutants of upstream activators of the p38 kinases, MAP kinase 
kinase 3b(E) (MKK3bE) and MAP kinase kinase 6b(E) (MKK6bE). Infected 
cardiomyocytes showed a hypertrophic response including enhanced sarcomeric 
organization, increased cell size, and increased ANP expression. MKK3bE-expressing 
cells were more apoptotic. The hypertrophic response was suppressed upon co-
expression of DN-p38. The apoptotic effect of MKK3bE was suppressed upon co-
expression of DN-p38 [33]. This study demonstrated that p38 is pro-apoptotic and 
p38 is pro-hypertrophic in neonatal myocytes. Additionally, in transgenic mice with 
myocyte-specific expression of MKK3bE or MKK6bE, both MKK3bE and MKK6bE 
transgenic hearts exhibited a marked increase in interstitial fibrosis, increased fetal gene 
expression, but no significant signs of hypertrophy. These mice also died at 7-9 weeks 
of age [34]. These studies suggest a detrimental effect of MKK3/6 and p38 activation; 
however, other studies have shown somewhat contradictory observations. For example, 
cardiac specific transgenic mice expressing DN-p38, DN-MKK3, or DN-MKK6 
developed enhanced hypertrophy at baseline as well as during pressure overload, or 
infusion of Ang II, isoproterenol, or phenylephrine. Enhancement of hypertrophy was 
attributed to the ability of DN-p38 to promote the nuclear localization of the 
transcription factor nuclear factor of activated T cells (NFAT) and hence increase the 
expression of NFAT-regulated genes. In addition to promoting a hypertrophic response 
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in the absence additional causative factors, DN-p38 and DN-MKK3 also produced an 
increase in interstitial fibrosis [35]. Mice having a cardiac-specific p38 knockout 
appear to possess a normal cardiac phenotype. However, after TAC, p38-/- hearts 
became hypertrophic similar to wild type, but display more extensive interstitial fibrosis 
in addition to cardiomyocyte apoptosis [36].  
Although the results from various studies seem contradictory, they do appear to 
indicate that p38 activation is detrimental in the heart. Recently, it has been shown that 
inducing the expression of constitutively active MKK3 (CA-MKK3) in the adult heart 
leads to cardiac hypertrophy, ECM remodeling, contractile dysfunction, fetal gene 
expression (ANP and -MHC), and lethal bradycardic heart failure within 8 days. 
However, removal of MK2, a well characterized downstream target of p38, in a CA-
MKK3 background rescued some aspects of the above pathological response [37]. 
Moreover, reduced apoptotic cell death in cultured myocytes and intact heart upon 
pressure overload or ischemia/reperfusion was observed upon pharmacological 
inhibition of p38/ activity using a specific inhibitor, SB203580 [38, 39]. Along the 
same lines, inhibition of p38/ during ischemia/reperfusion injury or myocardial 
infarction improved cardiac function and reduced remodeling [40, 41]. TAK1 (TGF--
activated kinase-1) is an MAPKKK that activates MKK3 and MKK6 [42], and is known 
to interact with type II TGF receptors (TBR II) and TRAF6 in cardiomyocytes [43]. 
Like TGF, TAK1 is activated by pro-inflammatory cytokines such as TNF and IL-1 
[44]. In the heart, TAK1 is implicated in pathological remodeling. Zhang et al generated 
a line of transgenic mice with cardiac-specific expression of activated TAK1. These 
mice revealed that constitutive activation of TAK1 was sufficient to induce cardiac 
hypertrophy, which was accompanied by fibrosis, apoptosis, severe myocardial 
dysfunction, fetal gene reactivation, and early lethality [45]. Hence, from a therapeutic 
point of view, there is great interest in the inhibition of p38/ kinase activity in the 
diseased heart. For this reason p38/ inhibitors have advanced to phase I clinical trials 
[46].  
In addition to canonical phosphorylation by upstream kinases MKK3/6, p38 
also undergoes autophosphorylation. In HEK 293 cells in response to TNF treatment, 
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TRAF6-TAB1-p38 form a complex in which TAB1 (transforming growth factor--
activated protein kinase 1 (TAK1)-binding protein 1) facilitates p38 
autophosphorylation [47]. This TAB1 dependent autophosphorylation of p38, which is 
independent of MKK3/6, has been implicated in p38 mediated ischemic/reperfusion 
injury in the heart [48]. Li et al. further showed the requirement of AMP-activated 
protein kinase (AMPK) for the TAB1 mediated autophosphorylation of p38 in AMPK 
knockout ischemic heart [49]. Moreover, ZAP70 (zeta-chain associated protein kinase, 
70 kDa) has been shown to induce p38 autophosphorylation in T cells. ZAP70 is a 
tyrosine kinase that, upon activation by a T-cell receptor, phosphorylates p38 on Tyr-
323, which then causes p38 autophosphorylation at residues Thr-180 and Tyr-182 in its 
activation loop [50].  
 TAB1 mediated non-canonical autophosphorylation of p38 is negatively 
regulated. In cardiomyocytes and other cells, p38 autophosphorylation was negatively 
regulated by the Hsp70-Cdc37 chaperone complex via direct binding of p38 with 
Cdc37. The Hsp70-Cdc37 complex inhibited both basal and TAB1 mediated p38 
autophosphorylation whereas it does not inhibit the phosphorylation of p38 by canonical 
upstream kinase MKK3 [51] . Furthermore, inhibition of Hsp70 activity increased p38 
autophosphorylation and apoptosis in myocytes [51]. In addition, p38 phosphorylates 
TAB1 at three different sites and causes the inhibition of TAK1 activation in response to 
pro-inflammatory cytokines or osmotic stress, resulting in feed-back inhibition of p38 
signaling as well as suggesting the importance of p38 in the regulation of TAK1 
downstream signaling such as JNK or IKK [52]. Canonical p38 phosphorylation is also 
negatively regulated by protein phosphatases, which interact with phosphorylated p38 
but not the non-phosphorylated form of p38 [53]. Mitogen-activated protein kinase 
phosphatase (MKPs) are dual-specificity phosphatases (DUSP) involved in the 
dephosphorylation, and hence inactivation of ERK1/2, JNK, and p38. There are ten 
proteins in this subgroup and they all show varying degrees of substrate specificity [54]. 
p38 is also negatively regulated by serine threonine phosphatase PP2C [53],    
 p38 regulates number of transcription factors, either directly or through different 
MKs as discussed below. GATA4 is an important transcription factor in heart required 
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for cardiac development and differentiation as well as cardiac survival and hypertrophy 
[55]. GATA4’s transcriptional activity is controlled through its Ser105 phosphorylation 
by ERK1/2 and p38 [56, 57]. p38 also phosphorylates NFAT (Fig. 4) and hence 
regulates its nuclear entry and transcriptional activity [35]. 
  
iii) Atypical MAPKs: ERK3/ERK4 
 ERK3 is a 720 amino acid protein of molecular mass 100 kDa and ERK4 is a 
587 amino acid protein with molecular mass 70 kDa. Both proteins share 73% sequence 
homology within their kinase domains. Atypical MAPKs are distinct in two aspects 
from conventional MAP kinases: first, conventional MAP kinases have dual phospho-
acceptor site (T-X-Y) while atypical MAPKs have a single phospho-acceptor site (S-E-
G) in their activation loop. Second, subdomain VIII in the kinase domain of 
conventional MAP kinases has the sequence A-P-E while all the ERK3 and ERK4 
orthologs have S-P-R. Having an arginine at this position makes ERK3/ERK4 unique 
within the human kinome. Subdomain VIII lies in the C-terminal lobe of the kinase 
domain and mutation of a glutamic acid residue within subdomain VIII of protein kinase 
A slightly reduces its affinity for substrates. Moreover, ERK3 and ERK4 also have C-
terminal extensions, downstream of an N-terminal kinase domain, that are 50% identical 
in the first 150 amino acids while the remaining C-terminus is divergent. In contrast to 
the conventional MAP kinases, ERK3 and ERK4 are only found in vertebrates 
(reviewed in [58]).  
 Coulombe et al. showed that unlike other MAPKs, ERK3 is a highly unstable 
protein, that is continually degraded in proliferating cells with a half life of only 30 min. 
Given that inhibition of the proteosome with inhibitors like MG-132 or lactacystin 
increased the half life of ERK3 from 30 min to over 2 hours, ERK3 degradation is likely 
mediated by the proteosome. Inactivation of the ubiquitin-activating enzyme E1, but not 
a phosphorylation-site mutation, kinase dead mutant, or truncation of the C-terminal 
extension, results in accumulation of ERK3 protein [59]. This suggests that proteolysis 
of ERK3 is dependent on its polyubiquitination and not on the phosphorylation of its 
activation loop, its kinase activity, or its C-terminal extension. Generally an internal 
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lysine residue is ubiquitinated by the ubiquitin-proteosome pathway. However, this is 
not the case with ERK3, as a lysine-less mutant of ERK3 is still ubiquitinated and 
degraded. In fact, ERK3 has a unique mode of ubiquitination. Mass spectrometry has 
shown that ERK3 is conjugated to ubiquitin via its free NH2 terminus and this 
observation was further reinforced by increasing the size of the N-terminal sequence tag 
leading to increased stability of the protein [60]. Along with post-translational 
regulation, ERK3 is also regulated at the transcriptional level. Inhibition of the 
proteosome activates p38 MAPK, possibly by regulating expression or stability of 
protein upstream of MKK3/6, which leads to an increase in ERK3 transcription and 
translation. Increased ERK3 expression reduced the anti-proliferative effect induced by 
proteosome inhibition, which might suggest an intracellular rescue mechanism against 
cell stress and damage induced by proteosome inhibition [61]. Additionally, ERK3 is 
also regulated at the level of protein stability during cell differentiation. For example, 
ERK3 protein accumulates during the differentiation of C2C12 myoblasts into muscle 
cells [59]. Unlike ERK3, ERK4 is a far more stable protein [62, 63]. 
 ERK3 has been implicated in insulin secretion by islet -cells induced by 
glucose and phorbol-12-myristate-13-acetate (PMA). In this pathway ERK3 associates 
with microtubule-associated protein 2 (MAP2) and increases MAP2 serine 
phosphorylation [64]. It has been shown that along with MAP2 phosphorylation there is 
an increase in serine phosphorylation of ERK3 upon activation of PKC by PMA, 
although the identity of this ERK3 serine residue is not known. In other studies there 
was no change in the phosphorylation of ERK3 at Ser-189 in HEK293 cells following 
PMA treatment, mitogenic or stress stimuli. However there are other serine residues in 
ERK3 that are phosphorylated. MK5 phosphorylates Ser-386 [65]. In addition, Ser-684, 
Ser-688, and Ser-705 are phosphorylated by cyclin B-Cdk1 [66]. Hence, the identity of 
the serine phosphorylation in -cells needs to be determined using ERK3 
phosphorylation-site specific antibodies or site-directed mutagenesis. Furthermore, 
ERK3 may also been involved in cancer. The great majority of tissue and peripheral 
blood samples from patients with oral cancer have increased levels of ERK3 [67]. Along 
similar lines, ERK3 levels are reduced in cells where PCNA (proliferating cell nuclear 
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antigen) expression has been down regulated by siRNA. PCNA has been shown to be 
up-regulated in a number of chronic myologenous leukemia (CML) patients [68]. These 
observations suggest that ERK3 may also play a role in carcinogenesis, although a direct 
link between ERK3 activation and the development or prevention of cancer has not yet 
been demonstrated.  
 In certain cell types, overexpression of ERK3 inhibits cell cycle progression 
[69]. In NIH 3T3 fibroblasts over-expression of ERK3 causes G1 arrest [59] and this 
inhibition of entry into S phase requires the nucleocytoplasmic shuttling of ERK3, as 
exclusively nuclear (ERK3-NES) or cytoplasmic (ERK3-NLS) ERK3 fusion proteins 
were less effective for cell cycle arrest than the wild type kinase [70]. Moreover, 
mutation of Ser-189 to either a non-phosphorylatable alanine residue or a 
phosphomimetic glutamic acid residue does not change the subcellular localization of 
ERK3 in NIH 3T3 fibroblasts [70]. These observations suggest that factors responsible 
for nuclear-cytoplasmic shuttling of ERK3, not the upstream kinase of ERK3, might be 
deciding the fate of ERK3 function in cell cycle G1 arrest. On similar lines  it has been 
suggested that the phosphatase hCdc14A might be keeping the signaling complex 
comprising  ERK3/4, MK5, and  cyclin D3 in the cytoplasm, resulting in G1 cell cycle 
arrest [71], but this still requires direct experimental proof. 
 As mentioned above, hCdc14A dephosphorylates ERK3 at sites phosphorylated 
by Cdk [71]. ERK3 is phosphorylated within its C-terminal extension at Ser-684, Ser-
688, Thr-698, and Ser-705 by cyclin B-Cdk1 during mitosis and dephosphorylated by 
hCdc14A and hCdc14B at the end of mitosis [66]. Each of these sites is followed by a 
proline residue, conserved in mammals, and lies within a minimal Cdk consensus 
phosphorylation site. This hyperphosphorylation of ERK3 reduces its mobility on SDS-
PAGE. Moreover, phosphorylation of these four residues increases the stability of 
ERK3 during mitosis [66]. Cyclin B-Cdk-1 activity is at its peak during mitosis and is 
required for the G2/M transition and cell cycle progression [72]. Cdc14 is a  proline-
directed phosphatase that opposes the actions of Cdk and hence plays a role in 
regulating a cells exit from mitosis [73]. This understanding of the regulation of ERK3 
by cyclin B-Cdk1 and hCdc14 during cell cycle and the stabilization of ERK3 by 
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phosphorylation provides important insights into the function of this kinase. It would be 
interesting to know about the purpose of increased ERK3 stability during mitosis as this 
may help to reveal the role of this kinase in other cellular functions.  
 Klinger et al. recently generated a line of ERK3 knockout mice in a C57BL/6 
background. These mice lack the 2nd, 3rd, and 4th exons in ERK3 and, because of a stop 
codon insertion in the gene, results in a null allele. ERK3-/- mice are born with normal 
Mendelian frequency but all neonates die within 24h due to acute respiratory failure. 
Loss of ERK3 leads to reduced lung cell proliferation (pulmonary hypoplasia) and 
abnormal maturation of the distal lung epithelium from an early stage in pulmonary 
development. Additionally, loss of ERK3 leads to a 10-15% reduction in fetal growth, 
along with a 25-40% reduction in the absolute weight of the lung, liver, and heart of 
E18.5 embryos. Also, serum levels of insulin like growth factor 2 (IGF-2) are reduced in 
ERK3-/- mice [74]. Like ERK3, IGF-2 has been implicated in fetal growth. IGF-2 
knockout mice show a 40% reduction in body weight compared to wild type littermates 
and this growth retardation begins in the embryonic period [75]. Evidence of 
intrauterine growth restriction (IUGR) in ERK3-/- mice, similar to other animal models 
and human population, puts ERK3 knockout mice at a higher risk for diabetes, 
hypertension and coronary heart disease later in life [74]. In humans, IUGR is defined as 
birth weight at or below 2 standard deviations for gestational age or approximating 
10th% gestational-age adjusted birth weight. So it would be interesting to follow 
cardiovascular function in these mice as they age.  
 
iv) JNK 
 Mice deficient in JNK1, JNK2, or JNK3 as well as double knockout of 
JNK1/JNK3 or JNK2/JNK3 survive normally, with the exception of JNK1/JNK2 double 
knockout mice, which are embryonic lethal and show dysregulation of apoptosis in the 
brain. During early brain development, JNK1 and JNK2 regulate region-specific 
apoptosis [76]. In the heart JNK1/2 regulates pro-apoptotic signaling during ischemia-
reperfusion. After ischemia-reperfusion injury in JNK1 or JNK2 knock-out mice as well 
as in mice expressing cardiac specific dominant negative JNK1/2, there was less injury 
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and apoptosis in the heart [77]. In contrast, JNK1 is cardiac protective during episodes 
of acute hemodynamic stress. JNK1 knockout, but not JNK2 or JNK3, mice showed 
increased apoptosis upon acute pressure overload. During periods of longer 
hemodynamic stress, function recovered in JNK1 knockout hearts, which could be due 
to a redundant function of JNK2 [78]. Similarly, an upstream activator of JNK, 
MEKK1, shows a cardiac protective role during periods of acute hemodynamic stress. In 
addition, in MEKK1 knockout mice the activation of JNK is abolished and cell death is 
increased in response to pressure overload [79]. Taken together, the studies described 
above suggest that the JNKs’ pro- and anti-apoptotic signaling is dependent on cell type 
as well as the nature and duration of the stress stimuli.   
NFAT is localized in the cytoplasm and moves into the nucleus upon 
dephosphorylation by calcineurin, which is activated in response to an increase in 
cytoplasmic Ca2+ concentration, where it activates gene expression [80]. JNK negatively 
regulates hypertrophy by phosphorylating NFAT and hence preventing its nuclear 
import. JNK1/2 knockout and cardiac specific dominant negative JNK1/2 mice show 
increased myocardial growth with age and following hemodynamic stress as a result of 
pressure overload due to decreased NFAT phosphorylation. Additionally, the increase in 
pressure overload-induced hypertrophy observed in JNK-deficient mice was diminished 
in a calcineurin-deficient background [81].  
 
v) ERK5/big MAPK (BMK) 1 
 ERK5 knockout mice show embryonic lethality associated with defective blood 
vessel and cardiac development [82]. Myocyte enhancer factor 2 (MEF2)-A, -C, and -D 
transcriptional activity is regulated by ERK5 and they are all well characterized 
substrates of ERK5 [83, 84]. Cardiomyocyte-specific ERK5 knockout mice are viable 
and show no apparent defects [85]. In the heart, ERK5 is pro-hypertrophic, pro-fibrotic 
and anti-apoptotic. Cardiac-specific ERK5 knockout mice show less hypertrophic 
growth and fibrosis, with increased apoptosis, following hypertrophic stimuli. The 
reduction in the hypertrophic growth in ERK5 knockout hearts is due to the reduced 
MEF-2 transcriptional activity [86]. A deficiency in MEK5, the upstream kinase of 
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ERK5, is also embryonic lethal and results in cardiovascular defects with increased 
apoptosis in the heart, head and dorsal region of the embryo [83]. These studies in 
knock-out mice demonstrate the importance of ERK5 in cardiac development and 
function. 

MAPK downstream signaling  
 Downstream of MAPKs are several MAPK-activated protein kinases 
(MAPKAPKs or MKs) such as MK2, MK3, and MK5. All MKs have a single kinase 
domain and have a similar consensus phosphorylation site within their activation loop 
(Ser or Thr followed by proline residue) for phosphorylation by proline-directed kinases 
such as p38 and p38 but not p38 or p38. Based on homology within the kinase 
catalytic domain, all MKs belong to the calcium/calmodulin-dependent protein kinase 
(CaMK) superfamily. MAPKs specifically interacts with their substrates through 
docking domains. All MKs have a similar D domain, a stretch of positively charged 
residues flanked by hydrophobic residues, where p38 binds through its CD motif, 
negatively charged residues flanked by hydrophobic residues [23]. 
 
(a) MK5/MAPKAPK5/PRAK 
 To date MK5 has been shown to be regulated by p38, PKA and ERK3/ERK4. 
 
(i) Regulation of MK5 by p38 
 New et al. and Ni et al. simultaneously identified MK5 and named it PRAK 
(p38-regulated/activated kinase) and MAPKAPK5 (MAPK-activated protein kinase 5), 
respectively [87, 88]. From this point forward, this kinase will be referred to as MK5. 
The mapkapk5 gene codes for a 473 aa protein kinase in humans and mice. Its 
orthologues are present in most of vertebrates but do not appear to be present in C. 
elegans or Drosophila. MK5 is expressed in the heart, brain, placenta, lung, liver, 
skeletal muscle, kidney, and pancreas, and shows a 33% amino acid sequence homology 
with MK2 and MK3. As found in other MKs, MK5 contains a conserved LXTP motif 
where threonine is the single phospho acceptor site. MK5 is phosphorylated at residue 
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Thr-182 by both p38 and p38 in vitro and in vivo. Upon stimulation of HeLa cells 
with pro-inflammatory cytokines or stress such as TNF, PMA, or arsenite, activated 
MK5 phosphorylates Hsp27, in manner which is sensitive to the p38/ specific 
inhibitor, SB203580, suggesting p38 specific activation [88]. In different cell lines 
(COS-1, HEK293, NIH 3T3, and HeLa cells) over-expressing MK5, Seternes et al. have 
shown that MK5 is primarily localized in the nuclear compartment, and shuttles between 
the nucleus and the cytoplasm. MK5 physically interacts with p38/ and upon 
stimulation with arsenite or sorbitol it translocates into the cytoplasm, and this nuclear 
export is sensitive to SB203580, suggesting a p38 dependent nuclear export. For p38 
mediated nuclear export of MK5, its Thr-182 phosphorylation, but not its kinase 
activity, is required, as generation of a kinase dead mutant of MK5, where lysine-51 is 
mutated to a glutamic acid, has no impact on MK5’s ability to move to the cytoplasm. 
Lys-51 is required for ATP binding. Furthermore, MK5 has both a nuclear localization 
signal (NLS) and a nuclear export signal (NES) in its C-terminal. The NLS and D 
domain (p38 binding site) sequences overlap, hence binding of phospho p38 to D 
domain (NLS) of MK5 it may block the binding of importin to the NLS and therefore 
cause nuclear export of MK5 [89, 90]. The subcellular distribution of MK5 in resting 
cells and stimulated cells is shown in Figure 5. 
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Fig. 5. Model for the regulation of MK5’s subcellular distribution. The top panel 
shows unstimulated cells where the NLS on MK5 is in an open conformation and hence 
both p38 and importin may compete for interaction. The lower panel shows stimulated 
cells, where binding of phospho p38 to D domain (NLS) may block the NLS binding to 
importin and moreover, phosphorylation of Thr-182 may cause conformational changes, 
which may lead to activation or unmasking of the NES (adopted from [89]) 

 Li et al. further dissected the regulation of MK5’s subcellular localization by 
p38 and p38 and its effect on proliferation of NIH3T3 cells. p38 and p38 lack an 
NLS and an NES and localize to both the nucleus and the cytoplasm. MK5 alone is 
localized in the nucleus, however when co-expressed with p38, the p38-MK5 
complex showed solely nuclear localization while the p38-MK5 complex was solely 
localized in the cytoplasm. The distinct subcelluar localization of these two complexes 
is determined by two amino acid residues in of p38/: Asp-145 and Leu-156 in p38, 
and Gly-145 and Val-156 in p38 [91]. Based on the crystal structure of p38 and its 
21

                                                                                                                          Introduction                         
complex with MK2 [92, 93], models of the p38-MK5 and p38-MK5 complexes show 
that Leu-156 in p38 and Val-156 in p38 differently affect the conformation of the 
MK5 NLS, and therefore its interaction with p38, but not with p38, may interfere 
with the binding of importin  with the MK5 NLS and prevent its nuclear import. 
Moreover, nuclear localization of MK5 by p38 reduces the proliferation of NIH3T3 
cells and this inhibition is removed with the cytosolic localization of MK5 by p38 [91]. 
This study has shown the importance of MK5’s cellular localization for its physiological 
function and suggests that phosphorylation of MK5 at Thr-182 causes its nuclear export 
thus removing its ability to inhibit cellular proliferation. 
 A greater understanding of the physiologic role of MK5 in mice came from 
studies by Sun et al. who developed a line of mice that did not express MK5 [94]. MK5-
null mice revealed the requirement for MK5 in ras-p38 induced senescence and tumor 
suppression. MK5-null mice on a mixed 129 X C57BL/6 genetic background are viable, 
fertile and show no apparent health or behavioral problems. These null mice are, 
however, more vulnerable to dimethylbenzanthracene (DMBA) induced carcinogenesis. 
DMBA is a well characterized skin carcinogenic mutagen, and after its administration to 
MK5+/+, MK5+/-, and MK5-/- mice, the MK5+/- (40%) and MK5-/- (62%) mice developed 
skin papillomas. More than 90% of DMBA induced skin tumors contain activated Ha-
ras and p38 is shown to play a major role in ras-induced senescence [94]. Other studies 
have shown that oncogene-induced senescence is a major barrier to tumorigenesis [95]. 
Given that MK5 is downstream of p38, this implies a possible role for MK5 in 
oncogene-induced senescence. Western blot and immunohistochemical analysis of 
tumors obtained from MK5+/- and MK5-/- mice were negative for the senescence-
associated -galactosidase (SA--gal), and showed reduced levels of p16INK4A, DcR2, 
and Dec1 senescence markers, which suggests deletion of MK5 abolishes DMBA-
induced senescence and hence promotes the development of tumors. Additionally, 
evidence for MK5’s role in senescence was further strengthened by gain of function 
studies, as MK5-/- primary mouse fibroblasts show expression of senescence markers 
after transduction with an activated ras allele along with the wild-type MK5, but not 
with activated ras and kinase dead mutant of MK5 (Lys-51-Met). Further understanding 
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of the signaling cascade was elucidated following assessment of MK5 activity, which 
was increased in ras and MKK3/6E transfected MEF cells and was inhibited by 
SB203580, an inhibitor for p38/, suggesting that MK5 activity was mediated by p38. 
Furthermore, MK5 regulates oncogene-induced senescence through p53 by 
phosphorylating Ser-37. In addition, reduced p53 activity in MK5-deficient cells was 
correlated with reduced p21WAF1 expression, which was previously shown to increase in 
ras-induced senescence. Moreover, the involvement of MK5 was specific to cancer 
causing conditions in which ras was involved and not in other signaling cascades that 
mediate tumor suppression through p53, as MK5 was not required for DNA-damage-
induced-G1 arrest regulated by p53-p21 signaling [94].  
Similarly, MK5 is implicated in replicative senescence that is associated with 
increased MKK4 abundance. MK5 Ser-93 and p38 phosphorylation were increased in 
senescent human diploid fibroblasts. This was shown to be due to an increase in the 
expression of MKK4, an upstream kinase of p38 and JNK. Conversely, p38 and MK5 
phosphorylation were decreased following over-expression of microRNAs miR-15b, 
miR-24, miR-25, and miR-141, which suppresses MKK4 translation [96]. This data 
further supports the notion that MK5 is involved in senescence. Unfortunately, MK5 
Ser-93 phosphorylation, has never been characterized and is not the site phosphorylated 
by p38, PKA, or ERK3/ERK4 (explained in the following text). These results suggest 
the existence of yet another kinase capable of phosphorylating MK5; however, 
phosphorylation of Ser-93 needs to be validated by site directed mutagenesis. 
 
(ii) Regulation of MK5 by PKA 
 cAMP-dependent protein kinase (PKA) is a tetrameric holoenzyme, which 
consists of two catalytic (C) and two regulatory (R) subunits. cAMP binds to the 
regulatory subunits and causes them to dissociate from the catalytic subunits, leaving the 
catalytic subunits free to phosphorylate its substrates. Cyclic AMP (cAMP) functions as 
an intracellular second messenger to transmit extracellular signals [97]. Gerits et al. have 
shown that PKA mediates microfilament rearrangement in PC12 cells through 
phosphorylation and nuclear export of MK5. Endogenous or exogenously expressed 
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MK5 showed cytoplasmic translocalization upon treatment with forskolin or co-
expression of the catalytic subunit of PKA tagged with a nuclear localization signal (C-
NLS) [98]. Forskolin is a diterpene obtained from an Indian plant, Coleus forskohlii, 
which directly activates adenylate cyclase, and increases cAMP levels that leads to the 
activation of PKA [99]. Over-expressed MK5 and the C subunit of PKA physically 
interact, allowing PKA to phosphorylate MK5 and increase its activity, while similar 
interaction between MK2 and PKA was not observed [98]. In contrast to a previous 
study where the nuclear export of MK5 mediated by p38 was dependent on Thr-182 
phosphorylation and not on its activity (MK5 Lys-51-Glu mutant) [89, 90], PKA-
mediated MK5 nuclear export requires both Thr-182 phosphorylation and kinase activity 
[98], suggesting differential requirements for nuclear export in signaling mediated by 
p38 and PKA. Dependence on MK5 kinase activity for PKA mediated nuclear export 
suggests the involvement of an MK5 substrate in nuclear export, which would require 
the identification of MK5’s substrate(s) and their possible role(s). Additionally, siRNA-
induced knockdown of MK5 inhibited the PKA mediated F-actin remodeling, 
suggesting MK5 is essential for this microfilament rearrangement [98]. Recently 
Kostenko et al. further elaborated the above findings in a similar cell line, showing that 
PKA-MK5 mediated F-actin rearrangement requires Hsp27 phosphorylation by MK5 
[100]. It is well known that the non-phosphorylated form of Hsp27 binds to the barbed, 
growing ends of actin filaments, which stabilizes them and inhibits further 
polymerization. Upon phosphorylation, Hsp27 no longer binds to actin, thus allowing F-
actin remodeling [101]. Numerous stimuli activate F-actin remodeling through 
p38/MK2 mediated Hsp27 phosphorylation [102]. However, p38 MAPK and MK2 were 
not activated following forskolin treatment, where PKA-MK5-Hsp27 mediates F-actin 
rearrangement [100], suggesting the possible existence of different mechanisms for 
regulation of microfilament rearrangement depending on the stimuli. In contrast, PKA 
has been shown to phosphorylate MK5 at Ser-115, causing it to translocate to the 
cytoplasm, and induce Hsp27 phosphorylation-dependent cytoskeletal remodeling. This 
process is independent of Thr-182 phosphorylation and MK5 kinase activity [103], 
which was shown to be required, by the same group, in PKA mediated nuclear export 
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[98]. Two different models have been proposed to explain this ambiguity. The first 
model implies that, Ser-115 might be inaccessible for PKA following Thr-182-Ala and 
Lys-51-Glu mutation because of conformational changes, while the second model 
suggests Ser-115 might be phosphorylated by PKA, but because of conformational 
changes induced by these mutations, NES exposure is prevented and MK5 remains 
within the nucleus. Moreover, nuclear export of MK5 mediated by p38, ERK3, and 
ERK4 do not require Ser-115 phosphorylation [103]. This makes Ser-115 a unique 
phosphorylation site, which is only regulated by PKA and not by other MK5 kinases. 
But again this was done in an over-expressed cellular environment and needs to be 
confirmed under more physiological conditions, which may reveal a role of MK5 in beta 
adrenergic signaling in the heart.  
14-3-3 proteins are acidic dimeric proteins that recognize phosphorylated or non-
phosphorylated Ser/Thr motifs in a sequence-specific manner and are involved in 
regulation of numerous signaling pathways. 14-3-3 has been shown to negatively 
regulate the F-actin remodeling mediated by MK5. HeLa cells over-expressing MK5 
show increased cell migration due to Hsp27 phosphorylation and F-actin 
polymerization, which was prevented when MK5 was co-expressed with 14-3-3. MK5 
dependent phosphorylation of Hsp27 was inhibited by 14-3-3. Both endogenous and 
exogenously, expressed MK5 and 14-3-3 interact physically, and this interaction 
inhibits MK5’s kinase activity. Conversely, the increase in cell migration observed upon 
transfection with MK5 was further augmented when 14-3-3 expression was knocked 
down using siRNA [104]. The interaction of MK5 with 14-3-3 represents an important 
mechanism for the negative regulation of MK5 activity. 
 Gerits et al. analyzed the MK5 promoter region in mouse, rat, and human and 
observed a number of consensus binding sites for transcription factors, but only cAMP-
responsive element (CRE) and heat shock factors were functional in PC12 cells. 
Treatment of cells with forskolin, which increases activity of CRE binding protein 
(CREB), or heat-shock increased MK5 mRNA without any change at protein levels, and 
the increased mRNA levels were not due to change in mRNA stability. Moreover, 
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reduction in CREB levels by siRNA reduced the mRNA levels of MK5, suggesting that 
CREB controls the basal level of MK5 expression [105].  
 
(iii) Regulation of MK5 by ERK3/ERK4 
 Shi et al. have generated a line of MK5 knockout mice by homologous 
recombination [106]. In this line of mice, exon 6, which codes for part of the kinase 
domain, was removed and hence these mice express a catalytically inactive form of 
MK5. Moreover, this deletion makes MK5 less stable, likely due to protein misfolding. 
The MK5 functional knockout mice described by Shi et al. and the MK5 null mice 
discussed above [94] are in a similar mixed 129 X C57BL/6 genetic background. Both 
the MK5 functional knockout and MK5-null mice are viable, fertile, and show no 
abnormalities in behavior, tissue morphology, or health. However, after back-crossing 
129 X C57BL/6 MK5 functional knockout mice onto a C57BL/6 genetic background, 
MK5 functional knockout mice showed embryonic lethality and were under represented 
after E12 [107]. Hence, depending on genetic background, the absence of MK5 activity 
may be embryonic lethal. As MK2 and MK5 are both downstream of p38 and have been 
shown to phosphorylate Hsp25 (mouse homologue of Hsp27), Shi et al. compared the 
phenotype of MK5-/- and MK2-/- mice. Unlike deletion of MK2, the absence of MK5 
activity had no effect on 1) lipopolysaccharide (LPS)-induced biosynthesis of cytokines 
such as tumor necrosis factor (TNF), interleukin-6 (IL-6), and gamma interferon (IFN-
), 2) cell migration, and 3) p38 stability. Moreover, when over-expressed MK5, unlike 
MK2, fails to physically interact with endogenous p38 in HEK 293 cells. Furthermore, 
the ability of arsenite to induce Hsp25 phosphorylation was abrogated in MEF cells 
deficient with MK2 but not MK5 [106]. This study has shown the differential functional 
properties of MK2 and MK5, and raised serious doubts regarding MK5’s role in 
downstream p38 signaling and its ability to phosphorylate Hsp25 in vivo. 
 The studies of Seternes and Kant et al. were a major breakthrough in our 
understanding of MK5 as well as ERK3/ERK4 signaling. These authors showed that 
MK5 is regulated by atypical MAPKs ERK3/ERK4 [63, 108]. Using a yeast two-hybrid 
assay, Seternes et al. found that MK5 interacts with ERK3. They have also shown that a 
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physical interaction with MK5 is required to maintain endogenous ERK3 protein levels 
and that ERK3 is able to phosphorylate and activate of MK5. Further experiments in 
RAW 264.7 cells showed a direct interaction between ERK3 and MK5, whereas no such 
interaction was observed between endogenous MK5 and p38. On the other hand ERK3 
fails to interact with MK2, MK3, MSK1 or MNK1, which are structurally related to 
MK5.  Heterologously expressed ERK3 was localized in both the nuclear and 
cytoplasmic compartments while MK5 was mainly nuclear. However, when co-
expressed, MK5 and ERK3 both co-localized to the cytoplasm, and this change in 
localization did not require the kinase activity of either ERK3 or MK5, or MK5 Thr-182 
phosphorylation [108], which was shown to be essential for p38-mediated nuclear 
export [89, 90]. Additionally, ERK3 binds to the C-terminal of MK5, downstream of its 
NLS where p38 binds [108]. This suggests different regulation of MK5 by p38 and 
ERK3 in terms of both their physical interaction and cellular redistribution. Similar to 
p38, ERK3 has been shown to phosphorylate MK5 on Thr-182 and increase its 
activation. Primary MEF cells derived from ERK3 knock-out mice showed a 25% 
reduction in MK5 activity in ERK3+/- and a 50% reduction in ERK3-/- cells compared to 
ERK3+/+ cells, without any change in protein levels [108]. This suggests that in vivo 
MK5 is regulated by ERK3. The 50% of MK5 activity that remained in the absence of 
ERK3 raises the possibility that other kinases are also involved. In addition, as 
mentioned above, the physical presence of MK5 is required for the stabilization of 
ERK3. Reducing MK5 expression using siRNA dramatically reduced the endogenous 
level of ERK3, and this was overcome by transfecting with MK5. Furthermore, a 
constitutively active mutant of MK5 phosphorylated ERK3 [108], suggesting that ERK3 
is a substrate as well as kinase for MK5.   
 Concurrently, Schumacher et al. also showed an interaction between MK5 and 
ERK3; however, they observed a cytoplasmic localization of ERK3 when expressed in 
HEK293 cells. They further showed that the site in ERK3 phosphorylated by MK5 is 
not Ser-189, the known phosphorylation site in the ERK3 S-E-G motif. ERK3 and MK5 
interact through their C-terminal amino acids 301-358 (ERK3) and 369-473 (MK5). 
Moreover, MK5-/- MEF cells had reduced levels of ERK3 [107], showing requirement 
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of MK5 for stabilization of ERK3. The catalytic activity of MK5 is required for its Thr-
182 phosphorylation, suggesting that ERK3 binding promotes the autophosphorylation 
of MK5 [107].  
During embryogenesis ERK3 mRNA expression peaks at day E11 and a similar 
pattern of expression was observed for MK5 mRNA, reinforcing the concept that a 
direct interaction with MK5 is required for ERK3 stability [107]. Other studies have 
shown that ERK3 accumulates during cell differentiation and that augmented ERK3 
levels inhibit cellular proliferation by inducing G1 arrest [59]. These observations 
suggest a possible role for ERK3-MK5 signaling during mouse development. 
 Similar to ERK3, MK5 interacts with and is regulated by another atypical kinase, 
ERK4 [63, 108]. When expressed in HEK 293 cells, ERK4 localizes to the cytoplasm 
and upon co-expression with MK5, which mainly localizes in the nucleus, led to the 
export of MK5 from the nucleus. The kinase activity of ERK4 is essential for MK5 
activation but not for its translocation. Similar to ERK3, ERK4 is phosphorylated by 
activated MK5 and binds at the same amino acid residues (e.g., 369-473) in the C-
terminus of MK5. However, in contrast to ERK3, the phosphorylated form of ERK4 
migrates slower on SDS-PAGE than the non-phosphorylated form [63]. Ablation of 
ERK3 by homologous recombination or siRNA-mediated knock down resulted in a 50% 
reduction in MK5 activity [108], and a similar reduction in MK5 activity was observed 
in siRNA mediated knock down of ERK4. Moreover, a combined siRNA-mediated 
knock down of both ERK3 and ERK4 resulted in a 80% reduction in MK5 activity [63], 
suggesting that both ERK3 and ERK4 are physiological regulators of MK5 activity. 
Unlike ERK3 [108], ERK4 is a stable protein and does not require the chaperoning 
activity of MK5 [63]. Over-expressed ERK4 forms a complex with ERK3. At 
endogenous levels, ERK4 interacts with MK5 in an ERK3-deficient background, as 
does ERK3 in an ERK4-deficient background [62, 63]. These observations suggest that 
MK5 interacts independently with either ERK4 or ERK3. It remains to be determined 
whether 1) MK5 exists in two separate complexes (e.g., ERK3-MK5, ERK4-MK5), 2) 
that MK5, ERK3, and ERK4 can form a single complex, or 3) if there is a pool of 
ERK3-ERK4 complexes without MK5.  
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 The typical MAP kinases (ERK1/2, p38, JNK) are activated by dual 
phosphorylation within a T-X-Y motif in the activation loop. Atypical MAPKs ERK3 
and ERK4 contain an S-E-G motif and have a single phospho-acceptor site, Ser-189 in 
ERK3 and Ser-186 in ERK4, within their activation loop. Independent of ERK4 or MK5 
kinase activity, over-expressed ERK4 is phosphorylated on Ser-186, suggesting the 
existence of an ERK4 kinase. Furthermore, this phosphorylation does not change 
following cellular treatment with extracellular stimuli such as PDGF, newborn calf 
serum (NCS), PMA, arsenite, H2O2, or UV-C, which activate the classical MAPKs 
[109]. Phosphorylated ERK4’s  reduced electrophoric mobility [63]  is not the result of 
Ser-186 phosphorylation, but is due to MK5-mediated phosphorylation at another site 
[109]. Moreover, co-expression of MK5 and ERK4 increased the phosphorylation of 
ERK4 at Ser-186; however, this phosphorylation does not require catalytically active 
MK5 [109]. This could be a result of MK5 protecting the site from dephosphorylation 
or, alternatively, the binding of MK5 to ERK4 might assist in the recruitment or 
activation of ERK4 Ser-186 kinase. Phosphorylation of ERK4 at Ser-186 is required for 
it to act as a substrate, for cytoplasmic anchoring, and activation of MK5. ERK4 and 
MK5 form a weak complex that is stabilized following Ser-186 phosphorylation in vivo 
and results in the phosphorylation and activation of MK5, which in turn phosphorylates 
ERK4 (site other than Ser-186), and results in a mobility shift [109].  
Concurrently Deleris et al. showed that ERK3 and ERK4 are phosphorylated on 
their S-E-G motif (Ser-189 for ERK3 and Ser-186 for ERK4) in resting cells and this 
phosphorylation is required for binding, activation and translocation of MK5 [65]. 
Similar to ERK4 [109], ERK3 phosphorylation of Ser-189 does not change following 
treatment with extracellular mitogenic or stress stimuli. A combination of 
phosphopeptide mapping and tandem mass spectrometric analysis showed the Ser-386 
phosphorylation site in ERK3/ERK4, which is conserved and could be the site for MK5 
mediated phosphorylation, lies in a putative MK5 consensus sequence, but this still 
needs more direct evidence [65]. 
Aberg et al. identified specific interaction sites in MK5 as well as in 
ERK3/ERK4 and gave detailed (molecular) insight into the MK5-ERK3 and MK5-
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ERK4 interaction [110]. Two separate C-terminal regions, encompassing residues 383-
393 and 460-465 in MK5 are required for it to interact with ERK3 and ERK4. Co-
expression of a  deletion mutant of ERK3 or ERK4 in either of these regions prevents 
the translocation of MK5. Unlike p38, the ERK3 and ERK4 CD and ED domains do not 
participate in the interaction with MK5. Peptide overlay assays have identified the MK5 
interaction motif (FRIEDE) in ERK3 (332-337) and ERK4 (328-333), which is in the 
L16 extension loop lying C-terminal to the CD domain [110]. The L16 loop of MAPKs 
has been proposed to be a protein-protein interaction motif required for 
homodimerization [111, 112]; however, the findings of Aberg et al. suggest it is 
involved in binding with its substrate. The substitution of isoleucine to lysine in the 
FRIEDE motif of ERK3 or ERK4 completely abrogates binding, activation, and 
translocation of MK5. Molecular modeling using the crystal structure of phosphorylated 
and unphosphorylated ERK2 suggests that phosphorylation of the ERK4 S-E-G motif 
results in a conformational change of the protein and exposure of Ile-330, concealed by 
the C helix in unphosphorylated ERK4, so that it is free to interact with MK5. The 
requirement of phosphorylation within the activation loop (S-E-G) and the resulting 
accessibility of the interaction motif (FRIEDE) suggests a switch mechanism whereby 
phosphorylation of the activation loop of ERK3/ERK4 regulates its interaction with 
MK5 [110]. The model for the activation of the ERK3/ERK4-MK5 complexes is shown 
in the Figure 6. 
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Fig. 6. A model of the activation of ERK3/ERK4-MK5 complexes. MK5 binds 
weakly to ERK3/ERK4, which helps to recruit a Ser-189/Ser-186 phosphorylating 
kinase. Alternatively, interaction with an ERK3/ERK4-kinase results in phosphorylation 
at Ser-189/Ser-186 phosphorylation, exposure of the interaction motif (FRIEDE), and 
subsequent recruitment of MK5. Activated ERK3/ERK4 phosphorylates Thr-182 on 
MK5, which fully activates MK5 and induces the phosphorylation of ERK3/ERK4 
probably on Ser-386 (acquired from [65]). 

Hansen et al. recently demonstrated an interaction between Cdc14A and ERK3, 
which affects the subcellular localization of MK5 [71]. Cdc14 is a serine/threonine 
phosphoprotein phosphatase. In humans cdc14 exists as two homologues, hCdc14A and 
hCdc14B, which differ within their C-terminal domain but have around 50% sequence 
identity within their catalytic domains. hCdc14A plays a role in the centrosome cycle, 
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mitosis, and cytokinesis and is selective for Cdk substrates [113]. Concerning ERK3 and 
hCdc14A, they form a complex when over-expressed in human U2-OS osteosarcoma 
cells and formation of this complex is independent of the phosphatase activity of 
hCdc14A. When over-expressed, both ERK3 and hCdc14A co-localized in interphase 
cells centrosome. hCdc14A dephosphorylates Cdk-mediated phosphorylation of ERK3 
within the region 316-721 [71], and hence does not alter phosphorylation at Ser-189. 
Furthermore, like ERK3/ERK4, the binding of hCdc14A to MK5 is independent of its 
catalytic (phosphatase) activity and results in the accumulation of MK5 in the 
cytoplasm. To date, it remains unclear whether hCdc14A interacts directly with MK5 or 
indirectly via binding to ERK3 [71]. 
 
(iv)   Pharmacological inhibitors of MK5 
Recently, several new MK5 inhibitors have been discovered such as 
noroxoaconitine, flavokavain A, epigallocatechin gallate (EGCG), GLPG0259, PF-
3644022[(10R)-10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-[1,4] 
diazepino[5’,6’:4,5]thieno[3,2-f]quinolin-8-one] and 2-(2-quinolin-3-ylpyridin-4-yl)-
1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one, which may help stimulate further 
research  and lead to therapies involving diseases where MK5 activity is implicated. The 
diterpenoid alkaloid noroxoaconitine inhibits MK5 activity (IC50=37.5M) against 
PRAKtide (MK5 substrate peptide) or Hsp27 and inhibits PKA-induced cytoplasmic 
localization. This compound also inhibits MK3 but not MK2 activity [114]. Similar to 
noroxoaconitine, flavokavain A (IC50=10 M) from kava inhibits MK5 and MK3 
activity but not MK2 [115]. Epigallocatechin gallate, derived from green tea, also 
inhibits MK5 activity (IC50 10 M) but its effect on MK2 and MK3 was not tested 
[116]. The potent MK2 inhibitor, 2-(2-quinolin-3-ylpyridin-4-yl)-1,5,6,7-tetrahydro-4H-
pyrrolo[3,2-c]pyridine-4-one (IC50=8.5 nM) is also able to inhibit MK5 (IC50=81 nM) 
more potently than the MK3 (IC50=210 nM) [117]. Similarly, PF-3644022 inhibit MK2 
and MK5 (IC50=5 nM) more potently than the MK3 (IC50=53 nM) [118]. Recently, 
Galapagos pharmaceutical have developed MK5 inhibitor GLPG0259 for use in the 
treatment of rheumatoid arthritis (RA). This compound has shown a good safety profile 
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in phase I studies and full results of phase-II clinical trials are expected in end of 2011 
(http://www.glpg.com/pharmaceuticals/ra.htm).  
 
(v) MK5 in the heart 
 Apart from its expression at mRNA and protein level [63, 88, 105] nothing is 
currently known about the role of MK5 in the heart. 
 
(b) MK2/MAPKAPK2 
 MK2 is considered to be a major downstream effector of p38 MAPK and it 
controls p38-mediated inflammatory regulation in immune cells. MK2 knockout (MK2-/-
) mice made by homologous recombination showed no apparent abnormalities in 
behavior, and they were viable and fertile, although they were resistant to LPS induced 
endotoxic shock. The increased resistance to stress was due to decreased production of 
cytokines such as tumor necrosis factor (TNF)- and interleukin (IL)-6. Following 
treatment with LPS, MK2-/- mice showed no increase in Hsp25 phosphorylation in the 
heart, suggesting that MK2 is the major kinase for Hsp25 in vivo [119]. MK2 controls 
the stability of IL-6 mRNA and inhibits the translation of TNF mRNA through the AU-
rich element (ARE) in the 3’untranslated region (3’UTR) of these cytokines’ mRNA 
[120]. MK2 is able to control the stability of these mRNAs through the phosphorylation 
of RNA-binding proteins such as tristetraprolin (TTP). TTP binds to the ARE in the 
3’UTR of mRNA and directs their degradation. Upon phosphorylation by MK2, TTP 
binds to a 14-3-3 protein and hence is unable to bind to and destabilize mRNA [102]. 
Along with TNF and IL-6, MK2 also controls the stability of IL-8, urokinase 
plasminogen activator (uPA), and cyclooxygenase-2 [121, 122].   
In addition to regulating the stability and translation of mRNA as mentioned 
above, MK2 also controls gene transcription through the phosphorylation of 
transcription factors such as serum response factor (SRF), CREB, and activating 
transcription factor (ATF). In fibroblasts derived from MK2 knockout mice, upon 
treatment with arsenite, there was no phosphorylation of SRF, suggesting MK2 
mediated regulation of SRF [123]. SRF also controls serum response element (SRE) 
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containing promoter activity of immediate early genes such as c-fos [124]. In addition to 
MK2, SRF phosphorylation is also under the control of ribosomal S6 kinase p90rsk, 
which is activated by serum via ERK, and CaM kinase II and IV, which are activated by 
increases in intracellular calcium concentration [125, 126]. Moreover, CREB and ATF-1 
transcriptional activity is controlled by MK2 phosphorylation in response to fibroblast 
growth factor (FGF) or stress [127]. MK2 and p38 mutually stabilize each other, as the 
protein level of p38 was significantly reduced in an MK2-deficient background, and 
similarly MK2 protein levels were reduced in p38-deficient embryonic fibroblasts 
[128, 129]. 
Streicher et al. demonstrated the importance of MK2 in MKK3-p38 signaling in 
the heart. These authors selectively induced the expression of activated MKK3 in the 
heart, which activated p38. These studies were performed in both MK2+/+ and MK2-/- 
mice. Induction of activated MKK3 led to cardiac hypertrophy, extracellular matrix 
remodeling, contractile dysfunction, activation of hypertrophic gene markers (ANP and 
-MHC), and lethal bradycardic heart failure within 8 days. However, removal of MK2 
in an activated MKK3 background rescued some aspects of the above pathological 
response, such as partially ameliorated hypertrophy and contractile dysfunction, and 
prevention of early lethality due to lethal bradycardic heart failure. Hence some of the 
pathological responses of p38 signaling are mediated by MK2. Additionally, these 
authors also noted that MK2 is involved in the regulation of COX-2 protein synthesis 
without having any effect on mRNA levels [37]. Inhibition of p38/ activity by 
SB203580 reduces apoptotic cell death in cultured myocytes and in intact heart upon 
exposure to pressure overload or ischemia/reperfusion [38, 39]. MK2-/- hearts have been 
shown to be resistant to myocardial ischemic reperfusion injury in terms of reduced 
myocardial infarct size, low number of apoptotic cardiomyocytes, and hence higher 
recovery of post-ischemic ventricular performance [130]. These observations further 
indicate that MK2 mediates some of the detrimental downstream effects of p38 
activation in the heart. 
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(c) MK3/3pK/MAPKAPK3 
 MK3 and MK2 are both serine/threonine protein kinases, share 75% sequence 
identity and have extensive similarity in terms of structure, substrate specificity, and 
regulation by upstream kinases [102]. Additionally, in vivo MK3 shows redundant 
functions to MK2. Ronkina et al generated MK3 knockout mice, which were viable and 
showed no apparent abnormal tissue morphology [131]. Unlike MK2 knockout mice 
[132], MK3 knockout mice did not show reduced levels of TNF, p38, or tristetraprolin, 
although double knockout of MK2 and MK3, showed further reduction in p38 stability, 
and in TNF, or tristetraprolin expression compared to MK2 knockout mice. Moreover, 
over-expression of MK3 in MK2 knockout MEF cells rescued Hsp25 phosphorylation 
upon stress, and prevented p38 breakdown [133]. The observed lack of a robust effect in 
MK3 knockout mice similar to MK2 knockout mice could be because of lower cellular 
MK3 expression levels and activity compared to MK2 [134].     
 
V) Extracellular matrix (ECM) regulation during cardiac hypertrophy 
 The quantity and quality of collagen in terms of its synthesis, cross-linking, and 
degradation are highly important for filling and ejection properties and the overall 
function of the heart. Fibrosis impairs both systolic and diastolic cardiac function. 
During hypertrophy, diastolic heart failure is coupled with an increase in collagen, 
whereas ventricular dilatation and systolic heart failure are coupled with degradation of 
collagen [6].  
 
a) ECM synthesis during cardiac hypertrophy 
 In the hypertensive heart, reactive and reparative fibrosis occur because of the 
expansion of the ECM [135]. In the normal heart, fibroblasts synthesize the ECM 
proteins. However, in pathological conditions, morphologically distinct cells, 
myofibroblasts, appear. These cells have specific characteristics: they are fibroblast-like 
in term of their expression of ECM proteins and smooth muscle-like in terms of 
migration and expression of -SMA. Fibroblast-to-myofibroblast differentiation and 
myofibroblast-mediated collagen turnover is regulated by autocrine and paracrine 
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factors produced in the myocardium as well as endocrine hormones from the circulation 
[6, 136]. The alteration in myocardial diastolic function because of increased stiffness 
during hypertension results from both an increase in myocardial total collagen content 
[137] and an increase in the amount of the collagen subtype with high tensile strength, 
type I, relative to other major subtype, type III [138]. The tensile strength of type I 
collagen, and its ability to withstand tensile stress, approximate that of steel [139]. 
Moreover, the increase in myocardial stiffness is also associated with an increase in 
collagen cross-linking [140].  
Transforming growth factor- (TGF-) has a major influence on fibroblast 
proliferation, their phenotypic conversion to myofibroblasts, and synthesis and secretion 
of ECM proteins including  collagen, fibronectin, and proteoglycans [141]. TGF- at the 
same time reduces the degradation of ECM by inhibiting the expression of matrix 
metalloproteinase (MMP) and by inducing synthesis of protease inhibitors, such as 
Plasminogen Activator Inhibitor-1 (PAI-1) and Tissue Inhibitors of Metalloproteinases 
(TIMPs) [142].  There are three TGF isoforms, TGF-1, TGF-2, and TGF-3, which 
are secreted by cells in their inactive form. The activity of mature TGF- is masked by 
non-covalent interaction with a dimer of its N-terminal pro-peptide, called latency 
associated protein (LAP), which is often linked with latent TGF- binding protein 
(LTBP) by a disulphide bond. Formation of this complex increases the stability of TGF-
 and targets it to the ECM and the cell surface. The inactive TGF- complex is 
activated by its proteolytic cleavage by plasmin or thrombospondin-1 (tsp-1) [143, 144]. 
Once activated, TGF-1 mediates its signaling through the activation of its receptor 
(TGF- receptor type 1 and type 2), which phosphorylate Smad 2 and 3. Co-Smad 
(Smad 4) binds to phospho Smad 2/3 and translocates to the nucleus where it acts as a 
transcription factor.  Smad’s transcriptional control depends on its interaction with co-
repressors or co-activators. Inhibitory Smads, Smad6 and/or Smad 7, compete for 
binding of Smad 2 and 3 to the type 1 receptor and prevent its activation as well as 
increase receptor degradation (reviewed in [145]). TGF-1 deficient mice show a 
marked reduction in collagen deposition and TGF-1 itself is insufficient to produce 
persistent fibrotic responses in vivo or in vitro. Synergy between TGF- and other 
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extracellular ligands, such as connective tissue growth factor (CTGF) and endothelin-1 
(ET-1), is required to induce and increase in interstitial fibrosis [146].  
The lack of complete prevention of bleomycin-induced pulmonary fibrosis, an 
animal model of idiopathic pulmonary fibrosis (IPF), by a TGF- antagonist, led Oga et 
al to discover TGF- independent regulation of IPF by prostaglandins in prostaglandin F 
(PGF) receptor (FP) knockout mice. They observed an attenuation of pulmonary fibrosis 
in FP knockout mice compared to wild type mice, where TGF- activity and 
downstream Smad phosphorylation were unaltered. Interestingly, FP deficiency and the 
TGF- receptor I kinase inhibitor SD-208 show additive effects with respect to reducing 
fibrosis, suggesting independent regulation of pulmonary fibrosis by these pathways. 
Moreover, the regulation of collagen expression by PGF2-FP involved Rho kinase-
ROCK (Rho-associated kinase) activity [147]. The regulation of fibrosis in other organs 
such as kidney, heart, liver, and skin are  the same as in the lung [148], so extrapolation 
of these studies in the cardiac fibrosis requires further study.   
 
b) ECM degradation during cardiac hypertrophy 
 ECM degradation is carried out by different matrix metalloproteinases (MMPs). 
The heart contains MMP1, MMP8, and MMP13. MMP13 initiates the process of ECM 
degradation by cleaving the -chain of type I and type II collagen. MMP2 and MMP9, 
then further process the collagen fragments [149]. MMPs are synthesized and secreted 
into the extracellular space as inactive pro-enzymes (pro-MMPs), that bind to specific 
extracellular proteins and stay inactive until their pro-peptide domain is cleaved by 
serine proteases, secreted MMPs, or the highly related membrane-type MMPs. MMPs 
are also regulated at the transcriptional level by hormones, cytokines, growth factors, 
and mechanical strain. Moreover, active MMPs are inhibited by TIMPs, which bind to 
the catalytic domain of MMPs and thus block substrate binding. There are four species 
of TIMPs, TIMP1-4, and they are regulated at the transcriptional level (reviewed in [9]). 
A growing number of studies show an increase in fibrosis causes diastolic heart failure 
with preserved systolic function, whereas degradation of collagen scaffolding by altered 
ratio of MMPs/TIMPs causes ventricular dilatation and reduced ejection fraction or 
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systolic heart failure. Laviades et al. detected increased levels of circulating TIMP1 and 
reduced levels of circulating MMP1 and collagen type 1 telopeptide (a product of 
collagen degradation) in patients with left ventricular hypertrophy [150]. In contrast, the 
MMP1:TIMP1 ratio was increased in tissue and serum samples of patients diagnosed 
with systolic heart failure and MMP1 levels were higher in patients with systolic heart 
failure compared to those with diastolic heart failure [151]. 
 
c) Regulation of ECM by microRNA 
 MicroRNAs (miRNAs) are small ribonucleic acid molecules of approximately 
22 nucleotides in length that act as gene silencers by inhibiting mRNA translation or 
promoting mRNA degradation. Many miRNAs are expressed in a cell- and tissue-
specific manner and there is currently estimated to be more than 1000 miRNAs encoded 
by the human genome [152]. In the heart, several miRNAs have been implicated in the 
regulation of fibrosis, such as mir-21, -29, -30, and -133.  Thum et al. have shown that 
mir-21 regulates fibrosis and hypertrophy, and implicated in regulation of ERK1/2. Mir-
21 levels are increased in fibroblasts of failing hearts. Mir-21 increases ERK1/2 activity 
through expression inhibition of Sprouty homolog 1 (Spry 1), a negative regulator of the 
ERK1/2 pathway. This results in fibroblast proliferation and fibrosis. Conversely, 
specific antagomir-mediated silencing of mir-21 in pressure overload-induced 
hypertrophy results in reduction of ERK1/2 activity, inhibition of interstitial fibrosis, 
and attenuation of cardiac dysfunction. Interestingly, mir-21 not only attenuates the 
hypertrophy and fibrosis induced by pressure overload, but actually reverses stress-
induced cardiac remodelling [153]. Moreover, mir-30 and mir-133 have been shown to 
regulate the expression of CTGF, a key pro-fibrotic factor. Mir-133 is expressed solely 
in cardiomyocytes while mir-30 is expressed in both cardiac fibroblasts and 
cardiomyocytes. CTGF expression is increased in mir-30 and mir-133 knock-down 
cardiomyocytes and fibroblast. Conversely, over-expression of these miRNAs decreased 
both CTGF and collagen expression. Additionally, in humans the expression of CTGF 
and mir-30 and mir-133 is inversely related in the extent of left ventricular hypertrophy 
[154]. Furthermore, to add to the growing number of miRNAs implicated in cardiac 
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disease, van Rooij et al. have shown the involvement of mir-29 in the expression of 
multiple ECM proteins, including collagens, fibrillins, and elastin. The mir-29 family of 
miRNAs are down regulated in regions adjacent to an infarct and down-regulation of 
mir-29 with anti-mirs in vitro and in vivo induces collagen expression. In contrast, over 
expression of mir-29 in fibroblasts reduces collagen expression [155]. Taken together, 
these studies provide an interesting insight into the regulation of cardiac remodelling by 
miRNAs, which can be exploited by manipulating miRNA levels for therapeutic 
purposes in pathological cardiac remodelling and heart failure. 
                                                                      
MATERIALS AND METHODS 

I) Materials 
Membrane grade (reduced) Triton X-100 (TX-100), leupeptin, and PMSF were from 
Roche Molecular Biochemicals, SDS-Polyacrylamide gel electrophoresis reagents, 
nitrocellulose, and Bradford protein assay reagents were from Bio-Rad Laboratories. 
The cAMP-dependent protein kinase inhibitor peptide (PKI, amino acid sequence 
TTYADFIASGRTGRRNAIHD) was from the University of Calgary Peptide Synthesis 
Core Facility. Canine hsp27, cloned into the pET24a expression vector [156], was a gift 
from Dr. William Gerthoffer (Reno, NV). His6-ERK3-GST, cloned into the pHGST.1 
expression vector was a gift from Dr. Sylvain Meloche [157]. Anti-GST from GE health 
care (27-4577-01), anti-EGFP was from BD Biosciences (# 8371-1), anti-MK5 (PRAK 
A-7) was from Santa Cruz Biotechnology (sc-46667), anti-V5 was from Invitrogen 
(R960-25), anti-Hsp27 was gift from Dr. William Gerthoffer (Reno, NV), anti-p38was 
from Santa Cruz Biotechnology (sc-535), anti-p38 was from upstate (#07-474), anti 
p38 was from cell signaling (#2308), anti-p38 was a gift from Dr. Jacques Landry, 
anti phopho-p38 MAPK was from cell signaling (#2911S), anti phospho-Hsp27 (S-82) 
was from cell signaling (#2401S), anti-phospho Hsp27 (S-15) was from Stressgen 
(SPA-525), anti-ERK3 (D-23) was from Santa Cruz Biotechnology (sc-155), anti-ERK4 
(N-20) was from Santa Cruz Biotechnology (sc-68169),  anti-GAPDH was from 
Ambion (#4300), alexa fluor secondary antibodies were from invitrogen, primers were 
synthesized from Invitrogen. HRP-conjugated secondary antibodies were from Jackson 
ImmunoResearch Laboratories. All other reagents were of analytical grade or best grade 
available. Plasmids were transformed to E. coli competent strain BL21 (DE3) and 
expression induced by the addition of 1 mM isopropyl--D-thiogalactopyranoside 
(IPTG). GST fusion proteins were purified by affinity chromatography on glutathione 
Sepharose.  
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II) Methods 
1) Total RNA isolation from mouse heart 
Mice were anesthetized with intraperitoneal injection of sodium pentobarbital 
(0.55 mg/ kg body weight). Hearts were then quickly dissected, trimmed, and ventricular 
blood removed after gently pressing the heart on tissue paper. Hearts were frozen in 
liquid nitrogen and total cellular RNA was isolated with RNeasy® Mini kit (Qiagen Inc. 
#74104) with minor modifications. Briefly, tissue was pulverized in mortar pestle in 
presence of liquid nitrogen and then homogenized in 2 ml of TRIzol reagent (Sigma) 
using a Polytron at 10,000 RPM (2 x 15 s). Samples were incubated for 5 min room at 
temperature (RT), 0.4 ml chloroform was added, vortexed and incubated again at RT for 
2-3 min. Following centrifugation for 15 min at 18,300 x g and 4 °C to promote phase 
separation, the aqueous (upper) phase was collected (1.3 ml). For simplification, the 
aqueous phase was divided into two 1.5 micro centrifuge tubes. From this point onward 
all manipulation were done at RT. RNA was precipitated by addition of an equal volume 
of 70% ethanol, immediately applied to Qiagen columns, and centrifuged for 15 sec at 
18,300 x g. Two columns were used for each heart homogenate. Columns were washed 
with 350 l RW1 buffer, centrifuged for 15 sec at 18,300 x g and then incubated with 
RNase-free DNase (27.27 Kunitz units) plus RDD buffer (70 l) for 15 minute. 
Columns were washed again with 350 l RW1 buffer and centrifuged (15 sec, 18,300 x 
g). Column collection tubes were changed and the columns washed twice with 500 l 
RPE buffer twice and centrifuged (15 sec, 18,300 x g). Columns were centrifuged for 1 
min to remove excess RPE buffer. To elute the RNA, collection tubes were changed, 
RNase free water (45 l) added, and the columns incubated at RT for 1 min, and then 
centrifuged at 18,300 x g for 1 min. The purified RNA from two different columns, 
corresponding to RNA isolated from the same heart, were pooled and kept on ice. RNA 
was quantified by determining absorbance (A) at 260 and 280 nm and only samples 
having an A260/A280 ratio greater than 1.8 were used in subsequent studies. RNA 
quality and DNA contamination was assessed by resolving 1 g of each  RNA sample 
on 0.8% agarose gels. A portion of the isolated RNA was used for cDNA synthesis and 
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the remainder was stored at -80 °C. RNA isolations were done as rapidly as possible, 
with no interruptions prior to cDNA synthesis or transfer to storage. 
 
2) Total RNA isolation from heart tissue sections 
After surgery mouse hearts were frozen in liquid nitrogen-chilled 2-methyl 
butane. Hearts were embedded in Tissue-Tek O.C.T. compound (Sakura Finetek USA, 
inc.), longitudinal cryosections (14 m) of the ventricles were prepared, sections 
transferred to 2 ml cryovials wth screw caps and O-rings, and frozen in liquid nitrogen. 
Total cellular RNA was isolated from cryosections using RNeasy® Micro kits (Qiagen 
Inc. #74004) with minor modifications. Total RNA was extracted by vortexing tissue 
section in 300 l TRIzol reagent (Sigma) and 66.7 pg/l carrier RNA for 30 sec, and 
incubated at RT for 5 min. Chloroform (60 l) was added, and tubes were vortexed and 
incubated at room temperature for 2-3 min. Phase separation was promoted by 
centrifugation for 15 min at 18,300 x g and 4 °C. After this stage all subsequent 
manipulations were done at RT. The upper (aqueous, 165 l) phase was collected, RNA 
was precipitated after addition of an equal volume of 70% ethanol, immediately applied 
onto Qiagen columns, and the columns centrifuged for 15 sec at 18,300 x g. Columns 
were washed with 350 l RW1 buffer and centrifuged. Columns were incubated with 
RNase-free DNase I (10 l) plus RDD buffer (70 l) for 15 min. Columns were washed 
again with 350 l RW1 buffer and centrifuged. The column collection tube was changed 
and the columns washed twice with 500 l RPE buffer and centrifuged. Columns were 
the washed with 500 l 80% ethanol and centrifuged at 18,300 x g for 2 min. The 
collection tubes ware changed and the columns centrifuged at 18,300 x g for 5 min with 
opened lids to facilitate the removal of the ethanol. The collection tubes were changed, 
14 l RNase-free water was added, and the columns were centrifuged at 18,300 x g for 1 
min to elute the RNA. As the RNA yeild was small, it was not feasible to quantify total 
RNA. Hence, cDNA synthesis was performed in a 20 l reaction volume containing 
10.9 l total RNA as described in the following section.  
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3) cDNA synthesis 
First strand cDNA synthesis was performed in a 20 l reaction volume containing 
1 g of total RNA, 100 ng of random primers, 1X First Strand buffer (50 mM tris-HCl 
pH 8.3, 75 mM KCl, 3 mM MgCl2), 0.5 mM dNTP, 10 mM DTT, 40 U RNaseOUT 
recombinant ribonuclease inhibitor, and 200 U of M-MLV reverse transcriptase 
(Invitrogen #28025-013) according to the manufacturer’s protocol. Total RNA (1 g) 
was added to microcentrifuge tubes containing 1 l 10 mM dNTP and 0.1 l (1g/l) 
random primers (Invitrogen #48190-011) and the final volume adjusted to 12 l by the 
addition of distilled water. Reaction tubes were heated to 65 °C for 5 min and then 
chilled on ice. Next, 4 l 5X first-strand buffer, 2 l 0.1 M DTT, and 1 l RNaseOUT  
Recombinant Ribonuclease Inhibitor (40 units/l) were added and the tubes incubated at 
37 °C for 2 min. Finally, 1 l (200 units) of M-MLV RT was added, tubes were mixed 
gently, and centrifuged to return the reaction mixture to the bottom of the tubes. cDNA 
synthesis was done in a PCR thermocycler with incubations at 25 oC for 10 min, 37 oC 
for 50 min, and 70 oC for 15 min. 
 
4) Quantitative real-time PCR (qPCR) 
qPCR was performed using a MX3000P QPCR system (Stratagene). Each 
amplification reaction mixture (25 l) contained 6.25 ng cDNA equivalent to reverse 
transcribed RNA, 300 nM forward and reverse primers, 30 nM ROX, 12.5 l platinum 
SYBR green mix (2X) (Invitrogen # 11733-046). qPCR reaction conditions were: 1 
cycle at 95 °C for 10 min, 40 cycles at 95 °C for 30 s, 55 °C for 30 s (temp. and time 
vary as per primer pair; see Table 1), and 1 cycle at 72 °C for 1 min. SYBR green 
fluorescence was measured at the end of the annealing and extension phases of each 
cycle. The specificity of each primer pair for a single amplicon was verified by 
analyzing the dissociation curve. In addition, to verify that the intended sequences were 
being amplified, amplicons were gel-purified and sequenced. The amplification 
efficiency for each primer pair was determined from a standard curve of 50-3.25 ng 
reverse-transcribed RNA isolated from the heart after two-fold serial dilutions. The 
efficiency for each primer pair was between 90-110%. Glyceraldehyde-3-phosphate 
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dehydrogenase (GAPDH) was employed as an internal control. Hence, all samples were 
normalized to GAPDH, which was amplified in parallel in the same run, with MxPro 
software (Stratagene).  
Primers specific for each mRNA of interest were designed using Clone Manager 6 
(Sci Ed Software, USA) and based on the cDNA sequences in the NCBI database: p38 
(NM_011951), p38 (NM_011161), p38 (NM_013871), and p38 (NM_011950), 
MK5 (NM_ 010765), GAPDH (NM_008084), ANP (AK147180), BNP (NM_008726), 
-MHC (AY056464), COL1A1 (NM_007742), TGF-1 (NM_011577), and TGF-3 
(NM_009368). The forward and reverse primers used are shown in Table 1.  
 
5) DH5 chemical competent cells 
DYT media (Tryptone 1.6%, Yeast extract 1%, NaCl 0.5%, pH 7.0) was 
innoculated with DH5 cells and incubated overnight at 37 °C with constant shaking. 
The next day, flasks containing 40 ml DYT media were innoculated with 1ml of 
bacterial culture and incubated 37 °C with constant shaking until the optical density at 
600 nm had reached 0.6. Cultures were then transferred to centrifuge tubes, incubated on 
ice for 15 min, 1 ml of CaCl2 (50 mM) was added, after 2 min. 19 ml of 50 mM CaCl2 
was again added, and the bacteria incubated on ice for 2 hrs. The bacterial suspension 
was centrifuged, the pellet suspended in 1 ml 50 mM CaCl2, and then diluted with an 
additional 3 ml 50 mM CaCl2 after a few min.  After incubation onernight on ice, 150 l 
aliquots of transformed DH5 were prepared in microcentrifuge tubes and frozen using 
an ethanol/dry ice slurry. Aliquots were then stored at -80 °C.   
 
6) Transformation of BL-21 or DH5 competent cells 
An aliquot (25 l) of frozen E. coli competent strain BL21 (DE3) bacteria 
(Novagen) was thawed on ice for 15 min, 1 l of construct was added, and the cells 
were incubated on ice for an additional 30 min. Bacteria were then incubated for 45 s in 
a 42oC water bath and then placed on ice for 2 min. SOC media (500 l) was then added 
and the cells were incubated for 60 min at 37oC with constant shaking. Cells were 
spread onto two DYT agar plates (DYT media + 1.5% agar) containing ampicillin (100 
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g/ml). The choice of antibiotic depends upon antibiotic resistance gene within the 
actual construct. Cells were incubated overnight at 37oC, an antibiotic-resistant colony 
was picked, transferred to a tube containing 10 ml of DYT media plus ampicillin (100 
g/ml), and grown for 6 h at 37 °C. 
Competent BL-21 cells were used for expression of fusion protein while DH5 
cells were used for construct amplification. Transformation of competent DH5 cells 
was as described for BL-21 cells except incubations were at 37 oC, instead of 42 oC. 
Moreover, when the construct contained a chloramphenicol resistant gene, 25 g/ml of 
chloramphenicol was included in the culture media.  
 
7) Cloning of p38 MAPK isoforms 
Human cDNA for p38 was purchased in pOTB7 vector (Open Biosystem), p38 
was in a pCMV-SPORT6 vector (Open Biosystem), p38 (a gift from Dr. Jiahuai Han) 
was in a pET 14b vector and, and p38 was in a pOTB7 vector (ATCC). Full-length 
inserts of each p38 isoform were subcloned into a modified pGEX-6P vector (GE 
Healthcare) in phase with, and located 3’ to, a GST-6His coding sequence as described 
in the following section.  
 
i) Cloning of p38 
E. coli competent strain DH5 was transformed with p38-pOTB7 and the 
plasmid amplified by growing the cells overnight at 37 °C in DYT media contained 
chloramphenicol (25 g/ml). The plasmid was extracted and purified using QIAprep 
spin miniprep kits (Qiagen) as per manufacturer’s protocol. PCR was employed to 
amplify a fragment of p38, extending from the 5’ terminus to the HindIII site, in a 
reaction containing 0.5 g of p38-pOTB7 template, 400 nM forward and reverse 
primers BA108 and BA105 (Table-1), 60 mM Tris-SO4 (pH 9.1), 18 mM (NH4)2SO4, 
1.8 mM MgSO4, and 1 l Elongase enzyme mix (Invitrogen). PCR cycles were: 1 cycle 
at 94 °C for 30 s, 25 cycles at 94 °C for 30 s, 55 °C for 30 s, 68 °C for 30 s and 1 cycle 
at 72 °C for 10 min. In parallel, primer BA106 (Table-1) was used as a template to 
amplify a construct encoding 6 His amino acid residues and BamHI restriction site in a 
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reaction (50 l) containing 400 nM forward and reverse primers BA103 and BA104 
(Table-1), and other reagents as mentioned above. PCR products from both the reactions 
(51 bp DNA from BA 106 and 393 bp DNA from p38-pOTB7) were separated on an 
agarose gel and purified using a QIAquick gel extraction kit (Qiagen). These two 
purified DNAs were mixed together and a PCR carried out using forward and reverse 
primers BA104 and BA105 (Table-1) as described above. The final PCR product (421 
bp DNA) was separated on an agarose gel and purified using a QIAquick gel extraction 
kit. This 421 bp DNA and p38-pOTB7 vector were digested separately with 60 units 
HindIII restriction enzyme, 10 mM Tris-HCl (pH 7.9), 50 mM NaCl, 10 mM MgCl2, 
1 mM DTT, 100 g/ml BSA at 37 °C for 5-6 h and then the restriction enzyme was 
inactivated by heating at 65 °C for 20 min. The HindIII digestion buffer was removed 
from both reactions using Centricon YM-30 centrifugal filtration units (Millipore). Both 
products were then digested with 60 units BamH1 restriction enzyme for 5-6 h at 37 °C 
in a buffer that contained 50 mM Tris-HCl (pH 7.9), 100 mM NaCl, 10 mM MgCl2, 1 
mM DTT, 100 g/ml BSA. The p38-pOTB7 BamH1 digest was then incubated with 
10 units alkaline phosphatase for 1 h at 37 °C. Both the 2539 bp phosphatase-treated 
p38-pOTB7 BamH1 and the 315 bp 6His-p38 5’ fragment were separated on agarose 
gel, extracted, and purified using a QIAquick gel extraction kit. Purified 2539 bp DNA 
vector and 315 bp DNA insert were mixed with a 1:7 ratio and incubated overnight at 16 
°C with 400 units of T4 DNA ligase in 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 1 mM 
ATP, and 10 mM DTT. The final ligated vector was transformed into DH5 competent 
cells, spread on DYT agar contained 25 g/ml chloramphenicol, and grown overnight at 
37 °C. Several antibiotic resistant colonies were picked and used to inoculate DYT 
media contained chloramphenicol. Cultures were grown overnight at 37 °C. Vector was 
then extracted and purified using QIAprep spin miniprep kits (Qiagen). In addition, the 
orientation of the insert within the vector (6His-p38-pOTB7) was confirmed both by 
BamHI and HindIII restriction enzyme digestion and by DNA sequencing.  
The 6His-p38 insert was transfered from pOTB7 into pGEX-6P as described in 
following text. 6His-p38-pOTB7 and pGEX-6P vectors were digested with BamHI as 
described above, separated on agarose gel, and purified using a QIAquick gel extraction 
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kit. Both the vectors were then digested for 5-6 h at at 37 °C with XhoI in 10 mM Tris-
HCl (pH 7.9), 50 mM NaCl, 10 mM MgCl2, 1 mM DTT, 100 g/ml BSA. pGEX-6P 
was then dephosphoryulated with 10 U alkaline phosphatase (1 h, 37 °C). DNA from 
both the reactions were separated on an agarose gel and purified using a QIAquick gel 
extraction kit. The digested and dephosphorylated pGEX-6P vector and digested 6His-
p38 DNA (insert) were ligated (1:3 ratio) as described above using T4 DNA ligase.  
The final ligated product (6His-p38-pGEX-6p) was transformed into DH5, the cells 
grown in DYT media contained 100 g/ml ampicillin, and then the plasmid extracted 
and purified using a QIAprep spin miniprep kit. The orientation and sequence of the 
6His-p38-pGEX-6p insert were confirmed by DNA sequencing. 
 
ii) Cloning of p38 
Human p38 cDNA was excised from pCMV-SPORT6 and inserted in phase, 3’ 
to GST-6His in pGEX-6P bacterial expression vector by cloning as described follows.  
DH5 were transformed with p38-pCMV and grown overnight at 37 °C in DYT 
media containing 100 g/ml ampicillin., p38-pCMV was extracted and purified using a 
QIAprep spin miniprep kit (Qiagen) as per the manufacturer’s protocol. A fragment of 
p38 between the 5’ terminus and the BamHI restriction site was amplified by PCR 
using 0.5 g p38-pOTB7 as a template and 400 nM forward and reverse primers (BA 
109 and 114 (Table-1)) as described above. In parallel, primer BA112 was used as a 
template to amplify a construct encoding a 6 His sequence plus an EcoRI restriction site  
in a PCR reaction mixture (50 l) that contained 400 nM forward and reverse primers 
(BA107 and 110 (Table-1)). PCR products (52 bp DNA from BA 112 and 506 bp DNA 
from p38-pCMV) were separated on an agarose gel and purified using QIAquick gel 
extraction kits (Qiagen). The two purified DNAs were mixed together along with 
forward and reverse primer BA110 and BA109 (Table-1) and amplified by PCR as 
described above. The resulting PCR product (534 bp DNA) was separated on agarose 
gel and purified using a QIAquick gel extraction kit. The 534 bp DNA fragment and 
p38-pCMV vector were separately digested for 5-6 h at 37 °C  with 60 units EcoRI 
restriction enzyme, 10 mM Tris-HCl (pH 7.9), 50 mM NaCl, 10 mM MgCl2, 1 mM 
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DTT, and 100 g/ml BSA. The PRC reactions were then incubated at 65 °C for 20 min 
to inactivate the EcoRI. The EcoRI digestion buffer was removed from both reactions 
using Centricon YM-30 centrifugal filtration units (Millipore) and both fragments were 
digested with 60 units BamH1 for 5-6 h at 37 °C in a buffer containing 50 mM Tris-HCl 
(pH 7.9), 100 mM NaCl, 10 mM MgCl2, 1 mM DTT, 100 g/ml BSA. The p38-pCMV 
fragment was dephosphorylated by incubating at 37 °C for 1 h with 10 U of alkaline 
phosphatase. The 6592 bp fragment from p38-pCMV and 516 bp 6His-5’-p38 
fragment were separated on an agarose gel, purified using an QIAquick gel extraction 
kit, combined in a 1:7 ratio (vector:insert), and ligated by incubating with 400 U T4 
DNA ligase in 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 1 mM ATP, 10 mM DTT at 16 
°C overnight. The ligated vector was transformed into DH5 competent cells and spread 
on DYT agar contained 100g/ml ampicillin and grown overnight at 37 °C.  Antibiotic 
resistant colonies were picked and used to inoculate DYT media contained ampicillin 
100 g/ml. Transformants were grown overnight at 37 °C and the plasmids isolated and 
purified using QIAprep spin miniprep kits (Qiagen). Finally, ligation of the insert in to 
the vector (6His-p38-pCMV) was verified both by PCR using 400 nM of forward and 
reverse primer (BA109 and 110 (Table-1)) for the expected 534 bp DNA amplicon and 
also by DNA sequencing. 
Following text explains the transfer of 6His-p38 DNA from pCMV vector in to 
pGEX-6p vector. 6His-p38-pCMV and pGEX-6p vectors were digested separately 
with EcoRI as described above and the digested DNAs were separated on agarose gel 
and purified using a QIAquick gel extraction kit. Both vectors were then digested (5-6 h, 
37 °C) with NotI in a buffer that contained 50 mM Tris-HCl (pH 7.9), 100 mM NaCl, 10 
mM MgCl2, 1 mM DTT, and 100 g/ml BSA. The pGEX-6P vector was 
dephosphorylated using alkaline phosphatase as described above. Both DNAs were 
separated on agarose gel and purified uisng a QIAquick gel extraction kit. pGEX-6P 
vector digested 6His-p38 (insert) were ligated (2:1 ratio) as described above. Ligated 
product (6His-p38-pGEX-6p) was transformed into DH5 and amplified by growing 
the transformants in DYT media containing 100 g/ml ampicillin. The vector was 
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purified uisng a QIAprep spin miniprep kit and the orientation and sequence of the insert 
was confirmed by DNA sequencing. 
 
iii) Cloning of p38 
Human p38 cDNA excised from pOTB7 and inserted in phase 3’ of GST-6His in 
pGEX-6P as described below. 
p38-pOTB7 was transformted into DH5 and the transformed cells grown in 
DYT media contained 25 g/ml chloramphenicol. The plasmid extracted and purified 
using a plasmid maxiprep kit (Sigma) as directed by the manufacturer. Following 
purification, p38-pOTB7 was concentrated by addition of 0.1 volume 3.0 M sodium 
acetate buffer (pH 5.2) and 0.7 volume isopropyl alcohol. The insert was confirmed to 
be human p38 by DNA sequencing using primer BA94 (Table-1) and alignment with 
the appropriate NCBI cDNA sequence (AF092535). The p38 cDNA was amplified by 
PCR using 0.5 g of p38-pOTB7 as a template along with 400 nM forward and reverse 
primers (BA95 and 96 (Table-1)) as described above. The PCR product was separated 
on a 2% agarose gel, extracted, and purified using a QIAquick gel extraction kit 
(Qiagen). The resulting purified DNA (12 g) was ligated with pCR2.1-TOPO vector 
following the manufacture’s protocol (Invitrogen), ligated vector was transformed into 
bacteria, and transformants grown on DYT agar plate containing ampicillin (100 g/ml) 
and X-Gal.  Numerous white (positive) clones were picked, used to inoculate DYT 
media containing ampicillin (100 g/ml), and grown overnight at 37 °C. hp38-pCR2.1 
was extracted from the bacteria and purified using a QIAprep spin miniprep kit. The 
insert’s orientation and sequence were confirmed by both digestion with EcoR1 and 
DNA sequencing. Subsequently, 3 g p38-pOTB7 and 15 g hp38-pCR2.1 were 
digested for 5-6 h at 37 °C with 60 units BamH1 in 50 mM Tris-HCl (pH 7.9), 100 mM 
NaCl, 10 mM MgCl2, 1 mM DTT, 100 g/ml BSA, the digestion products separated on 
agarose gels, extracted, and purified using QIAquick gel extraction kits. Both the 
digested and purified hp38-pOTB7 and hp38-pCR2.1 were again digested with 15 
units of BbsI in 10 mM Tris-HCl (pH 7.9), 50 mM NaCl, 10 mM MgCl2, 1 mM DTT, 
100 g/ml BSA at 37 °C for 5-6 h.  The hp38-pOTB7 was then dephosphorylation 
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using alkaline phosphatase as described above. Both digestion reactions were separated 
on agarose gels, the 3241 bp DNA from hp38-pOTB7, and 269 bp DNA from hp38-
pCR2.1 were purified using QIAquick gel extraction kits, and then incubated at a ration 
of 3:1 (insert:vector) with T4 DNA ligase as described above. The ligated vector was 
transformed in DH5 competent cells, plated on DYT agar contained 25g/ml 
chloramphenicol, and incubated overnight at 37 °C. Antibiotic resistant colonies were 
picked, used to inoculate DYT media contained chloramphenicol, and cells grown 
overnight at 37 °C. The plasmid was then purified using a QIAprep spin miniprep kit 
(Qiagen). Correct insertion into pOTB7 was confirmed by digesting with NdeI and 
EcoRI.  
p38 cDNA was excised from pOTB7 and inserted into a pGEX-6P-6His vector 
which was prepared previously. The insertion was done by digesting both p38- pOTB7 
and pGEX-6P-6His with NdeI and XhoI digestion. pGEX-6p-6His was dephosphoryated 
with alkaline phosphatase, and then resulting DNAs ligated using T4 DNA ligase 
enzyme as described above. Ligated pGEX-6p-6His-p38 was transformed into DH5 
competent bacteria, amplified, and then purified using a QIAprep spin miniprep kit 
(Qiagen). The orientation and integrity of the p38 insert were confirmed by DNA 
sequencing.  
 
8) Coomassie Brilliant Blue (R250) staining and destaining 
Acrylamide gels were stained for 30 min or overnight in closed container in 0.1 % 
w/v Coomassie Brilliant Blue R250 in H20:methanol:acetic acid, 45:45:10 under 
constant shaking. Gels were destained in H20:methanol:acetic acid, 75:20:5 as required.   
 
9) Expression and purification of GST-fusion proteins 
E. coli competent strain BL21 was transformed with the expression vectors 
described above and the transformate grown as mentioned in transformation of BL-21 or 
DH5 competent cells subsection.  The 6 h culture (10 ml) was used to inoculate 0.3 l of 
DYT media contained antibiotic. Once the optical density at 600 nm reached 0.6, 
expression of the GST-fusion protein was induced by the addition of 1 mM IPTG. 
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Following induction, bacteria were incubated at 37 °C with shaking (200 rpm) for 6-7 h 
or overnight. The bacterial suspension was centrifuged at 12,000 x g for 10 min in 
Sorval SLA-8000 rotor, the pellet was re-suspended with saline, and centrifuged at 
12,000 x g for 10 min. The bacterial pellet was suspended in cold phosphate buffer 
saline (PBS pH 7.5) containing 1% TX-100, 10 mM benzamidine, and 2 mM PMSF. 
Bacteria were lysed on ice by sonication 4 times at 35% amplitude (Sonics and 
Materials inc. Vibra-Cell) for one minute with 15 s intervals, and then incubated for 30 
min at 4 °C with stirring. Bacterial lysates were centrifuged for 1 h at 125,000 x g and 4 
°C in Beckman type 45Ti rotor. Cleared lysates were loaded onto GST-Trap columns 
using an FPLC system with the following program: wash column with 5 column 
volumes of TBSE (pH 7.3 at 4 °C) at 0.5 ml/min, load lysate at 0.2 ml/min, wash with 
10 column volumes of TBSE at 0.5 ml/min, and elute GST-fusion protein 3 column 
volumes of 10 mM glutathione in TBSE (pH 8.0 at 4 °C) at 0.5 ml/min. Fractions of 1.0 
ml were collected and absorbance at 260 nm (A260) was monitored. Fractions 
corresponding the the peak of A260 nm were pooled and dialyzed against TBSE at 4 °C 
to remove the glutathione, and then dialyzed once against storage buffer comprising 
50% glycerol, 50 mM Tris (pH 7.5 at 5 °C), 150 mM NaCl, 0.1 mM EGTA, 0.03% Brij 
35, 1 mM benzamidine, 0.2 mM PMSF, and 0.1% -mercaptoethanol. Finally, protein 
concentrations were determined by Bradford protein assay, aliquots were prepared, 
snap-frozen using liquid nitrogen, and stored at -80 °C.      
 
10)Immunocytofluorescence 
The subcellular localization of each MK5 variant was determined by confocal 
fluorescence microscopy. A total of 3 x 105 HEK293 cells were seeded onto laminin (15 
g/ml for 20 min)-coated glass coverslips in 12 well culture plates with Dulbecco's 
Modified Eagle Medium (DMEM) containing 10% fetal calf serum, and allowed to 
adhere for 24 h. Cells were then rinsed once with DMEM and transfected with 1.6 g of 
the indicated pIRES-EGFP-MK5-V5 variant construct using OptiMEM II (Gibco) and 
Lipofectamine 2000 (Invitrogen) as per the manufacturers’ protocols. After 5-6 h of 
transfection, the medium was replaced with DMEM containing 10% fetal bovine serum 
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and the cells incubated for an additional 24 h. At the end of this 24 h period, cells were 
serum starved for 6 h, treated with or without agonist, rinsed with ice-cold PBS, and 
fixed for 20 min in ice-cold PBS containing 2% paraformaldehyde (pH 7.2). The 
fixative was removed by washing three times with ice-cold PBS. Cells were blocked and 
permeabilized by incubating for 30 min in PBS containing 2% donkey serum and 0.1% 
(w/v) TX-100. Coverslips were rinsed once with ice-cold PBS and incubated  overnight 
in a humidified chamber with anti-MK5 antibody diluted (1:100) in PBS containing 1% 
donkey serum and 0.05% (w/v) TX-100. To remove excess primary antibody, cover 
slips were washed three times with ice-cold PBS. Coverslips were then incubated for 1 h 
in PBS containing 1% donkey serum, 0.05% (w/v) TX-100, Alexa fluor 555-conjugated 
donkey anti-mouse IgG antibody (1:600) and 1.5 M TO-PRO 3. Finally, coverslips 
were rinsed three times with ice-cold PBS, drained, and mounted onto glass slides using 
15 l of DABCO/glycerol medium. Excess DABCO/glycerol medium was drained and 
coverslips were sealed with nail polish. The intracellular localization of MK5, TO-PRO 
3, and EGFP were visualized using a LSM 510 confocal fluorescence microscope.  
 
11)Detection of p38 and p38 subcellular localization by confocal microscopy 
Cryosections (14 m) were prepared from mouse heart ventricles as described 
above. Three sections per heart were placed on precleaned microscope slides (Fisher 
Scientific) and fixed for 20 min using ice-cold 4% paraformaldehyde in PBS (pH 7.2). 
After fixation, cells were washed three times with ice-cold PBS (5 min) and then 
blocked and permeabilized for 60 min in a solution containing 2% donkey serum and 
0.5% Triton X-100 in PBS. The slides were rinsed once with ice-cold PBS and 
incubated for overnight with primary antibody (1:100 for p38 and 1.200 for p38) 
diluted in PBS containing 1% donkey serum, 0.1% TX-100 at 4 °C in closed humidified 
chamber. The next day, the sections were rinsed three times with ice-cold PBS and 
incubated for 1 h with Alexa fluor 488-labelled donkey anti-rabbit IgG (1:600) and 1.5 
M TO-PRO 3 iodide in PBS containing 1% donkey serum and 0.1% TX-100. Finally, 
slides were rinsed three times with ice-cold PBS, drained, and coverslips were mounted 
onto glass slides using 15 l of DABCO/glycerol medium. Excess DABCO/glycerol 
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medium was removed and the coverslips sealed with nail polish. The intracellular 
localization of p38, p38, and TO-PRO 3 (nuclear marker) were revealled using a 
scanning confocal fluorescence microscope (LSM 510 Carl Zeiss, Oberkochen, 
Germany). 
 
12)Preparation of murine cardiac lysates 
Mouse hearts were pulverized under nitrogen as described above. The powdered 
tissue was resuspended using a 2 ml Potter-Elvehjem tissue grinder (25-30 passes) in 1.2 
ml of ice-cold lysis buffer comprising 50 mM Tris (pH 7.5 at 4C), 20 mM -
glycerophosphate, 20 mM NaF, 5 mM EDTA, 10 mM EGTA, 1.0% TX-100, 1 mM 
Na3VO4, 1 M microcystin LR, 5 mM DTT, 10 g/ml leupeptin, 0.5 mM PMSF, and 10 
mM benzamidine. Homogenates were then cleared of cellular debris by centrifugation 
for 60 min at 100,000 x g (48,000 RPM) and 4C in a Beckman TLA-100.3 rotor. 
Finally, supernatants were collected, protein concentration determined by the Bradford 
method, aliquoted, snap-frozen using liquid nitrogen, and stored at -80C.  
 
13)Immunoprecipitation of endogenous MK5 
Heart lysates were prepared as described above. Protein A/G+-Agarose beads (50 
l of a 25% slurry; Santa Cruz Biotechnology) were washed once with lysis buffer (400 
l) and centrifuged at 1 min at 2300 x g, and 4 °C. Anti-MK5 antibodies (2 g) were 
diluted to 200 l with lysis buffer and precoupled to Protein A/G+-Agarose beads by 
incubating for 5 h at 4 °C with constant mixing. To remove any uncoupled primary 
antibody, antibody-coated beads were washed three times with lysis buffer prior to 
immunoprecipitation reactions. Heart lysates (2 mg) were added to the antibody-coated 
beads and IP reactions were incubated overnight at 4C with constant mixing. Beads 
were washed five times with lysis buffer (500 l), the bead pellets suspended in 20 l of 
2X SDS sample buffer, and heated at 70 °C for 90 s. The beads were pelleted by a brief 
centrifugation and the supernatants loaded immediately onto 10-20% acrylamide-
gradient SDS-PAGE gels. 
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14)GST-pull down assay 
HEK293 cells were seeded (6 x 105/35 mm dish) in DMEM containing 10% fetal 
bovine serum and allowed to adhere for 24 h. Cells were then rinsed once with DMEM 
and transfected with 3.2 g of the indicated pIRES-EGFP-MK5-V5 variant construct 
using OptiMEM II (Gibco) and Lipofectamine 2000 (Invitrogen) as per the 
manufacturer’s protocol. After 5-6 h of transfection, the OptiMEM II media was 
replaced with DMEM containing 10% fetal bovine and the cells incubated for and 
additional 24 h. At the end of this 24 h period, cells were rinsed with ice-cold PBS, 
lysed in 200 l lysis buffer (see above) on ice, scraped, transferred to 1.5 ml 
microcentrifuge tubes, and passed 30-40 times through a 21-gauge needle. Cell lysates 
were then cleared of cellular debris by centrifugation for 30 min at 100,000 x g and 4 °C 
in a Beckman TLA-100.3 rotor. The supernatants were aliquoted, snap-frozen using 
liquid nitrogen, and stored at -80 °C until use. His-ERK3-GST or GST (1 g) alone was 
mixed with 150 ug cell lysate and incubated for 1 h at 4 °C with constant mixing.  Next, 
20 l of a 50% slurry of glutathione Sepharose beads, washed once with lysis buffer and 
centrifuged for 1 min, at 2300 x g, and 4 °C, was added and samples incubated for 30 
min at 4C with constant mixing. Pull downs were washed three times with lysis buffer 
and twice with 50 mM Tris (pH 7.5 at 4 °C). The bead pellet was suspended in 20 l of 
SDS sample buffer and heated at 70 °C for 90 s. The beads were removed by a brief 
centrifugation and the supernatants loaded immediately onto 10-20% acrylamide-
gradient SDS-PAGE gels. 
 
15)Genotyping 
Genotyping was by PCR using mouse tail DNA. Mouse tail biopsies were frozen 
at -20 °C untill use. Samples were lysed for 2-3 h at 55 °C in 50 mM Tris (pH 8.0 at 
RT), 150 mM NaCl, 25 mM EDTA, 0.25% SDS, and 400 g/ml proteinase K. The 
volume of lysis buffer was 50-100 l, but it varied according to the length of each 
individual tail biopsy sample. During lysis, samples were vortexed at hourly intervals. 
Lysates were centrifuged for 15 s at 14,600 x g and RT, vortexed, and centrifuged again 
for 10 min. An aliquot (1 l) of each supernatant was diluted 200-fold with water, a few 
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mg of chelex-100 resin (Bio-Rad) was added, vortexed, centrifuged for 15 s, and heated 
at 95 °C for 10 min to inactivate the proteinase K. Samples were mixed, centrifuged, 
and PCR was done in a 25 l reaction volume comprising 10 l sample, 400 nM primers 
(5'-CGTAACACTAGCCACA GTTGTAACTGA-3’,5'-CATATACTTGTAAGCACAG CTCTGAGTT-3’), 
750 mM Tris-HCl (pH 8.8 at 25 °C), 200 mM (NH4)2SO4, 0.1% (v/v) Tween 20, 1.5 
mM MgCl2, 200 M dNTPs, and 1.25 U Taq DNA polymerase. PCR conditions were: 1 
cycle at 94 °C for 10 min, 40 cycles at 94 °C for 30 s, 58 °C for 45 s, 72 °C for 1 min, 
and 1 cycle at 72 °C for 10 min. 6X sample buffer was added to each PCR reaction, 
tubes were vortexed, and each sample loaded onto 2% agarose gels contained ethidium 
bromide. Electrophoresis was at 80 V for 30-45 min. 
 
16) Activation of p38 MAPK and determining its specific activity 
Purified GST-p38 isoforms were activated by incubating in the presence of 
constitutively active His6-MKK6(EE) as described previously [158]. To separate 
phosphorylated GST-p38 from His6-MKK6(EE), reaction mixtures were incubated with 
glutathione Sepharose beads for 2-3 h at 4 °C on a clinical rotor, centrifuged for 2 min at 
5,000 rpm and 4 °C, washed thrice with TBS containing 1 mM EDTA (TBSE), and 
bound GST-p38 eluted with reduced glutathione. Purified, activated p38 was then 
dialyzed against TBSE buffer followed by a storage buffer comprising 50% (v/v) 
glycerol, 50 mM Tris (pH 7.5 at 5 °C), 150 mM NaCl, 0.1 mM EGTA, 0.03% Brij 35, 1 
mM benzamidine, 0.2 mM PMSF, and 0.1% -mercaptoethanol. Protein concentrations 
for each isoform were determined following SDS-PAGE using BSA as a standard. 
Briefly, proteins were separated on 10-20% acrylamide-gradient gels and stained with 
Coomassie Brilliant Blue R250. Gels were scanned using a VersaDoc 4000 imaging 
system and GST-p38 and BSA band densities determined using Quantity One software 
(Bio-Rad Laboratories, Inc) and the quantity of p38 protein determined from the BSA 
standard curve by linear regression using GraphPad Prism version 4. The specific 
activity of each phosphorylated GST-p38 isoform was determined by incubating 
activated GST-p38 (20 ng) with 0.33 mg/ml MBP, 100 M [32P]-ATP (10 Ci), 1 mM 
EGTA, 10 mM MgCl2, 10 mM DTT, 10 g/ml leupeptin, 1 mM Na3VO4, and 1 M 
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microcystin LR at 30 °C for 2, 5, 8, and 10 min. Reactions were terminated with SDS-
PAGE sample buffer and separated on 10-20% SDS-PAGE, stained with Coomassie 
blue, the bands corresponding to MBP xcised from the gel, and 32P incorporation into 
MBP measured by liquid scintillation counting. 
 
17)In vitro protein kinase assay 
Rat heart cytosol and nuclear fractions were prepared as described previously 
[159]. Cytosolic or nuclear proteins (50 g) were incubated with GST-MK5 (1 mU), 10 
μM [32P]ATP (10 μCi), 25 mM Tris-HCl (pH 7.5 at 4 °C), 1 mM EGTA, 10 mM 
MgCl2, 10 mM DTT, 1 mM Na3VO4, 1 M microcystin LR, 10 g/ml leupeptin, and 1 
μM PKI for 60 min at 30 °C. Reactions were terminated using 4X SDS-PAGE sample 
buffer and proteins separated on 10-20% SDS-PAGE. Gels were stained with 
Coomassie Brilliant blue R250, dried and exposed to Kodak BioMax MS film. For 2D 
gels, following phosphorylation, proteins were precipitated and the resuspended in 
rehydration buffer (see below). Briefly, 1 μl 2% sodium deoxycholate was added to the 
phosphorylation assay and the tubes placed on ice. After 20 min., 10 μl 100% 
trichloroacetic acid was added, samples were vortexed, incubated on ice for 60 min, and 
then centrifuged for 15 min at 18,300 x g and 4 °C. The protein pellet was washed twice 
with cold acetone and dried in SpeedVac for 5 min. The dried, precipitated proteins 
were dissolved in rehydration buffer (8 M Urea, 2% CHAPS, 25 mM DTT, 0.2% Bio-
Lyte 3/10 ampholyte, bromophenol blue for faint color). Samples were resolved on 7 cm 
pH 3-10 IPG strips (Bio-Rad), under mineral oil, using a Bio-Rad Protean IEF cell with 
the following protocol: active rehydration at 50 V for 12 h, 250 V for 15 min, a linear 
gradient of 250-to-10,000 V over 3 h, 10,000 V for 4 h, followed by 500 V until the 
samples were removed from the IEF cell. After the run, the excess mineral oil was 
removed by gently touching the IPG strips to tissue paper. The strips were  incubated in 
equilibration buffer I (0.375 M Tris pH 8.8, 6 M urea, 2% SDS, 20% glycerol, and 130 
mM DTT) and then equilibration buffer II (0.375 M Tris pH 8.8, 6 M urea, 2% SDS, 
20% glycerol, and 135 mM iodoacetamide) for 10 min each with continuous, gentle 
shaking. Strips were rinsed free of excess equilibration buffer by dipping 3-4 times in 
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SDS-PAGE running buffer. For the second dimension, proteins were resolved on 10-
20% acrylamide-gradient SDS-PAGE. Briefly, strips were put on top of the acrylamide 
gel, without trapping air bubbles between strips and gel, then strips were covered with 
0.5% agarose prepared in running buffer containing a small amount of bromophenol, top 
and bottom reservoirs filled with running buffer, and electrophoresed for 6-7 h at 
constant current (25 mA/gel) and 15 °C. Gels were stained, dried, and exposed to film as 
described above. 
 
18)Miscellaneous methods 
Protein concentrations were determined by the Bradford method using bovine 
serum albumin (BSA) as a standard. 
 
19) Immunoblotting 
SDS-PAGE and immunoblotting were performed as described previously [159]. 
Following the transfer, nitrocellulose membranes were rinsed in PBS and fixed with 
glutaraldehyde [160].  
 
20)Statistical Analysis 
Quantitative analysis was performed by a single observer in a blinded manner. 
One-way ANOVA followed by Newman-Keuls post tests were performed using 
Graphpad Prism version 4 for Mac. Values were shown ± S.E.  ***, p < 0.001: **, p < 
0.01: *, p < 0.05. 
 
57

Materials and Methods 
58

Table 1. Primers used during cloning 
Name Primers 
BA 94 5’- ATG ACT GGC TAC GTG GTG ACC -3’ 
BA 95  5’- AGG GCA TCA CCA GGT AGA AGT CAT A -3’ 
BA 96 5’- GGA TCC CAT ATG AGC CTC ATC CGG AAA AAG GGC 
TTC -3’ 
BA 103 5’- AAC GTG GGC CTC TCC TGA GAC ATG T -3’ 
BA 104 5’- CTC AGG ATC CCA TCA TCA TCA TCA TC -3’ 
BA 105 5’- GAT AAG GAA CTG AAC ATG GTC -3’ 
BA 106 5’- CAT CAT CAT CAT CAT CAC ATG TCT CAG G -3’ 
BA 107 5’- GAA GCC GGC GCG AGG GCC CGA CAT G -3’ 
BA 108 5’- ATG TCT CAG GAG AGG CCC ACG TT -3’ 
BA 109 5’- AAA TCC AGG ATC CTG AGC TCA CAG -3’ 
BA 110 5’- TCT AGG AAT TCA TCA TCA TCA TC -3’ 
BA 112 5’- TCA TCA TCA TCA TCA CAT GTC GGG CCC TC -3’ 
BA 114 5’- ATG TCG GGC CCT CGC GCC GGC TTC -3’ 
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Hypothesis 
 In the heart, p38 MAP kinase has been implicated in the regulation of apoptosis 
(p38), hypertrophy (p38), and fibrosis. The means whereby this cascade modulates 
these distinct responses and the involvement of other isoforms (p38, p38) is still 
unknown, but must involve specific downstream signaling components of the p38 MAP 
kinase cascade. Downstream targets of p38 MAP kinase include transcription factors as 
well as MAP kinase activated protein kinases (MKs). The known MKs regulated by p38 
MAP kinase are MK2, MK3, and MK5. Little is known about p38 isoform-selective 
activation of the MKs or the substrates of the individual MK subtypes, in particular 
MK5. Additionally, MK5 is also known to be phosphorylated by atypical MAPKs 
ERK3 and ERK4. Thus far, the physiological role of MK5 as well as ERK3/ERK4 
remains unknown. The hypothesis of the current study is: in the heart, MK5 is 
involved in the detrimental effects associated with p38 activation and given that 
MK5 activity is also regulated by ERK3 and ERK4, they may also play some role.  
 
Objectives 
 The specific objectives to test the above hypothesis were; 
 To study the involvement of MK5, downstream of p38, in regards to regulation 
of any of the physiological effects induced by chronic pressure overload in mice 
heterozygous for a functional knockout of MK5 (MK5+/-). 
 To determine whether MK5 signaling in the heart is mediated by p38, ERK3, 
ERK4, or any combination of the three.   
 To determine involvement of ERK3 or ERK4, potential upstream regulators of 
MK5, in the regulation of any of the physiological effects of MK5 during 
hypertrophy using ERK3+/- and ERK4-/- mice. 
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 To identify substrates of MK5 and p38 isoforms in vitro using subcellular 
fractions (e.g. cytosol, cytoskeleton, nuclear membrane, and nucleoplasm) 
obtained from ventricular myocytes. 
 To characterize the expression and cellular distribution of all p38 isoforms the 
heart and determine the effects on chronic pressure overload.. 
 
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 ABSTRACT 
MK5, a member of the MAPK-activated protein kinase family, is highly 
expressed in the heart. Whereas MK2 and MK3 are activated by p38 MAPK, MK5 has 
also been shown to be activated by ERK3 and ERK4. We studied the regulation of MK5 
in mouse heart. mRNA for 5 splice variants (MK5.1–5.5), including the original form 
(MK5.1), was detected. MK5 comprises 14 exons: exon 12 splicing was modified in 
MK5.2, MK5.3, and MK5.5. MK5.2 and MK5.5 lacked 6 bases at the 3	-end of exon 12, 
whereas MK5.3 lacked exon 12, resulting in a frame shift and premature termination of 
translation at codon 3 of exon 13. MK5.4 and MK5.5 lacked exons 2–6, encoding kinase 
subdomains I–VI, and were kinase-dead. All 5 MK5 variants were detected at the 
mRNA level in all mouse tissues examined; however, their relative abundance was 
tissue-specific. Furthermore, the relative abundance of variant mRNA was altered both 
during hypertrophy and postnatal cardiac development, suggesting that the generation or 
the stability of MK5 variant mRNAs is subject to regulation. When expressed in 
HEK293 cells, MK5.1, MK5.2 and MK5.3 were nuclear whereas MK5.4 and MK5.5 
were cytoplasmic. A p38 MAPK activator, anisomycin, induced the redistribution of 
each variant. In contrast, MK5 co-immunoprecipitated ERK3, but not ERK4 or p38, in 
control and hypertrophying hearts. GST pull-down assays revealed unbound ERK4 and 
p38 but no free MK5 or ERK3 in heart lysates. Hence, 1) in heart MK5 complexes 
with ERK3 and 2) MK5 splice variants may mediate distinct effects thus increasing the 
functional diversity of ERK3–MK5 signaling. 
 
© 2010 Elsevier Inc. All rights reserved. 
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1. Introduction 
Mitogen-activated protein kinases (MAPKs) are protein serine/threonine kinases 
that respond to extracellular stimuli and regulate a broad range of essential cellular 
activities, including mitosis, metabolism, motility, survival, apoptosis, and 
differentiation. Five distinct MAPK pathways have been identified in mammals: 
extracellular signal-regulated kinases (ERKs) 1/2, ERK3/4, ERK5, c-jun amino-terminal 
kinases (JNKs) (1–3), and p38 MAPKs (, , , and ) [1]. Each pathway displays a 
characteristic hierarchical organization wherein MAPK kinase kinases (MAPKKK) 
phosphorylate and activate MAPK kinases (MAPKK), which in turn activate their 
respective MAPKs. Downstream of certain MAPKs lies an additional tier of protein 
kinases, the MAP kinase-activated protein kinases (MAPKAPKs): these include MK2, 
MK3 and MK5 (also known as PRAK) [2].  
MK2 is a major target for stress-activated p38 and p38 MAPKs. MK2-
deficient mice show resistance to endotoxic shock due to impaired production of pro-
inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha (TNF) 
[3]. MK2 and MK3 show 75% identity at the amino acid level [4]. However, although 
MK2 and MK3 show similarity in their consensus phosphorylation sites [5], not all 
MK2 substrates have been identified as substrates for MK3. Recent studies in 
MK2/MK3 double knock-out mice show that MK3 further reduces TNF production, 
expression of p38, and tristetraprolin (TTP), compared to MK2
/
 mice [6], suggesting 
that MK3 and MK2 have overlapping function. MK5, originally identified as a p38 
regulated and activated protein kinase (PRAK) [7] and [8], was shown to mediate 
senescence in response to induction of oncogenic ras and upon activation by p38 [9]. 
Unlike MK2
/
 and MK3
/
 mice, MK5-deficient mice show no destabilization of p38 
[6]. Furthermore, atypical MAPKs ERK3 and ERK4 are binding partners of MK5 [10], 
[11] and [12]. ERK3 and ERK4 show 50% homology with ERK1/2 within the kinase 
domain but have an S-E-G rather than a T-E-Y motif within the activation loop and 
contain a unique C-terminal extension [13]. Increased expression of ERK3 retains MK5 
in cytoplasm and facilitates the activation of MK5 by cis-autophosphorylation [11]. In 
contrast, ERK4 directly phosphorylates MK5 [14]. Hence, p38, ERK3 and ERK4 may 
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all be involved in regulating MK5 activity in vivo. Little is known about the downstream 
effectors or physiological function of MK5. 
Our present study demonstrates 4 novel splice variants of MK5, referred to 
herein as MK5.2–MK5.5, in murine cardiac ventricular myocardium. These variants 
result from both exon skipping and alternative splice site activation during pre-mRNA 
processing. MK5.4 and MK5.5 lacked a significant part of the kinase catalytic domain 
whereas MK5.3 lacked the putative ERK3/ERK4 binding domain. When expressed in 
HEK293 cells, MK5.1, MK5.2, and MK5.3 localized to the nucleus. In contrast, despite 
retaining NLS and NES sequences, MK5.4 and MK5.5 localized to the cytoplasm in 
resting cells. Furthermore, the relative abundance of MK5.3 mRNA decreased whereas 
MK5.4 + MK5.5 mRNA increased during cardiac hypertrophy. Finally, we demonstrate 
that MK5 co-immunoprecipitated ERK3, but not ERK4 or p38, in both control hearts 
and those exposed to pressure overload resulting from 3 d of transverse aortic 
constriction (TAC). Hence, in heart, MK5 may lie downstream of ERK3, rather than 
p38 or ERK4, and the novel MK5 splice variants may mediate distinct effects 
downstream of ERK3, thus increasing the functional diversity of the ERK3–MK5 
signaling pathway. 
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2.  Materials and methods 
2.1. Materials 
Membrane grade (reduced) Triton X-100 (TX-100), leupeptin, and PMSF were 
from Roche Molecular Biochemicals. SDS-polyacrylamide gel electrophoresis reagents, 
nitrocellulose, and Bradford protein assay reagents were from Bio-Rad Laboratories. 
The cAMP-dependent protein kinase inhibitor peptide (PKI) was from the University of 
Calgary Peptide Synthesis Core Facility. Canine hsp27, cloned into the pET24a 
expression vector [15], was a gift from Dr. William Gerthoffer (Reno, NV). His6-
ERK3-GST, cloned into the pHGST.1 expression vector was a gift from Dr. Sylvain 
Meloche [16]. Anti-EGFP antibodies were from BD Biosciences. Anti-MK5 antibodies 
(PRAK A-7) were from Santa Cruz Biotechnology and anti-V5 antibodies were from 
Invitrogen. HRP-conjugated secondary antibodies were from Jackson ImmunoResearch 
Laboratories. All other reagents were of analytical grade or best grade available. 
Plasmids were transformed to E. coli competent strain BL21 (DE3) and expression 
induced by the addition of 1 mM isopropyl--d-thiogalactopyranoside (IPTG). GST-
fusion proteins were purified by affinity chromatography on glutathione Sepharose. 
 
2.2. Cloning and purification of fusion proteins 
Total cellular RNA was isolated using RNeasy® Mini kits (Qiagen Inc.) with 
minor modifications. Briefly, tissue was homogenized in 2 ml of TRIzol reagent 
(Sigma) using a Polytron at 10,000 rpm (2 × 15 s), 0.4 ml chloroform added and phase 
separation induced by centrifugation for 15 min at 18,300 g and 4 °C. The aqueous 
phase was reserved and RNA was precipitated by addition of an equal volume of 70% 
ethanol, and then purified on Qiagen columns according to the manufacturer's 
instructions. RNA was quantified by determining absorbance (A) at 260 nm and only 
samples having an A260/A280 ratio greater than 1.8 were used. First strand cDNA 
synthesis was performed in a 20 μl reaction volume containing 1 μg of total RNA, 
100 ng of random primers, 1× First Strand buffer (50 mM Tris–HCl pH 8.3, 75 mM 
KCl, 3 mM MgCl2), 0.5 mM dNTP, 10 mM DTT, 40 U RNaseOUT recombinant 
ribonuclease inhibitor, and 200 U of M-MLV reverse transcriptase (Invitrogen), 
66

 Article-1  
according to the manufacturer's protocol. For PCR amplification of MK5, 2 μl aliquots 
of cDNA were amplified in 50 μl reactions comprising 60 mM Tris-SO4 (pH 9.1), 
18 mM (NH4)2SO4, 1.8 mM MgSO4, 200 μM dNTP, 1 μl Elongase (Invitrogen), and 
400 nM primers (FWD: CGT GGA TCC ATG TCG GAG GAC AGC GAC ATG GAG; 
REV: ACG AAT TCC TAC TGG GGC TCG TGG GGA AGG GTC). PCR reactions 
were: 1 cycle at 94 °C for 30 s, 25 cycles at 94 °C for 30 s, 58 °C for 30 s, 68 °C for 
2 min, and 1 cycle at 72 °C for 10 min. The forward and reverse primers used for PCR 
amplification of MK5 were designed according to the mouse MK5 cDNA sequence in 
the NCBI database (NM_010765). PCR products appeared as a diffuse band when 
electrophoresed on 1% agarose gels. The bands were excised, extracted using QIAquick 
Gel Extraction Kits (Qiagen), ligated into the pCR®2.1-TOPO® (Invitrogen) plasmid 
vector, and transformed into TOP10 competent cells. Several independent clones were 
sequenced. RT-PCR and cloning were performed 3 times using RNA prepared 
independently from 3 different animals. In total, 5 distinct mRNAs were obtained. Full 
length inserts of MK5.1, MK5.2, MK5.3, MK5.4, and MK5.5, in addition to MK5.1-
T182A, were subcloned in phase 3	 to the GST coding sequence in pGEX-2T vector 
(GE Healthcare). Each pGEX-2T-MK5 variant construct was transformed into E. coli 
competent strain BL21. Transformed E. coli were then selected on DYT agar media 
contained 100 μg/ml ampicillin. The transformed bacteria were grown in DYT media 
contained 100 μg/ml ampicillin to an optical density of 0.6 at 600 nm and then 
expression of the GST-fusion protein was induced by addition of 1 mM IPTG. 
Following induction, bacteria were maintained at 37 °C with shaking (200 rpm) for 6–
7 h. Each GST-MK5 variant was purified by affinity chromatography on GST-Trap 
columns (GE Healthcare). The integrity and purity of each fusion protein was 
determined by SDS-PAGE. 
 
2.3. RNA analysis 
Total RNA was isolated from mouse cardiac ventricles and ventricular myocytes 
using RNeasy® Mini kits (Qiagen Inc.) with minor modifications. Total cellular RNA 
was extracted by homogenizing tissue in TRIzol reagent and then purified on RNeasy 
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mini kit columns as per the manufacturer's protocol. Synthesis of cDNA was as 
described above. Quantitative real-time PCR (qPCR) was performed using a MX3000P 
QPCR system (Stratagene). Each amplification reaction mixture (25 μl) contained 
6.25 ng cDNA equivalent to reverse transcribed RNA, 300 nM forward and reverse 
primers, 30 nM ROX, 12.5 μl platinum SYBR green mix (2×) (Invitrogen). qPCR 
reactions were: 1 cycle at 95 °C for 10 min, 40 cycles at 95 °C for 30 s, 55 °C (68 °C for 
MK5.4 + MK5.5) for 30 s, and 1 cycle at 72 °C for 1 min. SYBR green fluorescence 
was measured at the end of the annealing and extension phases of each cycle. The 
specificity of each primer pair for the amplicon of interest was verified using the 
dissociation curve. In addition, amplicons were gel purified and sequenced. The 
amplification efficiency for each primer pair was determined from a standard curve of 
50–3.25 ng reverse transcribed RNA isolated from the heart after two-fold serial 
dilutions. The efficiency for each primer pair was between 90 and 110%. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was employed as an internal 
control. Hence, all samples were normalized to GAPDH, which was amplified in 
parallel in the same run, with MxPro software (Stratagene). Primers specific for MK5 
splice variants were designed using Clone Manager 6 (Sci Ed Software, USA) and based 
upon the sequence of murine MK5 cDNA (NM_010765). The forward and reverse 
primers used are shown in Table 1. 
 
2.4. Immunocytofluorescence 
The subcellular localization of each MK5 variant was determined by confocal 
fluorescence microscopy. AgeI–BSRgI inserts from pCR2.1-TOPO were ligated to 
AgeI–BSRgI digested pIRES-V5-EGFP vector. A total of 3 × 105 HEK293 cells were 
seeded onto laminin-coated glass coverslips in 12-well culture plates with Dulbecco's 
Modified Eagle Medium (DMEM) containing 10% fetal bovine serum and allowed to 
adhere for 24 h. Cells were then rinsed once with DMEM and transfected with 1.6 μg of 
the indicated pIRES-MK5-V5-EGFP variant construct using OptiMEM II (Gibco) and 
Lipofectamine 2000 (Invitrogen) as per manufacturer's protocol. After 5–6 h of 
transfection, the medium was replaced with DMEM containing 10% fetal bovine serum 
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for 24 h. At the end of this 24 h period, cells were serum starved for 6 h, treated with or 
without agonist, rinsed with ice-cold PBS, and fixed for 20 min in ice-cold PBS 
containing 2% paraformaldehyde (pH 7.2). The fixative was removed by washing three 
times with ice-cold PBS. Cells were blocked and permeabilized by incubating for 
30 min in PBS containing 2% donkey serum and 0.1% (w/v) TX-100. Coverslips were 
rinsed once with PBS and incubated overnight in a humidified chamber with anti-MK5 
antibody diluted (1:100) in PBS containing 1% donkey serum and 0.05% (w/v) TX-100. 
To remove excess primary antibody, cover slips were washed three times with ice-cold 
PBS. Coverslips were then incubated for 1 h in PBS containing 1% donkey serum, 
0.05% (w/v) TX-100, Alexa fluor 555-conjugated donkey anti-mouse IgG antibody 
(1:400) and 1.5 μM TO-PRO 3. Finally, coverslips were rinsed three times with ice-cold 
PBS, drained, and mounted onto glass slides using 15 μl of DABCO/glycerol medium. 
The intracellular localization of MK5, TO-PRO 3, and EGFP were visualized using an 
LSM 510 confocal fluorescence microscope (Carl Zeiss, Oberkochen, Germany) as 
described previously [17], [18] and [19]. 
 
2.5. Immunoprecipitation of endogenous MK5 
Mice were sedated with pentobarbital and then sacrificed. Hearts were rapidly 
removed, snap-frozen in liquid nitrogen, and pulverized under liquid nitrogen. The 
powdered tissue was resuspended in 1.2 ml of ice-cold lysis buffer (50 mM Tris–Cl (pH 
7.5 at 4 °C), 20 mM -glycerophosphate, 20 mM NaF, 5 mM EDTA, 10 mM EGTA, 
1.0% (w/v) TX-100, 1 mM Na3VO4, 1 μM microcystin LR, 5 mM DTT, 10 μg/ml 
leupeptin, 0.5 mM PMSF, and 10 mM benzamidine) using a 2 ml Potter-Elvehjem tissue 
grinder (15 passes, on ice). Homogenates were then cleared of cellular debris by 
centrifugation for 30 min at 100,000 g and 4 °C in a Beckman TLA-100.3 rotor. The 
supernatants were aliquoted, snap-frozen using liquid nitrogen, and stored at 
 80 °C 
until use. Prior to immunoprecipitation, 2 μg of anti-MK5 antibody was precoupled to 
50 μl of a 25% slurry of protein A/G+-Agarose beads (Santa Cruz Biotechnology) by 
incubating overnight at 4 °C with constant mixing. To remove uncoupled primary 
antibody, antibody-coated beads were washed three times with lysis buffer prior to 
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immunoprecipitation reactions. Supernatants (2 mg) were added to the antibody-coated 
beads and incubated overnight at 4 °C with constant mixing. Immunoprecipitations were 
washed three times with lysis buffer and twice with 50 mM Tris–Cl (pH 7.5 at 4 °C). 
The bead pellet was suspended in 20 μl of 2× SDS sample buffer and heated at 70 °C for 
90 s. The beads were pelleted by a brief centrifugation and the supernatants loaded 
immediately onto 10–20% acrylamide-gradient SDS-PAGE gels. 
 
2.6. GST-pull-down assay 
HEK293 cells (6 × 105/35 mm dish) were seeded in DMEM containing 10% 
fetal bovine serum and allowed to adhere for 24 h. Cells were then rinsed once with 
DMEM and transfected with 3.2 μg of the indicated pIRES-MK5-V5-EGFP construct 
using OptiMEM II (Gibco) and Lipofectamine 2000 (Invitrogen) as per the 
manufacturer's protocol. After 5–6 h of transfection, the OptiMEM II media was 
replaced with DMEM containing 10% fetal bovine serum for 24 h. At the end of this 
24 h period, cells were rinsed with ice-cold PBS, lysed in 200 μl lysis buffer (see above) 
on ice, scraped, transferred to 1.5 ml microcentrifuge tubes, and passed 30–40 times 
through a 21-gauge needle. Cell lysates were then cleared of cellular debris by 
centrifugation for 30 min at 100,000 g and 4 °C in a Beckman TLA-100.3 rotor. The 
supernatants were aliquoted, snap-frozen using liquid nitrogen, and stored at 
 80 °C 
until use. His-ERK3-GST or GST alone (1 μg) was mixed with 150 μg cell lysate and 
incubated for 1 h at 4 °C with constant mixing. Next, 20 μl of a 50% slurry of 
glutathione Sepharose beads was added and samples incubated for 30 min at 4 °C with 
constant mixing. Pull-downs were washed three times with lysis buffer and twice with 
50 mM Tris–Cl (pH 7.5 at 4 °C). The bead pellet was suspended in 20 μl of 2× SDS 
sample buffer and heated at 70 °C for 90 s. The beads were removed by a brief 
centrifugation and the supernatants loaded immediately onto 10–20% acrylamide-
gradient SDS-PAGE gels. 
 
2.7. Immunoblotting 
SDS-PAGE and immunoblotting were performed as described previously [17]. 
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2.8. Transverse aortic constriction 
Pressure overload hypertrophy was induced by transverse aortic constriction 
(TAC) in 10–12-wk old male C57BL/6 mice (20–30 g body weight; Charles River), as 
previously described [20]. Sham-operated mice underwent identical interventions except 
for the constriction of the aorta. All animal experiments were performed according to 
the guidelines of the Canadian Council on Animal Care. 
 
2.9. Miscellaneous 
Protein concentrations were determined by the Bradford method [21] using 
bovine serum albumin (BSA) as a standard. 
The sequences for the new murine MK5 splice variants shown in Supplementary 
Fig. 1 have been deposited in GeneBank under the accession number; MK5.2 
(AY533679), MK5.3 (AY533680), MK5.4 (AY533681), and MK5.5 (AY533682). 
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3. Results 
3.1. Molecular cloning and sequencing of murine MK5 splice variants 
MK5 was cloned from cDNA prepared from murine heart total RNA. Forward 
and reverse primers were based upon the sequence of murine MK5 cDNA in the NCBI 
database (NM_010765). PCR products were cloned and sequenced, revealing 5 different 
products: the form of MK5 originally found in the database and 4 others. An mRNA-to- 
genomic sequence (MGI:1333110) alignment (http://www.ncbi.nlm.nih.gov/IEB/ 
Research/Ostell/Spidey/) suggested the four products resulted from alternative splicing 
during RNA maturation. On the basis of their relative size, we refer to the form 
encoding full-length MK5 as MK5.1 and the novel shorter forms as MK5.2 
(AY533679), MK5.3 (AY533680), MK5.4 (AY533681), and MK5.5 (AY533682). 
Supplementary Fig. 1 shows alignments of the putative splice sites in MK5.1–MK5.5 
with the mouse genomic sequence. MK5.1 comprises 14 exons. MK5.4 and MK5.5 lack 
exons 2, 3, 4, 5, and 6 (Supplementary Fig. 1a,b). As shown in Supplementary Fig. 1c, 
MK5.2 and 5.5 lack 6 bases at the 3	-end of exon 12, presumably due to the use of an 
alternative 3	 splice site within this exon. MK5.3 lacks exon 12 (Supplementary Fig. 1c), 
resulting in a frame shift in translating exon 13 and an in-frame stop codon in the third 
position. MK5.1 has a 1422 base open reading frame (ORF) and is predicted to encode a 
473 amino acid protein (Fig. 1) whereas MK5.2 has a 1416 base ORF and encodes a 471 
amino acid protein. MK5.3 has an ORF of 1300 bases, and encodes a 369 amino acid 
protein. MK5.4 has a 975 base ORF, encoding a 324 amino acid protein. MK5.5 has an 
ORF of 969 bases and encodes a 322 amino acid protein. Aligning the predicted primary 
amino acid sequences for all 5 variants revealed that MK5.3 lacks the binding domain 
for ERK3 [11], and ERK4 [10] whereas MK5.4 and MK5.5 lack conserved protein 
kinase domains I, II, III, IV, V, VIa, and VIb (Fig. 1, Supplementary Fig. 2). In each 
case, both the nuclear localization sequence (NLS) and nuclear export sequence (NES) 
remain intact. Furthermore, each variant retained a threonine residue corresponding to 
Thr-182, the p38/ERK3/ERK4 MAPK phosphorylation site in MK5.1. 
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3.2. In vivo expression of MK5 splice variants in different tissue and MK2 deficient 
mice 
We next wanted to determine the relative quantity of each MK5 variant in heart. 
Expression of MK5 variants in vivo at the mRNA level was quantified by real-time 
quantitative PCR (qPCR). Primers (Fig. 2A, Table 1) were designed to specifically 
amplify amplicons of equal size from total MK5 (e.g., all 5 variants), MK5.2 + MK5.5, 
MK5.3, and MK5.4 + MK5.5. MK5.2 + MK5.5 and MK5.4 + MK5.5 were quantified 
together as they shared common deletions, thus precluding selective quantification. A 
forward primer complementary to sequence in exon 10 and reverse primer in exon 11, 
which are present in all variants, were employed to quantify total MK5 mRNA. Both 
MK5.2 and MK5.5 have a 6 base deletion at the exon 12/13 junction. Hence, to quantify 
mRNA for MK5.2 + MK5.5, the forward primer was designed to be selective for the 
exon 12/13 junction but with a 6-base deletion, whereas the reverse primer was 
complementary to a region in exon 14. For MK5.3, which lacked exon 12, a forward 
primer in exon 11 and reverse primer spanning the exon 11/13 junction were employed. 
MK5.4 and MK5.5 both lack exons 2–6, inclusively, and hence were quantified using a 
forward primer to the exon 1/7 junction and reverse primer to the exon 8/9 junction. 
Amplicons for each variant were confirmed by sequencing. In addition, the specificity of 
each primer was validated by assessing their ability to amplify a product from MK5.1 
cDNA in a pGEX-2T plasmid. With the exception of the ‘total’ MK5 primers, none of 
the primer pairs could amplify products from MK5.1 (results not shown). Using these 
variant-specific primers, the relative abundance of splice variant mRNAs was measured 
in mouse heart and isolated ventricular myocytes and expressed relative to the total 
abundance of MK5 transcripts (Fig. 2B). The variants MK5.2 + MK5.5 represented 
about 10% of total MK5 mRNA, MK5.3 was 1%, and MK5.4 + MK5.5 was 0.4%. 
Hence, in both mouse heart and isolated ventricular myocytes, the most abundant MK5 
variant, following MK5.1, was MK5.2. 
 Liver, kidney, skeletal muscle, brain, pancreas, and lung express high levels of 
MK5 [22]. Hence, we sought to determine if MK5 splicing was tissue-specific. 
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Alternatively spliced variants of MK5 were observed in all tissue examined. However, 
the abundance of total MK5 mRNA (Fig. 2C), as well as the relative abundance of each 
splice variant, was tissue-specific (Fig. 2D–F). In all tissues studied, the most abundant 
variant, following MK5.1, was MK5.2 (Fig. 2D). Interestingly, in murine heart, the 
relative abundance of MK5.3 and MK5.4 + MK5.5 mRNA was greater in comparison to 
other tissues examined (Fig. 2E,F), although the expression of total MK5 was lower 
(Fig. 2C). 
MK5 shows a 42% amino acid sequence similarity with MK2 and both are 
substrates for p38 MAPK. Furthermore, in certain tissues, including the heart, an MK2-
deficiency results in reduction in p38 protein levels [4]. Hence we examined the 
possibility that there may be compensatory changes in expression MK5 in MK2-
deficient mice. However, no changes were detected in either MK5 splicing or total MK5 
mRNA in hearts from MK2
/
 mice (Fig. 2G). This is consistent with previous results 
showing no change in MK5 expression in MEFs from MK2-deficient mice [23]. 
 
3.3.  Expression and characterization of recombinant MK5 variants 
We then sought to characterize the individual MK5 variants at the protein level. 
cDNAs for all MK5 variants were cloned into the bacterial expression vector pGEX-2T 
to generate fusion proteins with GST at the N-terminus, expressed in E. coli, and 
purified by affinity chromatography on glutathione Sepharose. Following purification, 
SDS-PAGE revealed GST-MK5.1, GST-MK5.2, GST-MK5.3, GST-MK5.4, GST-
MK5.5, and GST-MK5.1-T182A fusion proteins of approximately 80-kDa, 80-kDa, 68-
kDa, 63-kDa, 63-kDa, and 80-kDa, respectively (Fig. 3A). The identity of each band 
was confirmed by immunoblotting with both anti-GST and anti-MK5 antibodies 
(Fig. 3B). Purified preparations of GST-MK5.4 and GST-MK5.5 contained several 
proteins of lower molecular weight (e.g., 30–35-kDa; Fig. 3A) that were recognized by 
anti-GST but not by a C-terminal directed anti-MK5 antibody (Fig. 3B). Since the 
molecular weight of the GST moiety itself is 28-kDa, this suggests that GST-MK5.4 and 
GST-MK5.5 were expressed as full-length protein in E. coli, but were subsequently 
partially degraded. Similarly, when pIRES-MK5.4-V5-EGFP and pIRES-MK5.5-V5-
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EGFP were expressed in HEK293 cells, immunoblotting for the V5 epitope tag or MK5 
in the lysates of HEK293 cells revealed decreases in band intensity for MK5.4-V5 and 
MK5.5-V5 (Fig. 3C), whereas EGFP expression was not decreased. Taken together, 
these results suggest that, although all 5 variants were translated, MK5.4 and MK5.5 
may be less stable proteins than the other variants. A similar reduced stability was 
observed in MK5 exon 6-deficient macrophages [23].To determine the ability of each 
MK5 variant to support catalytic activity, we incubated each purified recombinant MK5 
with phosphorylated, active p38, p38, p38, or p38 plus purified recombinant hsp27 
(Fig. 3D). Whereas p38 and p38 phosphorylated each MK5 variant, p38 and p38 
were much less able to do so. p38-mediated phosphorylation of MK5.1 was virtually 
absent when Thr-182, the site phosphorylated by p38, was replaced with Alanine. As 
MK5.4 and MK5.5 lack protein kinase domains I–VI, they were predicted to be 
catalytically inactive. This was confirmed by in vitro phosphorylation assay where it 
was observed that, whereas MK5.1, MK5.2, and MK5.3, catalyzed the incorporation of 
32PO4 into hsp27, MK5.4 and MK5.5 showed no kinase activity (Fig. 3D). 
Returning to Fig. 1, an alignment of the primary amino acid sequences of all 5 
variants of MK5 reveals that MK5.3 lacks the binding domain for ERK3 [11] and ERK4 
[10]. GST-ERK3 pull-down assays confirmed that all MK5 variants except MK5.3 
bound to GST-ERK3 (Fig. 3E). These results also suggested that the apparent lability of 
MK5.4 and MK5.5 was likely not a result of these variants' inability to adopt a native 
conformation. 
 
3.4. Subcellular localization of exogenously expressed MK5 variants 
A crucial determinant of the relevance of the MK5 variants in vivo is that they be 
translated, whereas subcellular localization is a determinant of function. Hence, each 
MK5 variant was transiently expressed in HEK293 cells. Previous studies have shown 
that MK5 localizes to the nucleus and is exported to the cytoplasm upon activation of 
p38 MAPK [12], [22] and [24]. First we studied the time-dependence of p38 activation 
by sorbitol and anisomycin and p38-dependent nuclear export of MK5 by confocal 
immunofluorescence microscopy. As shown by the increased levels of phospho-p38, the 
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p38 pathway was activated by sorbitol (Fig. 4A) and anisomycin (Fig. 4B) within 
30 min and phospho-p38 levels remained elevated for at least 2 h. Hence, HEK293 cells 
were used to study the p38-dependent changes in the subcellular localization of 
endogenous MK5. In unstimulated HEK293 cells, endogenous MK5 localized to the 
nucleus. Following a 2 h stimulation with either sorbitol or anisomycin, MK5 
immunoreactivity had translocated into the cytosol (Fig. 4C). As this prolonged 
stimulation was not associated with breakdown of heterologously expressed MK5.1-V5 
(Fig. 4A,B) and induced translocation of endogenous MK5 (Fig. 4C), 2 h stimulations 
were employed in our subsequent studies of the localization and translocation of each 
MK5 variant. As with endogenous MK5, heterologously expressed MK5.1-V5 localized 
to the nucleus in unstimulated cells and was translocated to the cytoplasm upon 
activation of p38 MAPK with anisomycin (Fig. 5A). Thus, endogenous MK5 and 
exogenously expressed MK5-V5 behaved in the same manner in HEK293 cells. MK5.1-
T182A localized to nucleus and did not translocate to the cytoplasm upon activation of 
p38 (Fig. 5F), which is consistent with previous results [22] showing that 
phosphorylation at Thr-182 by p38 is required for export of nuclear MK5. Furthermore, 
nuclear export of MK5.1-V5 was prevented by preincubation with a p38/ inhibitor, 
SB203580 (Fig. 5A). Similar cellular localization and p38/-dependent nuclear export 
were observed for MK5.2-V5 and MK5.3-V5 (Fig. 5B,C). Interestingly, although each 
of the MK5 variants possessed both nuclear localization sequence (NLS) and nuclear 
export sequence (NES; Fig. 1, Supplementary Fig. 2), MK5.4-V5 and MK5.5-V5 were 
retained in the cytoplasm in unstimulated cells whereas small amounts of MK5.4-V5 
and MK5.5-V5 immunoreactivity was detected within the nucleus following p38 
activation (Fig. 5D,E). Leptomycin B, which blocks CRM1 (chromosome region 
maintenance 1)-dependent nuclear export, and prevents the activation-dependent 
translocation of both MK2 [25] and MK5.1 [24], did not alter the localization of either 
MK5.4-V5 or MK5.5-V5, suggesting that their cytoplasmic localization in unstimulated 
cells was not due to enhanced nuclear export (Fig. 5D,E). 
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3.5. Effect of cardiac hypertrophy and postnatal development on the expression and 
splicing of MK5 
The relative abundance of the MK5 variants differed in a tissue-specific manner 
(Fig. 2). This suggested that the splicing of MK5 may be subject to regulation. Hence, to 
determine if cardiomyopathy altered MK5 expression and/or splicing, we examined the 
effect of cardiac hypertrophy induced by 1 wk of TAC. Hypertrophy is associated with a 
reexpression of fetal genes, including atrial and B-type natriuretic peptides (ANP, BNP), 
-myosin heavy chain (-MHC) and -skeletal actin (-SKA) [26]. The establishment of 
a hypertrophic response induced by 1-wk TAC was confirmed by the increased 
expression of atrial natriuretic peptide and -myosin heavy chain (Fig. 6E,F). After 1 wk 
of TAC, there was no significant change in total MK5 mRNA (Fig. 6A); however, the 
abundance of MK5.3 mRNA had decreased whereas that of MK5.4 and MK5.5 had 
increased (Fig. 6C,D) relative to sham-operated mice. These results demonstrate that the 
pattern of MK5 splicing was altered during left ventricular hypertrophy, however this 
change was limited to the lowest abundance variants.We next investigated whether the 
expression and/or splicing of MK5 was altered in murine heart during postnatal 
development. Total MK5 mRNA decreased within the first 7 d, but returned to a level 
similar to that of the neonatal heart by 8 wk (Fig. 7A). The relative abundance of 
MK5.2 + MK5.5 did not change in young mice, but was significantly lower in the adult, 
indicating that when total MK5 mRNA increased, the generation of MK5.2 + MK5.5 
did not rise proportionately (Fig. 7B). A comparison of the data shown in Fig. 7B and D 
indicates that the variant changing in Fig. 7B, and accounting for up to 8–9% of the total 
MK5 mRNA, was MK5.2. Interestingly, while the abundance of total MK5 mRNA 
decreased during the first weeks of life, that of MK5.3 actually increased several-fold 
during this period (Fig. 7C). However, even at its peak of abundance, the actual amounts 
of MK5.3 mRNA were low in comparison to the total quantity of MK5 mRNA. A 
significant 2-fold increase in the abundance of MK5.4 + MK5.5 mRNA was also noted 
during postnatal development, but, as with MK5.3, the actual amount of 
MK5.4 + MK5.5 mRNA remained comparatively low (Fig. 7D). 
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3.6. MK5 signaling heart 
In further experiments, we sought to determine the expression of MK5 splice 
variants in mouse heart and mouse cardiac ventricular myocytes at the protein level. 
However, none of the currently available commercial antibodies was able to detect MK5 
immunoreactivity in heart lysates or cytosolic extracts (data not shown). Furthermore, 
attempts to raise a rabbit polyclonal antibody against intact MK5.1 did not result in 
antisera that was useful in heart. Given that all MK5 variants retained the p38 and, with 
the exception of MK5.3, ERK3/ERK4 binding sites (Fig. 3E), we decided to investigate 
endogenous expression of MK5 variants in heart after pull-down with either GST-ERK3 
or GST-p38. Surprisingly, none of endogenous MK5 variants was pulled down with 
either exogenously added GST-ERK3 or GST-p38 (Fig. 8A). The band detected at 50-
kDa in the input lane was also present in controls where the primary antibody was 
omitted (data not shown) and hence represents a non-specific interaction with the anti-
mouse secondary antibody. One plausible explanation for the lack of MK5 binding to 
exogenous GST-ERK3 or GST-p38 is that endogenous MK5 is bound in a manner 
such that the docking motifs are occluded and unable to interact with exogenous ERK3 
or p38. This was further studied by adding 1 μg of exogenous MK5.1 (treated with 
thrombin to remove the GST moiety) to heart lysates (2 mg) prior to the pull-down 
assay. In this case, MK5 immunoreactivity was detected in the both GST-ERK3 and 
GST-p38 pull-down assays, with GST-ERK3 being more efficient, suggesting higher 
affinity binding (Fig. 8B). These data suggest that MK5 is expressed at the protein level 
in mouse heart, but that it is present in complexes and, hence, unavailable to interact 
with exogenously added ERK3 or p38. To determine if endogenous MK5 was 
complexed with ERK3, ERK4, or p38, MK5 was immunoprecipitated and the immune 
complexes probed with anti-ERK3, anti-ERK4, or anti-p38 antisera. ERK3 
immunoreactivity was present in MK5 immunoprecipitates, but not the pre-immune 
serum control (Fig. 8C). In contrast, ERK4 and p38 immunoreactivity was not detected 
in MK5 immunoprecipitates. We then sought to determine if endogenous ERK3, ERK4, 
or p38 were free to interact with exogenous GST-MK5. Exogenously added GST-
MK5.1 was able to pull-down ERK4 and p38 but not ERK3 (Fig. 8D). The slower 
78

 Article-1  
migrating band observed in the MK5 pull-down is consistent with the 
hyperphosphorylated form of ERK4 showing higher affinity for MK5 [27] and [28]. 
Based upon our results showing a stable interaction between ERK3 and MK5 in heart, 
we attempted to demonstrate the expression of MK5 splice variants at the protein level 
by immunoprecipitating ERK3 and then doing an MK5 immunoblot on the immune 
complexes; however, the ERK3 antibody was unsuitable for immunoprecipitating 
endogenous MK5 from heart lysates (data not shown). 
 The results shown in Fig. 8A–D were obtained in lysates prepared from 
unstressed hearts. TAC-induced pressure overload results in activation of p38 MAPK 
that peaks after 3 d of TAC and induces cardiac hypertrophy within 2 wk (Dingar et al., 
in preparation). Hence, to determine if MK5 dissociates from ERK3 and associates with 
p38 upon activation of the p38 MAPK pathway, we assessed if ERK3, ERK4 or p38 
co-immunoprecipitated with MK5 in lysates from 3-d TAC hearts. In both TAC- and 
sham-operated hearts, ERK3 co-immunoprecipitated with MK5 whereas p38 
immunoreactivity was not detected (Fig. 8E). Similarly, no association of MK5 with 
ERK4 was observed in stressed hearts. Immunoblotting using an anti-phospho-p38 
antibody confirmed activation of the p38 pathway following 3 d of TAC (Fig. 8E). 
ERK3 is an unstable protein and down-regulation of MK5 expression results in 
reduction of ERK3 protein levels [11] and [12]. Hence, if ERK3 were to be displaced 
from MK5 upon activation of the p38 pathway, one may expect to detect a decrease in 
ERK3 immunoreactivity. However, following 3-d TAC, no change in ERK3 levels was 
detected by immunoblotting (Fig. 8F). ERK4 expression was also unaffected (Fig. 8F). 
These data suggest that in heart, most or all endogenous ERK3 and MK5 were in 
complexes, whereas at least some of the endogenous pool of ERK4 and p38 was 
available to interact with the exogenous GST-MK5.1. Furthermore, MK5 complexes 
included ERK3 but not ERK4 or p38, and this was independent of the activation status 
of the p38 MAPK pathway, indicating that, in heart, MK5 is regulated by ERK3 and not 
ERK4 or p38. 
  
 
79

 Article-1  
4. Discussion 
Mapkapk5, the gene encoding MK5, lies on the negative strand of murine 
chromosome 5 and comprises 14 exons and 13 introns (Fig. 2A). We have demonstrated 
4 novel variants of MK5, which we named MK5.2, MK5.3, MK5.4, and MK5.5. These 
variants appear to have resulted from a combination of exon skipping and activation of 
alternative splice sites during RNA maturation. MK5.2 had a 6 base deletion at the 3	-
end of exon 12, perhaps arising from the selection of an alternative splice site. In 
MK5.3, exon 12 was totally absent. The deletion of exon 12 in MK5.3 produced a shift 
in reading frame in exon 13 resulting in an in-frame stop codon rather than an amino 
acid in position 3 of exon 13. Thus, the predicted amino acid sequence indicates that 
MK5.3 lacks C-terminal amino acids 370 through 473. MK5.4 resulted from skipping of 
exons 2 through 6, inclusively. Finally, MK5.5 lacked both exons 2–6 as well as the 6 
bases at the 3	-end of exon 12 also absent from MK5.2. As a result of the deletion of 
exons 2–6, MK5.4 and MK5.5 lack kinase subdomains I–VIb. All MK5 variants 
retained both a nuclear export sequence (NES) and a nuclear localization sequence 
(NLS) within the C-terminus. The NLS overlaps with the p38 docking site (D-domain) 
[29] and p38-mediated nuclear export requires both phosphorylation of Thr-182 and 
masking of the NLS [22]. The predicted amino acid sequence suggests that all MK5 
variants possess the D-domain that interacts with the CD domain in p38 (Fig. 1). MK5 
also interacts with atypical MAPKs ERK3 and ERK4. However, while the D-domain in 
MK5 does not interact with the CD domains in ERK3 and ERK4, it does interact with 
last 50 amino acids of their C-termini [12] and [14]. Hence, with the exception of 
MK5.3, which lacks 106 amino acids in its C-terminus, all MK5 variants retain the 
binding site for ERK3 and ERK4 (Fig. 2E). 
Although, as discussed above, one possible explanation for the 6 base deletion 
found in MK5.2 and MK5.5 is the activation of an alternative splice site at the 3	-end of 
exon 12, a search of the NCBI murine database revealed a predicted ORF that appears to 
encode MK5.2. This predicted ORF has been named “similar to MK5 type 2” 
(XM_001479242, gene ID 100047833) and lies 96.5-Mbp 3	 to Mapkapk5 on the 
negative strand of chromosome 5. Hence, an alternative explanation would be that there 
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are only 2 splice variants, which are derived from Mapkapk5 and similar to MK5 type 2 
primary RNA transcripts. MK5.3, which lacks exon 12, may arise from both gene 
transcripts, as the 6 bases missing in the similar to MK5 type 2 ORF are found at the 3	-
end of exon 12. MK5.4, which lacks exons 2–6, might result from alternative splicing of 
the Mapkapk5 transcript whereas MK5.5, which lacks exons 2–6 along with the 3	-end 6 
bases in exon 12, would be derived from the similar to MK5 type 2 transcript. As both 
Mapkapk5 and similar to MK5 type 2 have the same intron/exon structure, with the 
exception of a 6 base deletion at the 3	-end of exon 12 in similar to MK5 type 2, and 
both are located on chromosome 5, this would be difficult to prove experimentally. 
MK5 is expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney 
and pancreas [7]. Analysis by qPCR revealed the presence of mRNA for five MK5 
variants in each of the above tissues; however, the abundance of each variant relative to 
the level of total MK5 was tissue-specific. In each of the tissues examined, the most 
abundant variant after MK5.1 was MK5.2. The relative expression of MK5.3, which 
lacks the ERK3 and ERK4 binding domain, was highest in the heart compared to the 
other tissues examined (Fig. 2C–F). MK2 and MK3 show 42% amino acid sequence 
homology with MK5 and all are substrates for p38 MAPK. Furthermore, in certain 
tissues, including the heart, an MK2-deficiency results in reduction in p38 protein 
levels [4]. Therefore, we examined the possibility that a deficiency in MK2 may induce 
compensatory changes in the expression and/or splicing of MK5. However, no changes 
in the abundance of MK5 splice variants were detected (Fig. 2G). These results are 
consistent with previous results suggesting that there is no functional overlap between 
MK5 and MK2 [23], despite the structural similarity [8] and evolutionary relatedness 
[30]. In the heart, the p38 cascade is activated by pro-hypertrophic stimuli including 
endothelin-1, phenylephrine, angiotensin II, mechanical stretch and pressure overload 
[31] and [32]. The role of MK5 in heart, as well as its substrates, remains to be 
elucidated. Interestingly, the relative abundance of MK5.3 mRNA was reduced after 
1 wk of TAC. Further work is needed to understand the mechanism(s) regulating MK5 
splicing during hypertrophic cardiomyopathy and the functional role of MK5 in the 
myocardium. 
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MK5 has been shown to localize to the nucleus when inactive and to translocate 
to the cytosol upon overexpression or activation of p38 [7], [22] and [24]. All MK5 
variants carry both NLS and NES. When exogenously expressed in HEK293 cells, 
MK5.1–MK5.3 localized to the nucleus and translocated to the cytoplasm upon p38 
activation. Translocation was blocked by SB203580, an inhibitor of p38/ activity. 
Hence, the deletion of 2 amino acids in MK5.2 and 106 amino acids in the C-terminus 
of MK5.3 had no effect on their ability to form a stable interaction with p38 and 
undergo phosphorylation at Thr-182. Unexpectedly, MK5.4 and MK5.5 remained in the 
cytoplasm in unstimulated cells and a small amount of immunoreactivity was observed 
within the nucleus upon p38 activation. The translocation of MK5.4 and MK5.5 into the 
nucleus was not blocked by SB203580. Furthermore, their cytosolic localization was not 
altered by leptomycin B, suggesting that this altered localization was due to an inability 
to enter the nucleus rather than enhanced nuclear export. One possible explanation for 
the appearance of immunoreactivity within the nucleus following activation of p38 is 
that cytoplasmic MK5.4 and MK5.5 interact with p38 and enter the nucleus as 
heterodimers with activated p38. 
The mechanisms regulating the activation and subcellular localization of MK5 
are currently controversial. Both p38 and atypical MAPKs ERK3 and ERK4 have been 
implicated. MK5 was originally identified in HeLa cells where it was shown to be 
activated by p38 and p38 in response to stress, including anisomycin, or 
overexpression of a constitutively activated form of MKK6 [7]. As with MK2 and MK3, 
MK5 is primarily in the nucleus in non-stressed cells and relocalizes to the cytosol upon 
activation of p38. However, nuclear export of MK2 in response to arsenite or sorbitol 
treatment is more rapid than that of MK5, suggesting differences in regulation [24]. In 
addition, although stress-induced translocation of MK5 involves activation of p38, 
expression of kinase-dead p38 or p38 [24] as well as non-activatable p38 [22] also 
cause nuclear export of MK5, suggesting that the binding of p38 to MK5 may be 
sufficient to induce translocation. However, whereas p38 stability and stress-induced 
hsp27-kinase activity are reduced in MK2-deficient mice, no such effects are observed 
in an MK5 knock-out model [3] and [23]. Furthermore, no change in the 
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phosphorylation of endogenous hsp25 (the mouse homolog of hsp27) following 
treatment with arsenite was observed in MK5
/
 MEFs [23]. Finally, immune complex 
assays fail to show activation of MK5 following treatment of MK5+/+ MEFs with either 
arsenite or sorbitol [23]. These results suggest MK5 activation may not be regulated by 
p38 in vivo. 
Further understanding of the regulation of MK5 activity came with the studies of 
atypical MAPKs ERK3 and ERK4, which bind MK5 [10], [11] and [12]. Increased 
expression of ERK3 retains MK5 in cytoplasm and facilitates the activation of MK5 by 
cis-autophosphorylation [11]. In contrast, ERK4 directly phosphorylates MK5 [14]. As 
ERK3 expression increases in terminally differentiated cells and growth-arrested cells 
[33], perhaps both ERK3/4 and p38 regulate MK5 activity depending upon the 
differentiation status and nature of the cell system being studied. As adult cardiac 
ventricular myocytes are terminally differentiated cells, one would predict that ERK3 
regulation of MK5 would predominate in these cells whereas p38 may play a significant 
role in regulating MK5 activation in other cellular systems. In the present study, in HEK 
cells, translocation of both endogenous and heterologously expressed MK5 was induced 
by anisomycin and prevented by the p38/ inhibitor SB203580. In contrast, in heart, 
under conditions where p38 activity was minimal, no association of MK5 with p38 was 
observed. Activation of p38 by TAC-induced pressure overload did not alter this 
association. Furthermore, no free MK5 was detected and at least some of the 
endogenous MK5 was associated with ERK3. In both ERK3
/
 fibroblasts and HeLa 
cells following an siRNA-mediated knock-down of ERK3, 40–60% of the endogenous 
MK5 activity remained [12] and this was shown to be due to the interaction of MK5 
with ERK4 [14]. Similarly, in HeLa cells, a knock-down of ERK4 reduces endogenous 
MK5 activity by 50% whereas simultaneous targeting of both ERK3 and ERK4 reduces 
MK5 activity by 80% [14]. In contrast, no interaction of MK5 with ERK4 was detected 
in heart. The presence of MK5-ERK3 complexes in heart raises questions concerning 
the regulation of MK5 activity. Current literature indicates that ERK3 must be 
phosphorylated within its activation loop in order to bind MK5 and this binding results 
in activation and cytosolic relocalization of MK5 [27]. In the present study we were 
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unable to determine the subcellular localization of MK5 in heart due to a lack of suitable 
antibodies. 
The regulation, substrate specificity, and physiological functions of ERK3 and 
ERK4 are currently poorly understood. Neither is regulated by extracellular stimuli that 
activate the classical MAPKs ERK1/2, p38s, and JNKs but are constitutively 
phosphorylated within the S-E-G motif in their activation loop [27] and [28]. ERK3 
activity appears to be regulated both at the level of expression and protein stability: it is 
an unstable protein that is constitutively degraded by the ubiquitin–proteosome pathway 
[33], [34] and [35]. The ERK3 that is expressed in excess of the abundance of certain 
ERK3 binding partners appears to be degraded. To date, the only protein known to 
stabilize ERK3 in vivo is MK5 and deletion of MK5 results in a reduction in ERK3 
protein levels [11]. In contrast to ERK3, ERK4 is a more stable protein [10] and [14]. 
Furthermore, whereas ERK3 is detected in both the nucleus and the cytosol, ERK4 is 
strictly detected in the cytosol [14]. The differences in protein stability and subcellular 
localization suggest different mechanisms regulate the activity of ERK3–MK5 and 
ERK4–MK5 complexes. Whereas activation of MK5 by ERK4 is absolutely dependent 
upon ERK4 being catalytically active, catalytically inactive ERK3 is able to 
phosphorylate and activate MK5, albeit to a lesser extent that wild-type ERK3 [10] and 
[14]. The implication based upon studies in cell expression systems is that ERK3–MK5 
signaling would be constitutively active. It is possible that following overexpression, 
conditions are created where the abundance of the ERK3–MK5 complex exceeds the 
cellular content of other proteins that would normally bind to, and regulate the activity 
of, the ERK3–MK5 complex, resulting in apparent constitutive activation. Along these 
lines, it was recently shown that the phosphoprotein phosphatase Cdc14A both interacts 
with ERK3 and MK5 and dephosphorylates a C-terminal fragment of ERK3 following 
phosphorylation by Cdk1 kinase [36]. It remains to be determined if Cdc14A 
dephosphorylates ERK3 in vivo or at sites other than those phosphorylated by Cdk1 
kinase; however, association with a phosphatase could conceivably provide a means 
whereby the activation of ERK3–MK5 complexes could be regulated in response to 
physiological stimuli. 
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5. Conclusion 
We have cloned and expressed 4 novel splice variants of MK5, named MK5.2–MK5.5. 
These variants were phosphorylated by p38 and p38 in vitro and when exogenously 
expressed in HEK293 cells each variant was translated and translocated upon activation 
of endogenous p38 MAPK. The relative abundance of the MK5 variant mRNAs was 
altered in the ventricular myocardium during pressure-induced hypertrophy and 
postnatal cardiac development. We demonstrated for the first time that MK5 associates 
with ERK3, but not ERK4 or p38, in both control hearts and those exposed to pressure 
overload resulting from 3 d of TAC. Hence, in heart, MK5 may be downstream of 
ERK3 signaling, rather than p38 or ERK4. MK5 splice variants may mediate distinct 
effects downstream of ERK3, thus increasing the functional diversity of the ERK3–
MK5 signaling pathway. The physiological significance of ERK3–MK5 signaling in 
heart remains to be determined. 
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MK3, MAP kinase-activated protein kinase-3; MK5, MAP kinaseactivated protein 
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Figure Legends 
Fig. 1. Sequence comparison of murine MK5 splice variants. Figure shows the 
predicted amino acid sequences. Roman numerals above sequence refer to subdomains 
(I–IX) conserved in all protein kinases. The catalytic domain (residues 22–304) is 
indicated by a solid line above the sequence. The consensus nuclear export sequence 
(NES) is underlined with a solid line and the nuclear localization sequence (NES) is in 
bold letters. Thr-182, the site of phosphorylation by p38 MAPK is indicated by an 
asterisk. The ERK3/4 binding site is indicated. Dashes represent gaps. 
Fig. 2. Detection of MK5 variants in murine tissues. (A) Schematic 
representation of the intron–exon structure of MK5 showing the location of the primers 
used for quantification of MK5 variant mRNAs. (B) The relative abundance of spliced 
MK5 mRNAs was measured in total RNA isolated from murine heart and cardiac 
ventricular myocytes by qPCR. (C) The relative abundance of total MK5 in various 
murine tissues. Abundance of (D) MK5.2 + MK5.5, (E) MK5.3, and (F) 
MK5.4 + MK5.5 mRNA expressed as percentage of total MK5. (G) Detection of MK5 
variants in hearts from 12-wk old MK2
/
 versus MK2+/+ littermate mice. Shown are the 
mean ± S.E. (n = 3).  
Fig. 3. Expression of recombinant MK5 splice variants. GST-MK5 fusion 
proteins were expressed in E. coli and purified by chromatography on glutathione 
Sepharose. Aliquots of purified protein were separated on 10–20% acrylamide-gradient 
SDS-PAGE and either (A) visualized using Coomassie Brilliant blue R250 stain or (B) 
transferred to nitrocellulose and probed with anti-GST (left) or anti-MK5 (right) 
antibodies. (C) HEK293 cells were transfected with the indicated pIRES-MK5-V5-
EGFP construct. After 24 h, lysates were prepared, separated on 10–20% acrylamide-
gradient SDS-PAGE, transferred to nitrocellulose, and probed with an anti-MK5 (top), 
anti-V5 (middle), or anti-EGFP (bottom) antibodies. (D) Activated p38 was incubated 
along with purified GST-MK5, hsp27, and radiolabeled [32P]ATP. Proteins were 
separated on 10–20% SDS-PAGE and 32P incorporation was detected by 
autoradiography. (E) GST pull-down assays were performed on lysates from HEK293 
cells transfected with the indicated expression vectors using either recombinant ERK3-
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GST or GST alone. Bound MK5 was detected by immunoblotting using an anti-V5 
antibody. Equal expression of the MK5 variants was verified by loading 10% total cell 
lysate input. Numbers at the left indicate the positions of the molecular mass marker 
proteins (in kDa).  
Fig. 4. Activation of p38 MAPK induces translocation of endogenous MK5 in 
HEK293 cells. HEK293 cells were transfected with pIRES-MK5.1-V5-EGFP. After 
24 h cells were serum starved for 6 h and then treated with or without sorbitol (0.3 M) 
(A) or anisomycin (15 μg/ml) (B) for the indicated times and then lysates were prepared. 
Activation of p38 was detected by immunoblotting using an anti-phospho p38 antibody. 
The stability of exogenous MK5 and endogenous p38 during prolonged stress was 
verified by immunoblotting using anti-V5 and anti-p38 antibodies. (C) Untransfected 
HEK293 cells were grown for 48 h, serum starved for 6 h, and then treated with or 
without sorbitol (0.3 M) or anisomycin (15 μg/ml) for 2 h. Cells were then fixed and 
MK5 was visualized by staining with an anti-MK5 antibody and an Alexa 555-coupled 
secondary (anti-mouse) antibody. The upper panels are the fluorescence images whereas 
the lower panels contain differential interference contrast images of the same cells. 
Images were acquired using a 63×/1.4 plan-apochromat oil DIC objective lens. 
Fig. 5. p38 MAPK activation alters the subcellular localization of MK5-V5 
variants. HEK293 cells were transfected with (A) pIRES-MK5.1-V5-EGFP, (B) pIRES-
MK5.2-V5-EGFP, (C) pIRES-MK5.3-V5-EGFP, (D) pIRES-MK5.4-V5-EGFP, (E) 
pIRES-MK5.5-V5-EGFP, or (F) pIRES-MK5.1-T182A-V5-EGFP. After 24 h of 
transfection cells were serum starved for 6 h and then treated with or without 
anisomycin (15 μg/ml, 2 h), SB203580 (20 μM), or LMB (3 ng/ml, 10 min). Where 
indicated, cells were preincubated with SB203580 for 10 min prior to the addition of 
anisomycin. Following treatment, cells were fixed and MK5 was visualized by staining 
with an anti-V5 antibody and Alexa 555-coupled secondary (anti-mouse) antibody 
(upper panels). Nuclei were visualized by TO-PRO 3 iodide (1.5 μM) staining (lower 
panels). Several fields of cells were examined and representative images are shown.  
 
91

 Article-1  
Fig. 6. Pressure overload-induced hypertrophy alters MK5 splicing. Pressure 
overload hypertrophy was induced in mice by transverse aortic constriction (TAC). 
Sham animals underwent the identical surgical procedure, however the aortae were not 
constricted. After 1 wk of TAC, mice were sacrificed, the hearts were removed, and 
total RNA was isolated. MK5 variants were quantified at the mRNA level by qPCR. 
GAPDH mRNA was employed as an internal control and the abundance of total MK5 
mRNA (A) is expressed relative to 1 randomly chosen sham sample. The abundance of 
MK5.2 + MK5.5 (B), MK5.3 (C), and MK5.4 + MK5.5 (D) mRNAs is expressed as a 
percentage of total MK5 mRNA. Expression of cardiac fetal genes atrial natriuretic 
peptide (ANP) (E) and -myosin heavy chain (-MHC) (F) are expressed relative to 
GAPDH. Shown are the mean ± S.E. (n = 6). ***, p < 0.001: **, p < 0.01: *, p < 0.05: 
one-way ANOVA with Newman–Keuls post-hoc analysis.  
Fig. 7. Regulation of MK5 splicing in heart during postnatal maturation. Mice 
were sacrificed at birth, 7 d, 20 d, or 8 wk (adult) of age and mRNA levels of MK5 
variants were quantified by qPCR. The abundance of total MK5 mRNA (A) is 
normalized to GAPDH and expressed relative to 1 randomly chosen neonatal sample. 
The abundance of MK5.2 + MK5.5 (B), MK5.3 (C), and MK5.4 + MK5.5 (D) mRNAs 
is expressed as a percentage of total MK5 mRNA. Shown are the mean ± S.E. (n = 3). 
***, p < 0.001: **, p < 0.01: one-way ANOVA with Newman–Keuls post-hoc analysis.  
Fig. 8. MK5 interacts with ERK3 in heart. (A) GST pull-down assays were 
performed on murine ventricular myocardium lysates (2 mg) using either GST-p38, 
ERK3-GST, or GST alone. Bound MK5 was detected by immunoblotting using an anti-
MK5 monoclonal antibody. As a control, 50 μg lysate (input) was loaded in lane 1. (B) 
To validate the GST-pull-down assay, lysates (2 mg) were ‘spiked’ with 1 μg of 
thrombin-cleaved MK5.1 prior to performing the pull-down assay using either GST-
p38, ERK3-GST, or GST alone. Bound MK5 was detected by immunoblotting using 
an anti-MK5 monoclonal antibody. As a positive control, 10 ng of MK5.1 was loaded 
onto the gel. (C) Murine ventricular myocardium lysates were prepared and MK5 was 
immunoprecipitated. Purified rabbit IgG was employed in control immunoprecipitations. 
Co-immunoprecipitated ERK3, ERK4, or p38 was detected by immunoblotting. (D) 
92

 Article-1  
GST pull-down assays were performed on murine ventricular myocardium lysates 
(2 mg) using either GST-MK5.1 or GST alone. Bound ERK3, ERK4, or p38 was 
detected by immunoblotting. As a control, 50 μg of lysate (input) was loaded in lane 1. 
(E) Pressure overload hypertrophy was induced in mice by transverse aortic constriction 
(TAC). Sham animals underwent the identical surgical procedure, however the aortae 
were not constricted. After 3 d of TAC, mice were sacrificed, the ventricular 
myocardium was isolated, lysates were prepared, and MK5 was immunoprecipitated. 
Purified rabbit IgG was employed in control immunoprecipitations. Co-
immunoprecipitated ERK3, ERK4, p38, phospho p38, and GAPDH were detected by 
immunoblotting. Aliquots (50 μg) of lysate from TAC and sham hearts were included as 
controls (Input). Results shown are representative of 3 animals in each group. (F) 
Lysates (50 μg) from 3-d TAC and sham hearts were analyzed by SDS-PAGE and 
immunoblotting using an anti-ERK3 or anti-ERK4 antibodies. Shown are the 
mean ± S.E. (n = 3). 
Fig. S1. Genomic alignment of cDNA sequence of MK5 variants cloned from 
murine heart. Panels a and b show that the 5	 deletion in MK5.4 and 5.5 corresponds to 
the skipping of exons 2 through 6. Panel c shows that the 6 base deletion in MK5.2 and 
MK5.5 corresponds to skipping of the last 6 bases of exon 12 when removing intron 12. 
This results in the absence of 2 amino acids, Lys and Gly. This panel also shows that 
MK5.3 results from skipping of exon 12, resulting in a shift in reading frame in exon 13, 
generating an in-frame stop codon in the third intact codon in exon 13 (bold). This 
variant is not the product of altered splicing at the 3	 intron/exon boundary of exon 11 as 
the sequence in MK5.3 does not correspond the sequence in the 5	 region of intron 11 
(bold italics) or exon 12 (not shown), but aligns with the sequence in exon 13. In-frame 
codons flanking the sites of intron excision are underlined. NLS, nuclear localization 
signal; NES, nuclear export signal. Dashes represent gaps.  
Fig. S2. Schematic representation of MK5 variants. NLS, nuclear localization 
signal; NES, nuclear export signal. 
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Tables
Table 1. Primers used during real-time qPCR 
Target  Primers 
Total MK5 S 
Total MK5 AS 
5’-GAC AGA GGC CCT GGA TAA TGT GC-3’ 
5’-GAG TGC AGG GGT TTG AGG CTG-3’ 
MK5.2+5.5 S 
MK5.2+5.5 AS 
5’-TAT CCT CCC CCA GGC TGG AG-3’ 
5’-CTT CGA TCA CCT GCT TTA CCA CC-3’ 
MK5.3 S 
MK5.3 AS 
5’-GCG GGG ATC CAG CAG GCG CAC GCC GAG-3’ 
5’-CTT CTC ATC TTC ATT CTC TCC CCA-3’ 
MK5.4+5.5 S 
MK5.5+5.5 AS 
5’-AGA AAG CCA TCA AGG ACG CCC-3’ 
5’-CCA CAA GTC ACA GCT CTT GTT G-3’ 
ANP S 
ANP AS 
5’-GTG CGG TGT CCA ACA CAG A-3’ 
5’-TTC TAC CGG CAT CTT CTC CTC-3’ 
-MHC S 
-MHC AS 
5’-AGG GTG GCA AAG TCA CTG CT-3’ 
5’-CAT CAC CTG GTC CTC CTT CA-3’ 
GAPDH S 
GAPDH AS 
5’-CTG CAC CAC CAA CTG CTT AGC-3’ 
5’-ACT GTG GTC ATG AGC CCT TCC A-3’ 
S, sense; AS, anti-sense; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; MK, 
MAPK-activated protein kinase; qPCR, quantitative polymer chain reaction; ANP, atrial 
natriuretic peptide; -MHC, -myosin heavy chain
 
ARTICLE-2 

Dingar D, Merlen C, Grandy S, Gillis MA, Villeneuve LR, Mamarbachi AM, Fiset C, 
and Allen BG. “Effect of pressure overload-induced hypertrophy on the expression and 
localization of p38 MAP kinase isoforms in the mouse heart.” Cell Signal. 2010 
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ABSTRACT 
 p38 mitogen-activated protein kinases (MAPKs) are serine/threonine specific 
protein kinases that respond to cellular stress and regulate a broad range of cellular 
activities. There are four major isoforms of p38 MAPK: , , , and . To date, the 
prominent isoform in heart has been thought to be p38. We examined the expression of 
each p38 isoform at both the mRNA and protein level in murine heart. mRNA for all 
four p38 isoforms was detected. p38 and p38 were expressed at protein levels 
comparable to p38 and 38, respectively. In the early phase of pressure-overload 
hypertrophy (1–7 days after constriction of the transverse aorta), the abundance of p38, 
p38 and p38 mRNA increased; however, no corresponding changes were detected at 
the protein level. Confocal immunofluorescence studies revealed p38 and p38 in both 
the cytoplasm and nucleus. In the established phase of hypertrophy induced by chronic 
pressure overload (7–28 days after constriction of the transverse aorta), p38 
immunoreactivity accumulated in the nucleus whereas the distribution of p38 remained 
unaffected. Hence, both p38 and p38 are prominent p38 isoforms in heart and p38 
may play a role in mediating the changes in gene expression associated with cardiac 
remodeling during pressure-overload hypertrophy. 
 
© 2010 Elsevier Inc. All rights reserved. 
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1. Introduction 
 Five distinct mitogen-activated protein kinase (MAPK) pathways have been 
classified in mammalian cells: c-jun amino-terminal kinases (JNKs) 1, 2, and 3; p38 
MAP kinases , , , and ; extracellular signal-regulated kinases (ERKs) 1, 2; ERK3/4; 
and ERK5 [1]. The principle MAPKs investigated in cardiac myocytes are ERK1/2, 
which are activated by hypertrophic stimuli, and JNK and p38 MAPK, which are 
activated by cellular stress [2]. p38 and p38 are ubiquitously expressed, while p38 is 
expressed in striated muscle and p38 is expressed in lung, kidney, testis, pancreas, and 
small intestine [3] and [4]. To date p38, p38, and p38 have been detected in heart [3] 
and [5]. 
p38 MAPK is activated by phosphorylation of the TGY motif within the 
activation loop by upstream kinases MKK3, MKK6, and MKK4. In addition, there 
exists at least 3 means whereby p38 activation is independent of MKK activity. 
Interactions with TAB1 or ZAP-70 [6] and [7] induce autophosphorylation of p38 
within the activation loop whereas interactions with Hsp90-Cdc37 supressed this 
autophosphorylation [8]. Although the exact role of each p38 isoform remains to be 
determined, each p38 isoform has been independently knocked out in mice: p38-
deficient mice show embryonic lethality due to placental defects, whereas p38-, p38-, 
and p38-null mice appear to have normal phenotypes [9]. Transgenic mice expressing 
dominant negative forms of p38 and p38 are resistance to cardiac fibrosis during 
pressure overload [10]. 
Due to the availability of pharmacological inhibitors, p38 and p38 have been 
far more extensively studied than p38 and p38. Inhibition of p38/ activity reduces 
apoptotic cell death in cultured myocytes and intact heart upon pressure overload or 
ischemia/reperfusion [11] and [12]. Additionally, improved cardiac function and 
reduced remodeling is observed upon inhibition of p38/ during ischemia/reperfusion 
injury or myocardial infarction [13] and [14]. p38 is the only MAPK containing a PDZ 
binding domain sequence (KETXL) within its carboxyl-terminus [15], which makes it 
unique in the MAPK family. In addition, p38 expression is induced during muscle 
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differentiation [16] and it localizes in cytoplasm whereas p38 and p38 are present in 
the cytoplasm and nucleus in isolated cardiac myocytes [3]. 
p38 isoforms are currently thought to serve non-redundant functions. We have 
studied the expression of each p38 isoform in mouse heart to determine their presence 
and relative abundance. In addition, we examined the effect of pressure overload-
induced cardiac hypertrophy on their expression and subcellular localization. 
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2. Materials and methods 
2.1. Materials 
SDS-polyacrylamide gel electrophoresis reagents, nitrocellulose, and Bradford 
protein assay reagents were from Bio-Rad Laboratories. Membrane grade (reduced) 
Triton X-100 (TX-100), leupeptin, and PMSF were from Roche Molecular 
Biochemicals. Anti-HSP27 was gift from Dr. William Gerthoffer (Reno, NV). Anti-
p38 was from Santa Cruz Biotechnology (sc-535). Anti-p38 was from Upstate 
Biotechnology (#07-474), anti-p38 was a gift from Dr. Jacques Landry, anti-p38 
(#2308), anti-phospho p38 MAPK (#2911S) and anti-phospho HSP27 (S-82) were from 
Cell Signaling Technology. Anti-phospho HSP27 (S-15) was from StressGen 
Biotechnologies Co. (SPA-525). Mouse anti-GAPDH was from Ambion Inc. (#4300). 
ALEXA fluor 488-conjugated donkey anti-rabbit secondary antibody was from 
Invitrogen. HRP-conjugated secondary antibodies were from Jackson ImmunoResearch 
Laboratories. All other reagents were of analytical grade or best grade available. Primers 
for PCR and qPCR were from Invitrogen. GST fusion proteins were purified by affinity 
chromatography on glutathione Sepharose (GE Healthcare). 
 
2.2. Preparation of murine cardiac lysates 
Mice were sacrificed after sedation with pentobarbital. Hearts were rapidly 
removed, snap frozen in, and pulverized under, liquid nitrogen. Heart powders were 
divided into two and used for both RNA extraction and protein extraction. To prepare 
lysates, powdered tissue was resuspended using a 2 ml Potter-Elvehjem tissue grinder 
(25–30 passes) in 1.2 ml of ice-cold lysis buffer comprising 50 mM Tris (pH 7.5 at 
4 °C), 20 mM -glycerophosphate, 20 mM NaF, 5 mM EDTA, 10 mM EGTA, 1.0% 
TX-100, 1 mM Na3VO4, 1 M microcystin LR, 5 mM DTT, 10 g/ml leupeptin, 
0.5 mM PMSF, and 10 mM benzamidine. Homogenates were then cleared of cellular 
debris by centrifugation for 30 min at 100,000 × g (48,000 rpm) and 4 °C in a Beckman 
TLA-100.3 rotor. Finally, supernatants were collected, aliquoted, snap-frozen using 
liquid nitrogen, and stored at 
80 °C. 
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2.3. Cloning and purification of fusion proteins 
Human cDNA for p38 was purchased in the pOTB7 vector (Open Biosystems), 
p38 was in pCMV-SPORT6 (Open Biosystems), p38 was in pET 14b (a gift from Dr. 
Jiahuai Han), and p38 was in pOTB7 (ATCC). Full length inserts for each p38 isoform 
was then subcloned into pGEX-6P (GE Healthcare) in phase 3	 to a GST-6His coding 
sequence. Insertion of cDNA in to pGEX-6P was confirmed by electrophoresis on 
agarose gels and sequencing. Each pGEX-6P p38 construct was transformed into E. coli 
competent strain BL21 (DE3) (Novagen). Transformed E. coli were then selected on 
DYT agar media containing 100 g/ml ampicillin. The transformed bacteria were 
inoculated in DYT media contained 100 g/ml ampicillin, grown to an optical density of 
0.6 at 600 nm, and then expression of the GST-fusion protein induced by addition of 
1 mM isopropyl--D-thiogalactoside for 6–7 h at 37 °C with constant shaking. p38-
fusion proteins were purified by affinity chromatography on glutathione Sepharose (GE 
Healthcare). The integrity and purity of each fusion protein was determined by SDS-
PAGE. 
 
2.4. RNA analysis 
Mouse heart total RNA was isolated using RNeasy® Mini kits (Qiagen Inc.) 
with minor modifications. Briefly, total RNA was extracted by homogenizing tissue 
powders in 2 ml of TRIzol reagent (Sigma) using a Polytron at 10,000 rpm (2 × 15 s). 
Chloroform (0.4 ml) was added (for phase separation) and then samples were mixed and 
centrifuged for 15 min at 18,300 × g and 4 °C. The upper aqueous phase was collected, 
diluted with an equal volume of 70% ethanol, loaded onto Qiagen columns, and purified 
according to the manufacturer's instructions. Total RNA concentrations were determined 
by measuring the optical density and only samples having an 260/280 ratio between 1.8–
2.1 were used. cDNA synthesis was performed in a 20 l reaction volume containing 
1 g of total RNA, 100 ng of random primers, 1× First Strand buffer (50 mM tris–HCl 
pH 8.3, 75 mM KCl, 3 mM MgCl2), 0.5 mM dNTP, 10 mM DTT, 40 U RNaseOUT 
recombinant ribonuclease inhibitor, and 200 U of M-MLV reverse transcriptase 
(Invitrogen), according to the manufacturer's protocol. Real-time qPCR was performed 
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using a MX3000P QPCR system (Stratagene). Each amplification reaction mixture 
(25 l) contained 12.5 ng cDNA equivalent to reverse transcribed RNA, 300 nM 
forward and reverse primers, 30 nM ROX passive reference, 12.5 l platinum SYBR 
green mix (2×) (Invitrogen). PCR parameters were 95 °C for 10 min, and 40 cycles of 
95 °C for 30 s, 55 °C for 30 s, and 72 °C for 1 min. SYBR green fluorescence was 
measured at the end of the annealing and extension phases of each cycle. p38 isoform-
specific primers were designed using Clone Manager 6 (Sci Ed Software, USA) and 
were based on the cDNA sequences in the NCBI database (p38, NM_011951; p38, 
NM_011161; p38, NM_013871; p38, NM_011950). The forward and reverse primers 
used are shown in Table 1. The ability of each primer pair to selectively amplify a single 
target sequence was verified by analyzing the dissociation curve. In addition, amplicons 
were gel purified and sequenced to assure amplification of the correct target sequence. 
The amplification efficiency for each primer pair, determined from a standard curve of 
50–3.25 ng reverse transcribed RNA isolated from the murine heart after two-fold serial 
dilution, was found to be between 90–110%. All samples were normalized to GAPDH, 
which was amplified in parallel.  
 
2.5. Subcellular localization of p38 and p38 
Following surgical removal, mouse hearts were frozen in 2-methyl butane 
chilled with liquid nitrogen. Tissue was embedded in Tissue-Tek O.C.T. compound 
(Sakura Finetek USA, Inc.). After trimming, 14 m transverse ventricular cryosections 
were prepared and stored at 
80 °C prior to further use. Three sections per heart were 
fixed for 20 min in ice-cold 4% paraformaldehyde in PBS (pH 7.2). After fixation, 
sections were washed three times with ice-cold PBS (5 min), blocked and permeabilized 
in a PBS solution containing 2% donkey serum and 0.5% TX-100 for 60 min. Slides 
were rinsed once with ice-cold PBS and incubated with primary antibody diluted (1:100 
for p38 and phospho p38; 1:200 for p38) in PBS containing 1% donkey serum and 
0.1% TX-100 overnight at 4 °C in a closed humidified chamber. The next day, slides 
were rinsed three times with ice-cold PBS and incubated for 1 h with ALEXA fluor 488-
labeled donkey anti-rabbit IgG antibody (1:600) and 1.5 M TO-PRO 3 iodide in PBS 
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containing 1% donkey serum and 0.1% TX-100. Finally, slides were rinsed three times 
with ice-cold PBS, drained and mounted using 15 l of DABCO/glycerol medium. 
p38, p38, and TO-PRO-3 (binds dsDNA) were visualized using an LSM-510 confocal 
fluorescence microscope (Carl Zeiss, Oberkochen, Germany) as described previously 
[17], [18] and [19]. Control experiments were performed omitting the primary antibody. 
 
2.6. Activation of p38 
Purified GST-p38 isoforms (0.5 mg/ml) were activated by incubating in the 
presence of constitutively active His6-MKK6(EE) (0.16 mg/ml) in the presence of 
1 mM ATP, 10 mM MgCl2, 0.62 mM EGTA, 0.25 mM DTT, 1 mM Na3VO4, 10 g/ml 
leupeptin, and 1 M microcystin in PBS overnight at room temperature without mixing 
[20]. This procedure has been shown previously to give complete dual (TGY) 
phosphorylation of p38 [20]. To separate phosphorylated GST-p38 from His6-
MKK6(EE), reaction mixtures were incubated with glutathione Sepharose beads for 2–
3 h at 4 °C on a clinical rotor, centrifuged for 2 min at 5000 rpm and 4 °C, washed thrice 
with TBS containing 1 mM EDTA (TBSE), and bound GST-p38 eluted with reduced 
glutathione. Purified, activated p38 was then dialyzed against TBSE buffer followed by 
a storage buffer comprising 50% glycerol, 50 mM Tris (pH 7.5 at 5 °C), 150 mM NaCl, 
0.1 mM EGTA, 0.03% Brij 35, 1 mM benzamidine, 0.2 mM PMSF, and 0.1% -
mercaptoethanol. Protein concentrations for each isoform were determined on 10–20% 
SDS-PAGE using BSA as a standard. Proteins were separated on gels and stained with 
Coomassie Brilliant Blue R250. Gels were scanned using a VersaDoc 4000 imaging 
system and p38 and BSA band densities determined using Quantity One software (Bio-
Rad Laboratories, Inc). The specific activity of each phosphorylated p38 isoform was 
determined by incubating activated p38 (20 ng) with 0.33 mg/ml MBP, 100 M 
[32P]ATP (10 Ci), 1 mM EGTA, 10 mM MgCl2, 10 mM DTT, 10 g/ml leupeptin, 
1 mM Na3VO4, and 1 M microcystin LR at 30 °C for 2, 5, 8, and 10 min. Reactions 
were stopped with SDS-PAGE sample buffer and separated on 10–20% SDS-PAGE, 
stained with Coomassie blue, the MBP band excised from the gel, and 32P incorporation 
in MBP measured by liquid scintillation counting. 
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2.7. Immunoblotting 
SDS-PAGE and immunoblotting were performed as described previously [17]. 
Following the transfer, nitrocellulose membranes were rinsed in PBS and fixed by with 
glutaraldehyde [21]. 
 
2.8. Pressure-overload hypertrophy 
Chronic pressure-overload was induced in male C57BL/6 mice (10 weeks old) 
by transverse aortic constriction (TAC) for 1, 3, 7, 14, and 28 days as described [21]. 
Sham mice underwent the same surgical procedure except the aortae were not 
constricted. 
Animal handling followed the guidelines of the Canadian Council of Animal 
Care. 
 
2.9. Miscellaneous methods 
Protein concentrations were determined by the method of Bradford [22] using 
bovine serum albumin (BSA) as a standard. 
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3. Results
3.1. Expression of p38 isoforms in heart 
Although the expression of p38, p38, and p38 in heart has been shown 
previously [5], nothing is known about the expression of p38 or the relative abundance 
of each isoform. To further our understanding of p38 signaling in heart we quantified 
the relative mRNA abundance for each p38 isoform using real time quantitative PCR. 
As the p38 isoforms show high degree of DNA sequence homology (> 60%), primers 
were directed towards regions of lower homology and on different exons. In addition, 
primers were designed to specifically amplify amplicons of similar size (p38 271 
bases, p38 264 bases, p38 269 bases, and p38 202 bases). Equal amplicon size 
allowed us to better compare the relative expression levels. The specificity of each 
primer pair was verified both by melting curve and sequencing. Using these isoform 
specific primers (Table 1), the mRNA abundance was measured in mouse heart and 
expressed relative to the abundance of p38 mRNA. We detected mRNA for all four 
p38 isoforms with p38 and p38 mRNAs being the most abundant followed by p38 
(10.6%), and p38 (0.08%) (Fig. 1A). 
As it's the level of protein that is important with respect to function, we 
examined the expression of each p38 isoform by immunoblotting. At the amino acid 
level p38 isoform have more than 60% sequence homology [23], hence there is 
possibility that antibodies may cross react. We first used purified recombinant p38 
isoforms (Fig. 1B) to assess the isoform-selectivity of each antibody. Different 
commercially available antibodies were screened against pure p38 isoforms and only 
those that were specific for the intended isoform were employed in subsequent studies 
(Fig. 1C). Using these isoform-specific antibodies, expression of each p38 isoform in 
hearts lysate was assessed by immunoblotting. All four p38 isoforms were detected 
(Fig. 1D). We then quantified the expression of p38 isoform expression by 
immunoblotting using purified GST-p38 isoforms as standards. Similar to mRNAs, 
p38 and p38 were the most abundant isoforms at the protein level, followed by p38 
(0.018%) and p38 (0.016%) (Fig. 1E). In conclusion p38 is expressed in heart and at a 
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level comparable to p38. Furthermore, p38 and p38 are expressed at similar levels, 
indicating that p38 might also play an important role in regulating cardiac function. 
 
3.2. p38 expression during chronic pressure overload 
p38/ dominant negative transgenic mice are resistant to cardiac fibrosis during 
pressure overload [10]. In addition, inhibition of p38/ activity reduces apoptotic cell 
death in cultured myocytes and intact heart during pressure overload or 
ischemia/reperfusion [11] and [12]. However, although they are activated by similar 
upstream kinases, there is very little known about the function of p38 and p38. Our 
results (Fig. 1A and E) showed p38 is expressed at levels similar to p38. Therefore, 
we examined the effect of chronic pressure overload on the expression of each p38 
isoform to see if any particular isoform shows alterations in expression, as this would 
suggest potentially a more prominent role in cardiac pathophysiology. Chronic pressure 
overload was induced by transverse aorta constriction and mice were sacrificed after 1, 
3, or 7 days. Total RNA was subsequently isolated and the relative mRNA abundance of 
each p38 isoform was quantified by qPCR. There was no change in the quantity of p38 
mRNA. In contrast, p38 and p38 mRNA increased within 1 day of pressure overload 
and remained elevated whereas p38 mRNA showed an initial increase but had returned 
to basal levels by day 7 (Fig. 2A). However, although increases in mRNA abundance 
were observed for p38, p38, and p38, the protein level of each isoform was unaltered 
within this time-frame (Fig. 2B). 
Chronic pressure overload induces a hypertrophic response that is associated 
with both the re-expression of fetal genes and activation of the p38 MAPK pathway. To 
verify the establishment of a hypertrophic response, we assessed the levels of atrial 
natriuretic peptide (ANP) and -myosin heavy chain (-MHC) [24] mRNA in sham and 
banded hearts by qPCR. ANP and -MHC mRNA was increased in TAC hearts on day 
1 and gradually increased further through day 7 (Fig. 2D). The time-course for 
activation of p38 signaling was also examined. We examined the effect of pressure 
overload on the phosphorylation of p38 MAPK and its downstream effector hsp25 using 
phospho-specific antibodies to the T-G-Y motif in p38 and Ser-15 and Ser-82 in hsp25 
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(Fig. 2C). p38 phosphorylation was increased on day 1, peaked on day 3, and then 
declined but remained elevated, relative to sham animals, on day 7. The phospho-p38 
antibody revealed a doublet on day 3, suggested at least 2 isoforms were activated. A 
similar time course was observed for phosphorylation of hsp25 (Fig. 2C). Hence, 
although chronic pressure overload include a sustained increase in ANP and -MHC 
mRNA, high levels of p38 activation were not sustained. 
Similar to ANP and -MHC, the abundance of p38 and p38 mRNA increased 
in response to pressure overload. ANP and -MHC are fetally expressed genes that 
become re-expressed during pathological cardiac hypertrophy. We sought to determine 
the temporal expression of each p38 isoform in the ventricular myocardium during post-
natal development. mRNA was isolated from neonatal, 7 day, 20 day, and adult 
(8 week) hearts. Analysis by qPCR showed that (relative to neonatal hearts) p38 
mRNA was reduced by 2-fold at 7 and 20 days (Fig. 3A), p38 mRNA dropped 2-fold 
at 20 days (Fig. 3B), p38 mRNA was reduced at 7 and 20 days (Fig. 3C), and p38 
mRNA dropped more than 3-fold within 7 days of birth (Fig. 3D). However, whereas 
the mRNA content for p38, p38, and p38 had returned to levels comparable to those 
in the neonatal heart by 8 weeks, p38 mRNA remained low in the adult heart. 
 
3.3. Specific activity 
The level of expression is only one determinant of the impact an enzyme may 
have on cellular function. Other factors include its subcellular localization, substrate 
specificity, activation, and turnover number. Therefore we examined the specific 
activity of each p38 isoform, following phosphorylation in vitro by His6-MKK6(EE) 
and repurification, towards MBP. The specific activity of p38 was 75.70 U/mg 
(Fig. 4A), p38 was 76.05 U/mg (Fig. 4B), p38 was 96.13 U/mg (Fig. 4C), and p38 
was 190.9 U/mg (Fig. 4D). Hence, the specific activity of p38 towards MBP was more 
than two fold higher than the other isoforms. However, this cannot compensate for the 
comparatively low levels of p38 protein relative to p38 and p38, and suggesting 
p38 and p38 may play more prominent roles in the heart. 
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3.4. Subcellular distribution of p38 and p38 during pressure overload-induced 
hypertrophy 
Although each p38 isoforms are activated, with variable efficiency, by similar 
upstream kinases MKK3, MKK4, and MKK6 [25], no study to date has described the 
effect of chronic pressure overload on the cellular localization of p38. Hence, we studied 
TAC induced pressure-overload in mice. Mice were sacrificed 7, 14, and 28 days after 
surgery, time-points where molecular and morphological changes associated with 
pathological hypertrophy were clearly apparent. These time points were chosen to 
examine localization once hypertrophy had been established rather than during the acute 
or early phases of the response to pressure overload [26]. Cryosections of the ventricles 
were prepared and immunostained with anti-p38, anti-p38, or anti-phospho-p38 
antibodies. As immunoblotting showed p38 and p38 1) were in far lower abundance 
and 2) their antibodies reveal non-specific bands, we did not determine the subcellular 
localization of these isoforms. p38 and p38 localized to the cytoplasm and nucleus in 
sham hearts. However, increased nuclear localization of p38 was observed in sections 
from TAC hearts at 7, 14, and 28 days (Left panel of Fig. 5A, B and C). In contrast, no 
nuclear accumulation of p38 was observed (Right panel of Fig. 5A, B and C). 
Reexpression of BNP and -MHC confirmed a persistent hypertrophic response in these 
hearts (Fig. 5D). No differences between TAC and sham were observed with the anti-
phospho-p38 antibody (results not shown), which is consistent with the low levels of 
phospho-p38 detected by immunoblot after day 3 (Fig. 2C). These results suggest that 
p38 and p38 respond differently to chronic pressure overload in terms of their 
subcellular localization. These differences in localization would result in access to 
different substrates and hence distinct functional effects. Nuclear accumulation for p38 
and not p38, as well as differential regulation at transcriptional level during heart 
development and hypertrophy strongly suggests non-redundant roles of p38 and p38 
in the heart as well as a potential role for p38 in the maintenance and/or progression of 
pathological ventricular hypertrophy. 
To understand the consequences of the nuclear localization of p38, we sought to 
identify substrates in cytosolic and nuclear fractions from rat heart specific to 
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phosphorylated, activated GST-p38/// upon incubation in the presence of 
[32P]ATP. However, no isoform-specific phosphorylation was observed in either 
subcellular fraction (results not shown). The failure to detect added incorporation of 32P 
into proteins in the cytosolic and nuclear fractions might reflect low copy number or 
phosphorylation status of target proteins in these fractions or, perhaps, the absence of a 
suitable scaffolding protein. 
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4. Discussion 
To date p38, p38, and p38 have been reported in heart with p38 being 
considered to be the dominant isoform [3], [4] and [5]. We now show that p38 is 
expressed in the mouse heart at protein levels that are comparable to p38. In addition, 
at both the mRNA and protein levels, expression of p38 and p38 are similar, 
suggesting that both play important roles in the heart. Finally, p38 was shown to 
accumulate in the nucleus in hearts hypertrophying due to chronic pressure overload. 
p38 was detected in mouse heart by immunoblotting and found to be expressed 
at levels similar to p38. There are numerous reports suggesting that, although 
expressed at levels much lower than p38, p38 plays a distinct role in the heart. p38 
and p38 are activated in the heart in response to ischemia and reperfusion [27] and 
pressure overload [26], as well as following the exposure of cardiac myocytes to 
cytokines [28], hypertrophic agonists [29] and mechanical stretch [30]. In simulated 
ischemia phosphorylation of p38 increases whereas that of p38 decreases [31]. 
Moreover inhibition of p38 during ischemia has a protective effect [31] and [32]. 
Similarly, p38+/
 mice are resistant to infarction [33]. In contrast, during 
preconditioning, activation of p38 decreases and that of p38 increases [31], 
suggesting that p38 is protective whereas p38 is detrimental. Expression of 
constitutively active MKK6bE or MKK3bE along with wild-type or dominant negative 
p38 (DN-p38) or p38 (DN-p38) in neonatal myocytes indicates p38 mediates 
apoptosis whereas p38 is involved in the hypertrophic response [34]. Mice expressing a 
dominant-negative form of 14-3-3 (DN-14-3-3) are unable to compensate for pressure 
overload resulting in increased myocyte apoptosis and mortality. DN-14-3-3/DNp38 
mice, and to a lesser extent DN-14-3-3/DN-p38 mice, show reduced mortality and 
cardiac myocyte apoptosis in response to pressure overload [35]. Taken together, these 
data indicate that, although expressed at lower levels than p38 or p38, p38 plays a 
distinct role in the heart. Hence, further study might also reveal a unique role for p38 in 
the heart. 
The anti-apoptotic role of p38 and p38 has been studied in pressure overload 
hypertrophy and ischemia/reperfusion [11] and [12]. However, little is known regarding 
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the roles of p38 or p38. We therefore studied the effect of chronic pressure overload 
on the expression and subcellular localization of p38 isoforms in the mouse heart. No 
change in expression of p38 mRNA was observed in response to chronic pressure 
overload, whereas mRNA levels for p38// was increased. However, no 
corresponding change in expression was detected at protein level during the first 7 days 
following TAC. It has been shown in transfected HEK293T cells overexpressing p38 
and p38 that p38 activation reduces p38 protein via activation of the c-jun-dependent 
ubiquitin–proteosome pathway [36]. However, in heart, although there was a peak of 
p38 phosphorylation at day 3 of TAC, p38 protein levels were unaffected. 
p38 was detected in the cytoplasm and nucleus. Due to the -KETXL sequence 
in its C-terminus [15] p38 is able to bind PDZ domains. As a result of this, p38 binds 
to a number of PDZ-containing proteins such as 1-syntrophin, SAP90/PSD95, and 
SAP97/hDlg [15] and [37]. These proteins are scaffold proteins that are usually targeted 
to the cytoskeleton. Upon phosphorylation by p38, hDlg is released from the 
cytoskeleton [37]. Other substrates include the microtubule-associated protein tau [38] 
and CapZ-interacting protein [39]. Although p38 was previously reported to be 
exclusively cytosolic in neonatal rat ventricular myocytes [3], in the present study, p38 
immunoreactivity accumulated in the nuclei during chronic pressure overload. Nuclear 
substrates for p38 identified to date include transcription factors such as ATF2, AP-1, 
Elk-1, MEF2A, p53, SAP1 and SAP2 [40], [41] and [42]. MEF2 transcription factors 
are involved in the regulation of inducible gene expression during hypertrophy and 
MEF2 activity is increased during pressure or volume overload [43]. Activation of 
MEF2A and MEF2C is stimulated by p38; however, p38 may be more efficient than 
p38 at activating MEF2 [44], [45] and [46]. Expression of an active variant of p38 
attenuates, whereas active p38 induces, expression of AP-1-driven reporter genes [42]. 
Furthermore, in the skeletal muscle cell line C2C12, over expression of p38 leads to 
differentiation from myoblasts to myotubes whereas expression of dominant negative 
p38 prevents this differentiation [16] and [47]. Given that p38 is a prominent p38 
isoform in heart and it accumulated in the nucleus during chronic pressure overload, it is 
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quite possible that p38 plays a role in the changes in gene expression associated with 
pathological hypertrophy. 
Nuclear translocation of p38 but not p38 7–28 days after the initiation of 
pressure overload may result from 1) the activation of TAB-1, which binds to and 
activates p38 independently of MKK3/6 but retains the activated p38 in the cytosol 
[48], 2) the sustained activation of a p38-specific MKK resulting in its nuclear 
translocation, 3) the interaction of p38 with a PDZ-domain containing protein that 
shuttles p38 into the nucleus, or 4) the interaction of activated p38 with a nuclear 
PDZ-domain containing protein which retains p38 within the nucleus. Similar to p38, 
YES kinase-associated protein (YAP) contains the PDZ-binding motif -FLTWL in its C-
terminus that is essential for both translocation of YAP from the cytosol to the nucleus 
and its ability to promote apoptosis in response to low serum [49]. It is thought that one 
or more yet unidentified PDZ-domain containing proteins are responsible for the 
nucleocytoplasmic shuttling of YAP. In addition, PDZ-containing proteins including the 
Ca2+/calmodulin-associated Ser/Thr kinase (CASK), l-periaxin, ZO-1, MAGI-1c, and 
LIM-kinase 1 contain nuclear localization signals and shuttle between the cytoplasm and 
the nucleus [50], [51], [52], [53], [54] and [55]. 
The small GTP-binding protein RhoA activates p38, but not p38, through 
MKK3/6 [41]. Similarly, overexpression of the MEK kinase Cot in NIH3T3 cells 
activates cotransfected p38, but not p38 or p38 [56]. MKK6 activates all p38 
isoforms but the efficiency varies between isoforms and with the nature of the stimuli 
[57]. Remy et al. recently characterized the phosphorylation and activation of each p38 
isoform in mouse embryonic fibroblasts (MEF) lacking MKK3 and/or MKK6 in 
response to hyperosmotic shock, ultraviolet (UV) radiation, anisomycin, and TNF [25]. 
These authors showed that MKK3 and MKK6 are both essential for full activation of 
p38, p38 and p38 by environmental stress, whereas MKK6 is the major p38 
activator in response to TNF. In contrast, MKK3 mediated p38 activation in response 
to UV radiation, hyperosmotic shock, anisomycin or TNF. In the absence of MKK3 
and MKK6, MKK4 mediates the activation of p38 [58] but not p38// to UV 
radiation [25]. These authors concluded that the ability of MKK3 versus MKK6 to 
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activate an individual p38 isoform is dependent upon the nature and intensity of the 
stimulus as well cell-specific properties such as the expression level of MKK3, MKK6 
and of the p38 isoforms. As the actual effect of activation of a given isoform would, 
then depend upon its subcellular localization and substrate specificity, p38 signaling 
may actually be spatially and temporally compartmentalized in physiological systems. 
Further study is required to understand role of p38 in the myocyte nucleus during 
chronic pressure overload. 
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5. Conclusions 
We have shown that p38 and p38 are present at comparable protein levels in 
the mouse heart. In addition, 38 is expressed at protein levels similar to p38. Although 
the mRNA abundance for p38, p38, and p38 changed in response to chronic pressure 
overload, the corresponding protein levels remained unchanged. Furthermore, p38 
accumulated in nucleus in hypertrophying hearts whereas p38 did not, which might 
suggest a distinct role for p38 during the maintenance or progression of ventricular 
hypertrophy in response to chronic pressure overload. 
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Figure Legends 
Fig. 1. Cardiac expression of p38 in murine heart. (A) The abundance of the 
mRNA for each p38 isoform was measured in murine heart total RNA by qPCR. Shown 
are the mean ± S.E. (n = 5). (B) Purified GST-p38 isoforms (2 g) were separated on 
10–20% acrylamide-gradient SDS-PAGE and visualized using Coomassie Brilliant Blue 
R250. (C) Isoform selectivity of p38 antibodies. Purified GST-p38 isoforms (5 ng) were 
separated on 10–20% acrylamide-gradient SDS-PAGE, transferred to nitrocellulose, and 
probed with the indicated p38 isoform-specific antibodies. (D) Detection of p38 
isoforms in mouse heart lysates. Lysates (50 g) from 2 separate hearts (a, b) were 
separated on 10–20% acrylamide-gradient SDS-PAGE, transferred to nitrocellulose and 
probed with the indicated p38 isoform-specific antibody. Detection conditions were 
separately optimized for each isoform. (E) Quantification of p38 isoforms in mouse 
heart lysates. Standard curves were constructed for each isoform using the purified 
recombinant p38 isoforms shown in Fig. 1B. Heart lysates (5 and 50 g) and were 
resolved, together with a standard curve of the appropriate p38 isoform, on 10–20% 
acrylamide-gradient SDS-PAGE, transferred to nitrocellulose, and probed with an 
appropriate isoform specific antibody. The absolute amount of each isoform was 
calculated (in fmol), using the predicted molecular mass of the GST-p38 isoform, and 
expressed per microgram of heart lysate. Numbers at the left indicate the positions of the 
molecular mass marker proteins (kDa).  
Fig. 2. Effect of pressure-overload hypertrophy on p38 expression. Mice were 
sacrificed 1, 3, and 7 days after constriction of the transverse aorta (TAC) and the hearts 
isolated. (A) mRNA for each p38 was quantified by qPCR and normalized to GAPDH 
expression. Shown are the relative abundance of p38, p38, p38, and p38 mRNA. 
(B) To assess p38 expression at the protein level, 50 g heart lysate were separated on 
10–20% acrylamide-gradient SDS-PAGE, transferred to nitrocellulose and probed the 
indicated antibodies. Detection conditions were separately optimized for each isoform. 
(C) Phosphorylation of p38 and HSP25 was studied using phosphospecific antibodies. 
(D) Cardiac fetal gene expression. To confirm that TAC induced a hypertrophic 
response, in each heart atrial natriuretic peptide (ANP) and -myosin heavy chain (-
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MHC) mRNA was quantified by qPCR. Shown are the mean ± S.E. (n = 6). ***, 
p < 0.001: **, p < 0.01: *, p < 0.05: one-way ANOVA with Newman–Keuls post-hoc 
analysis.  
Fig. 3. Changes of p38 mRNA during post-natal heart development. The 
abundance mRNA each p38 isoform was determined during post-natal heart 
development. Total RNA was isolated from neonatal, 7 day, 20 day, and adult (8 weeks) 
hearts and the level of mRNA quantified by qPCR. ((A) p38, (B) p38, (C) p38, and 
(D) p38). Samples were normalized to GAPDH. Shown are the mean ± S.E. (n = 3). 
***, p < 0.001: **, p < 0.01: *, p < 0.05: one-way ANOVA with Newman–Keuls post-
hoc analysis.  
Fig. 4. Specific activity of p38 isoforms. An aliquot (20 ng) of each activated 
p38 isoform was incubated with MBP (0.33 mg/ml) and [32P]ATP. Reactions were 
terminated after 2, 5, 8, or 10 min by addition of SDS-PAGE sample buffer. Proteins 
were separated on 10–20% SDS-PAGE, stained with Coomassie blue, the MBP band 
excised and 32P incorporation in MBP determined by scintillation counting. 32P 
incorporation was plotted against time for (A) p38, (B) p38, (C) p38, and (D) p38. 
Shown are the mean ± S.E. (n = 2). 
Fig. 5. Subcellular localization of p38 and p38 during chronic pressure 
overload. Mice were sacrificed after 1, 2, or 4 weeks of TAC and 14 m sections 
prepared. After fixation and blocking, sections were probed with anti-p38, anti-p38 or 
anti-phospho-p38 (not shown) antibodies and visualized using an ALEXA fluor 448-
coupled secondary (anti-rabbit) antibody followed by confocal microscopy. 
Immunolocalization of p38 and p38 after (A) 7 days, (B) 14 days, and (C) 28 days of 
TAC. Nuclei were visualized by staining with TO-PRO 3 iodide. In 14-d samples, actin 
distribution was also revealed using phalloidin. Shown are the representative images of 
n = 3 and 3 sections per heart. (D) To confirm that TAC induced a hypertrophic 
response, sections from each heart were also assessed for expression of B-type 
natriuretic peptide (BNP) and -myosin heavy chain (-MHC). Shown are the 
mean ± S.E. (n = 3). ***, p < 0.001: **, p < 0.01: *, p < 0.05: one-way ANOVA with 
Newman–Keuls post-hoc analysis. 
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Table 1. Primers used during real-time QPCR.  
Target Primers 
p38 S 
p38 AS 
5’- AAT CTC CTC AGA GTC TGC AAG -3’ 
5’- GCT CTT CCA CTC ATC TAT GAG AAG G -3’ 
p38 S 
p38 AS 
5’- GAC CTC AGC AGT GTC TTC CAT -3’ 
5’- GAG CTG TGA GGG TTC CAG G -3’ 
p38 S 
p38 AS 
5’- TTT GCC TCT GTC CTG ACC AAC -3’ 
5’- GGA ACT CTG GCT CCT AGC TGC -3’ 
p38 S 
p38 AS 
5’- GAT TTC ACA CAG CTC TTT CCA CGC -3’ 
5’- CCA CAC TGA GTT TCT CAT GTT CT -3’ 
ANP S 
ANP AS 
5’-GTG CGG TGT CCA ACA CAG A-3’ 
5’-TTC TAC CGG CAT CTT CTC CTC-3’ 
BNP S 
BNP AS 
5’- GTT TGG GCT GTA ACG CAC TGA-3’ 
5’-GAA AGA GAC CCA GGC AGA GTC A-3’ 
-MHC S 
-MHC AS 
5’-AGG GTG GCA AAG TCA CTG CT-3’ 
5’-CAT CAC CTG GTC CTC CTT CA-3’ 
GAPDH S 
GAPDH AS 
5’-CTG CAC CAC CAA CTG CTT AGC-3’ 
5’-ACT GTG GTC ATG AGC CCT TCC A-3’ 
S, sense; AS, anti-sense; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; QPCR, 
quantitative polymer chain reaction; ANP, atrial natriuretic peptide; BNP, B-type 
natriuretic peptide; -MHC, -myosin heavy chain. 
 
 
 
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Dingar D, Shi Y, Gillis MA, Meloch S, Gaestel M, Tardif JC, and Allen BG. “ERK3-
MK5 regulates interstitial fibrosis in mouse heart during chronic pressure-overload.” In 
preparation. 
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ABSTRACT 
Chronic pressure overload induces cardiac left ventricular hypertrophy, fibrosis, 
and contractile dysfunction, resulting in impaired cardiac function. p38 MAPK is 
activated during pressure overload and has been implicated in cardiac fibrosis. MK5 is 
activated by p38 and highly expressed in the heart, but its physiological role remains 
unknown. This study was to determine if MK5 mediates any of the detrimental effects 
induced by chronic pressure overload. We studied the effect of transverse aortic 
constriction (TAC)-induced pressure overload in mice heterozygous for a functional 
knockout of MK5 (MK5+/-) and their wild-type (MK5+/+) littermates. Following 2 wks 
of TAC, heart weight/body weight ratios were significantly and similarly increased in 
both MK5+/- and MK5+/+ hearts. Transthoracic echocardiography revealed TAC 
impaired left ventricular diastolic and systolic function in MK5+/+, but not in MK5+/- 
hearts. Interestingly, regional differences were observed: MK5 haploinsufficiency was 
more protective in the basal septum than in the LV basal lateral wall segment. Interstitial 
fibrosis was not observed in MK5+/- hearts 2 or 3 wks post-TAC. Furthermore, TAC-
induced increases in collagen alpha 1 type 1 (COL1A1) mRNA levels were significantly 
lower in MK5+/- hearts. MK5 is also activated by the atypical MAPKs, ERK3 and 
ERK4. In both sham and 3 wk TAC hearts, MK5 immunoprecipitates contained ERK3, 
but not ERK4 or p38. In ERK3+/- mice, pressure overload failed to induce fibrosis and 
the induction of COL1A1 expression was attenuated. MK5+/- or ERK3+/- 
haploinsufficiency did not attenuate the increase in TGF1 mRNA induced by pressure 
overload. Our results demonstrate that ERK3-MK5 signaling plays a role in cardiac 
fibrosis during pressure overload. 
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1. Introduction 
Cardiac hypertrophy in which individual myocytes grow in length (sarcomeres 
added in series) and/or width (sarcomeres added in parallel) occurs as a way of 
decreasing ventricular wall tension and increasing cardiac pump function. It occurs 
when the myocyte is continuously exposed to increased external stimuli such as stretch, 
hemodynamic overload and/or an increase in neurohormonal factors. Cardiac 
hypertrophy is an adaptive response for maintaining cardiac output in response to stress. 
However, in the long term, hypertrophy predisposes individuals to arrhythmia, heart 
failure, and sudden death. Hypertrophic stimuli activate a wide variety of signaling 
pathways in cardiac tissues, such as the mitogen activated protein kinase (MAPK) 
pathways, calcineurin-nuclear factor of activated T cells (NFAT), and the 
phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) pathway [1]. Five distinct 
MAPK pathways have been identified in mammals: extracellular signal-regulated 
kinases (ERKs) 1/2, ERK3/4, ERK5, c-jun amino-terminal kinases (JNKs) (1-3), and 
p38 MAPKs (, , , and ) [2]. Each pathway displays a characteristic hierarchical 
organization wherein MAPK kinase kinases (MAPKKK) phosphorylate and activate 
MAPK kinases (MAPKK), which in turn activate their respective MAPKs. Downstream 
of certain MAPKs lies an additional level of protein kinases, the MAP kinase-activated 
protein kinases (MAPKAPKs): these include MK2, MK3 and MK5 (also known as 
PRAK) [3]. 
Increased wall stress, due to pressure overload leads to the release of local ligands 
such as angiotensin II and endothelin-1[4, 5], as well as activation of intrinsic stretch 
receptors in cardiomyocytes, which includes the integrin family of transmembrane 
proteins [6, 7]. Furthermore, cultured cardiomyocytes subjected to mechanical stress 
leads to the activation of extracellular signal regulated kinases (ERK1/2), c-jun N-
terminal kinase (JNK), and p38 MAPK, while stress induced release of angiotensin II 
and endothelin-1 activates ERKs [5, 8], while stretch, independent of angiotensin II 
release, strongly activates JNK [9], suggesting that JNK might be directly activated by 
stretch. In the heart, ERK1/2 regulates hypertrophy and also reduces contractility, while 
p38 MAPK regulates fibrosis, and JNK regulates both fibrosis and hypertrophy [10]. 
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Fibrosis reduces three-dimensional organizations in heart muscle and increases stiffness 
of myocardium, which causes diastolic dysfunction [11, 12]. Additionally, mice 
expressing a constitutively active form of MEK5, which activates ERK5, show eccentric 
cardiac hypertrophy associated with the addition of sarcomeres within individual 
cardiomyocytes [13]. Finally, atypical MAPKs ERK3 and ERK4 are known to be 
expressed in the heart but their physiological role remains unknown [14, 15] 
MK5 originally classified as a p38 Regulated/Activated Protein Kinase (PRAK) 
[16, 17], mediates senescence upon activation by p38 in response to induction of 
oncogenic ras [18]. MK5 has 5 splice variants which are regulated during hypertrophy 
and postnatal heart development [14] and can also be phosphorylated by atypical 
MAPKs ERK3 and ERK4 [15, 19, 20]. ERK3 and ERK4 show 50% homology with 
ERK1/2 within the kinase domain but have an S-E-G rather than a T-E-Y motif within 
the activation loop, contain a unique C-terminal extension and are exclusively found in 
vertebrates [21]. ERK3 expression is regulated both during transcription [22, 23] and at 
the protein level via the ubiquitin-proteosome pathway [24, 25]. However, ERK4 is 
found to be a far more stable protein [15, 26]. In intact cells, ERK3/ERK4 serine is 
phosphorylated in the S-E-G motif and is required for a stable interaction with, 
enzymatic activation, and subcellular relocalization of MK5. Once activated, MK5 
phosphorylates Ser-386 in both ERK3/ERK4 [27]. ERK3 knock-out mice die within a 
day after birth from acute respiratory failure, have lower heart, lung, liver, and body 
weight, and lower insulin-like growth factor (IGF)-2 serum levels [28]. We have 
previously shown that MK5-ERK3 are in complex, that neither exist alone and that the 
complex is unaltered during pressure overload, where p38 MAPK is activated [14]. This 
observation may shed some light on the lack of stable endogenous ERK3 in a MK5 
depleted background [20]. Furthermore, MK5-/- mice are viable and show no change in 
tissue morphology and behavior [29]. Despite having knockout mice the physiological 
roles of MK5 and ERK3 remain unknown. Although we thought that MK5 may be 
involved in mediating some of the detrimental effects of p38 activation, given the 
phosphorylation of MK5 by ERK3/4, we would not be able to exclusively attribute any 
effects observed in the MK5+/- mice to its activation by p38. As we have show 
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previously that ERK3, but not ERK4 or p38, co-immunoprecipitate from heart lysates 
with MK5 [14] the effects of chronic pressure overload was examined in both MK5 and 
ERK3 haploinsufficient mice. Here we show that MK5+/- or ERK3+/- mice were resistant 
to pressure overload-induced cardiac interstitial fibrosis.  
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2. Materials and methods 
2.1. Materials 
Membrane grade (reduced) Triton X-100, leupeptin, and PMSF were from 
Roche Molecular Biochemicals, SDS-polyacrylamide gel electrophoresis reagents, 
nitrocellulose, and Bradford protein assay reagents were from Bio-Rad. All other 
reagents were of analytical grade or best grade available.  
 
2.2. Knockout mice 
MK5 [29] and ERK3 [28] knock-out mice have been described previously. MK5 
knockout mice were rederived and backcrossed twice onto a C57BL/6 background. 
Twelve- to 13-wk old male wild type and knockout mice were used in these studies. 
MK5-/- mice show embryonic lethality with incomplete penetrance resulting in only 
about 50% of the expected number of MK5-/- embryos detectable after day E12. 
Surviving MK5-/- mice fail to reproduce. MK5+/- mice are healthy. ERK3-/- mice do not 
show embryonic lethality but die within 24 hours of birth. Heterozygous mice were 
compared with wild-type littermates in the experiments described herein. 
All animal experiments were approved by the local ethics committee and 
performed according to the guidelines of the Canadian Council on Animal Care.  
 
2.3. Transverse aortic constriction 
Baseline assessments of cardiac structure and function were performed by 
transthoracic echocardiography (see below). The following day, transverse aortic 
constriction was done in adult (12-13 wks) male mice sedated with isofluorane gas as 
described [30]. Sham animals underwent the identical surgical procedure but the aorta 
was not constricted. The surgeon was blinded to the genotype of the mice. Two- or 3- 
weeks after surgery, assessment by transthoracic echocardiography was repeated. The 
next day, mice were anesthetized with pentobarbital and in vivo cardiac function was 
assessed using a Millar Micro-Tip catheter. Mice were then sacrificed, the hearts 
removed and heart weighed, snap-frozen in liquid nitrogen-chilled 2-methyl butane, and 
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stored at -80°C.  The surgeon was blinded with respect to the transgenic status of the 
mice. 
 
2.4. Transthoracic Echocardiography and Calculations 
Transthoracic echocardiography was performed on mice, mildly sedated with 
isofluorane, 1 day before TAC and 1 day before sacrifice using a Vivid 7 Dimension 
ultrasound system (GE Healthcare Ultrasound, Horten, Norway) and i13L probe (10-14 
MHz). Ascending aortae were visualized in a modified parasternal long axis view to 
assess flow at the site of constriction: peak velocity, peak and mean gradient were 
measured using sample volume enlarged pulsed wave Doppler (PW). Left ventricular 
(LV) M-mode spectrum was obtained in parasternal short axis view at the level of 
papillary muscle. LV dimensions at both end cardiac diastole (LVDd) and systole 
(LVDs) were measured, the thickness of LV anterior wall (LVAW) and that of LV 
posterior wall (LVPW) at end cardiac diastole were also measured at this view; LV mass 
was calculated by (((LVDd + LVAW + LVPW)3- LVDd 3) x 1.04) x 0.8 + 0.14 [31] 
corrected by LVDd, and body weight (BW). LV fractional shortening (FS) was 
calculated by (LVDd – LVDs) / LVDd x 100%. LV basal lateral and septal peak systolic 
velocities (Sm) were derived by tissue Doppler imaging (TDI) to study LV regional 
contractility. To study LV diastolic properties: pulsed wave Doppler was used to 
evaluate transmitral flow in apical 4-chamber view, peak velocities in early filling (E), 
atrial filling (A) were measured. Mitral annulus movement was recorded by TDI, 
velocities during early filling Em, and atrial filling Am were measured for both lateral 
and septal annulus, lateral and septal E/Em were calculated. LV isovolumic relaxation 
time (IVRT) was measured using sample volume enlarged PW at the conjunction of LV 
inflow and outflow in apical 5-chamber view, and was corrected by the square root of R-
R interval IVRT/(RR)1/2] on simultaneously recorded ECG.  The time intervals from 
the end of Am to the beginning of Em (b), and from the beginning to the end of Sm (a) 
were measured in both lateral and septal TDI, LV regional myocardial performance 
index (MPI) was calculated by (b-a)/a x 100% for both basal lateral and basal septal 
wall.The average of three consecutive cardiac cycles was used for each measurement. 
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Special care was taken to obtain similar imaging planes during pre-operative and pre-
sacrifice assessments for each animal. The echocardiographer was blinded to the 
genotype of the mice.  
 
2.5. Histological analysis 
Hearts were embedded in Tissue-Tek O.C.T. compound (Sakura Finetek USA, 
inc.) and longitudinal cryosections (8 m) of the ventricles were prepared and stained 
with Masson trichrome. Images were taken at 10X. 
 
2.6. Quantitative real time-PCR 
Total cellular RNA was isolated from longitudinal cryosections (14 m) of 
murine ventricular myocardium using RNeasy® Micro kits (Qiagen Inc.) with minor 
modifications. Total RNA was extracted by vortexing tissue section in 300 l TRIzol 
reagent (Sigma) for 30 s. After incubating at ambient temperature for 5 min, 60 l 
chloroform was added, samples were again vortexed, and maintained at ambient 
temperature for an additional 2-3 min. After centrifugation for 15 min at 18,300 x g and 
4°C, the upper aqueous phase was collected, diluted with an equal volume of 70% 
ethanol, and total RNA purified on Qiagen columns according to the manufacturers 
instructions. Finally total RNA was eluted with 14 l of distilled, RNAse-free water. As 
the quantity of RNA recovered was too small to permit quantification of total RNA, 
cDNA synthesis was performed with 11 l of the isolated total RNA in 20 l reaction 
volume as described previously [14]. The primers used are shown in Supplemental 
Table 1.  
 
2.7. Immunoblotting 
SDS-PAGE and immunoblotting were performed as described previously [32]. 
Following the transfer, nitrocellulose membranes were rinsed in PBS and fixed with 
glutaraldehyde [33] prior to blocking. 
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2.8. Statistical Analysis 
Quantitative analysis for qPCR was performed by single observer in a blinded 
manner. One-way ANOVA followed by Newman-Keuls test was performed for the 
statistical comparisons. Values were shown mean and SEM, ***, p < 0.001: **, p < 
0.01: *, p < 0.05. 
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3. Results 
Chronic pressure overload induces cardiac hypertrophy, reexpression of fetal 
genes, interstitial fibrosis, and activation of MAPKs, including p38 [34]. Chronic 
activation of p38 induces interstitial fibrosis, but not hypertrophy [35]. In contrast, acute 
activation of p38 results in the rapid induction of a severe cardiomyopathy that includes 
myocyte hypertrophy, interstitial fibrosis, and contractile dysfunction [36]. MK5 is a 
downstream effector of p38 [3, 17, 37] that is expressed in the heart yet has, as of yet, no 
identified physiological or pathophysiological function. The objective of the present 
study was to determine if MK5 plays a role in pathological cardiac remodeling induced 
by chronic pressure overload. We employed mice heterozygous for a functional 
knockout of MK5 (MK5+/-) and their wild-type (MK5+/+) litter mates. These mice have 
been described elsewhere [29]. 
 
3.1. Transthoracic echocardiographic characterization of MK5 haploinsufficient 
mice. 
Echocardiographic examination of 12-wk old male MK5+/+ and MK5+/- mice 
revealed no significant differences in cardiac structure, systolic, or diastolic function 
(Supplemental Table 2). 
 
3.2. Effect of MK5 haploinsufficiency on pressure overload-induced hypertrophy 
MK5+/+ and MK5+/- mice underwent transverse aortic constriction (TAC) and 
were sacrificed 2 wks post-surgery. All mice were assessed by transthoracic 
echocardiography 1 day before surgery and 1 day prior to sacrifice. Direct 
hemodynamic assessment using a Millar Micro-Tip catheter showed that TAC induced 
comparable increases in systolic and mean arterial pressure (Table 1) as well as peak left 
ventricular pressure in MK5+/+ and MK5+/- mice (Fig. 1A). Echocardiographic imaging 
of the ascending aorta was performed to assess cross-TAC aortic flow and revealed 
comparable changes in hemodynamics (Table 2). Following TAC, heart weight to body 
weight ratios (HW/BW) were increased by 32% in MK5+/+ (from 4.9±0.4 mg/g to 
6.5±0.4 mg/g, p<0.01) and by 42% in MK5+/- (4.5±0.1 mg/g to 6.4±0.3 mg/g, p<0.01) 
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(Fig. 1B). The increased HW/BW ratio in MK5+/+ and MK5+/- indicated the 
development of similar levels of hypertrophy in both groups. Echocardiographic 
analysis of LV mass/body weight ratio (LVM/BW) confirmed similar levels 
hypertrophy in MK5+/+ and MK5+/- hearts post-TAC (Table 2). In MK5+/+ mice the 
LVM/BW ratio increased by 29% after TAC (from 7.8±0.4 mg/g to 10.1±0.3 mg/g, 
p>0.05), and in MK5+/- by 23% (from 8.0±0.2 mg/g to 9.8±0.5 mg/g, p<0.05). Hence, 
MK5 haploinsufficiency did not alter left ventricular hypertrophy in response to 
pressure overload. 
 
3.3. Gene expression in MK5+/- mice following TAC 
Pathological LV hypertrophy is associated with the re-expression of cardiac fetal 
genes atrial and B-type natriuretic peptides (ANP, BNP) and beta-myosin heavy chain 
(-MHC)  [38]. Hence ANP, BNP, and -MHC mRNA levels were quantified by qPCR. 
Pressure-overload increased -MHC, ANP, and BNP mRNA levels in MK5+/+ and 
MK5+/- hearts; however, the increase in BNP mRNA was less pronounced in MK5+/- 
hearts and the increase in ANP mRNA failed to reach significance (Fig. 2). There was 
no significant difference in ANP, BNP, and -MHC mRNA levels between MK5+/- and 
MK5+/+ in sham-operated hearts. In summary, MK5-deficiency did not prevent 
molecular remodeling in response to pressure overload: however, the increases in ANP 
and BNP mRNA abundance were attenuated. 
 
3.4. Echocardiographic characterization of MK5+/- mice following TAC 
Ventricular function was assessed by echocardiography. LV Fractional 
shortening (FS) and ejection fraction (EF) were similarly reduced in MK5+/+ and MK5+/- 
mice following 2 wk of pressure overload (Table 2). In response to TAC, early 
transmitral flow velocity (E) was significantly increased (p<0.05) in MK5+/- mice 
whereas in MK5+/+ mice the increase in E wave velocity did not reach significance. 
Tissue Doppler imaging was employed to assess systolic (Sm) and early diastolic (Em) 
myocardial velocities of the basal segments of interventricular septum and basal lateral 
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LV wall. Lateral-Sm was reduced by pressure overload in both MK5+/+ and MK5+/- 
hearts whereas septal-Sm was reduced in MK5+/+ but not MK5+/- hearts. Lateral-Em was 
unaffected by pressure overload in MK5+/+ mice whereas septal-Em was actually higher 
in MK5+/- hearts following pressure overload. The ratio of early transmitral flow 
velocity to diastolic myocardial velocity (E/Em), an index of LV filling pressure, was 
significantly higher in banded MK5+/+ mice than in both sham mice and band MK5+/- 
mice. Furthermore, isovolumetric relaxation time (IVRT, IVRTc) and myocardial 
performance index (MPI) were elevated in banded MK5+/+ but not MK5+/- hearts. 
Hence, MK5 haploinsufficiency had a beneficial effect on myocardial tissue velocities 
during chronic pressure overload that was more pronounced in the basal septal than the 
basal lateral LV segment. Furthermore, hearts from MK5+/- mice showed improved 
diastolic function during chronic pressure-overload in comparison with MK5+/+ hearts.  
 
3.5. MK5+/- hearts are resistant to fibrosis 
In addition to LV hypertrophy and molecular remodeling, pressure overload 
induces interstitial fibrosis, resulting in increased myocardial stiffness. Hence, collagen 
accumulation was examined in cryosections of the ventricular myocardium by Masson 
trichrome staining. Pressure overload resulted in increased collagen deposition (stained 
blue) in MK5+/+ hearts but not in MK5+/- hearts (Fig. 3A,B). No genotype-dependent 
differences in collagen deposition were observed in sham hearts. Collagen type 1 
accounts for approximately 85% of the total collagen content of the heart. Consequently, 
collagen alpha 1 type 1 (COL1A1) mRNA levels were measured by qPCR and found to 
increase as a result of pressure overload (Fig. 3C). This increase, however, was reduced 
by 50% in MK5+/- hearts compared with MK5+/+ hearts. No significant difference was 
observed in COL1A1 mRNA levels between sham MK5+/+ and MK5+/- hearts, 
suggesting that formation of a normal extracellular matrix was not adversely affected in 
MK5+/- mice. 
To determine if the effect of MK5 haploinsufficiency was preventing or merely 
delaying interstitial fibrosis, a separate group of mice underwent TAC and were 
sacrificed 3 wk post-surgery. Unexpectedly, although direct assessment of 
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hemodynamic function indicated TAC induced similar increases in peak aortic BP and 
peak LVP (supplemental Fig 1A, Supplemental Table 3) in MK5+/+ and MK5+/- mice, 
HW/BW increased by 64% in MK5+/+ mice (from 4.4±0.2 mg/g to 7.3±0.4 mg/g, 
p<0.001) following 3 wk of pressure overload, whereas MK5+/- hearts showed only a 
27% increase (from 4.5±0.2 mg/g to 5.8±0.6 mg/g) (Supplemental Fig. 1B). MK5 
haploinsufficiency did not alter body weight (data not shown). Three weeks of pressure-
overload increased -MHC, ANP, and BNP mRNA levels in MK5+/+ and MK5+/- hearts 
(Supplemental Fig. 1C,D,E). As observed following 2 wk of pressure overload, Masson 
trichrome staining revealed increased collagen deposition in MK5+/+ but not MK5+/- 
hearts 3 wk post-TAC (Fig. 3B). Similarly, the increase in COL1A1 mRNA induced by 
pressure overload was significantly reduced in MK5+/- hearts (Fig. 3C). These results 
suggest that MK5 activation is involved in cardiac interstitial fibrosis in response to 
pressure-overload. 
 
3.6. MK5-ERK3 signaling in the heart 
Atypical MAPKs ERK3 and ERK4 are known bind to and regulate the activation 
of MK5, and it is currently controversial whether MK5 is regulated by p38 and/or 
ERK3/4 in vivo. In lysates prepared from control, sham-operated, or 3-d post-TAC 
mouse hearts, ERK3, but not ERK4 or p38, co-immunoprecipitated with MK5 [14]. 
Given the involvement of MK5 activity in reactive fibrosis, we sought to determine if 
chronic exposure to pressure overload altered the composition of MK5 complexes in 
mouse heart. To this end, we assessed if ERK3, ERK4, or p38 co-immunoprecipitated 
with MK5 in lysates from sham and TAC hearts 3-wks post-surgery. In each case, 
ERK3 co-immunoprecipitated with MK5 whereas p38 and ERK4 immunoreactivity 
was not detected (Fig. 4A). Immunoblotting using an anti-phospho-p38 antibody 
confirmed activation of the p38 pathway in banded hearts. ERK3, ERK4 and p38 
protein levels were unaffected by pressure overload (Fig. 4B). Thus, MK5 is in a 
complex with, and regulated by, ERK3 in the mouse heart during pressure overload. 
Hence we sought to determine if ERK3 also plays a role in reactive fibrosis. 
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3.7. Transthoracic echocardiographic characterization of ERK3 haploinsufficient 
mice. 
Conventional echocardiographic examination of 12-wk old male ERK3+/+ and 
ERK3+/- mice revealed no significant differences in left ventricular diameter, wall 
thickness, MPI, as well or transmitral flow velocities (Table 3). Tissue Doppler imaging 
revealed no change in basal lateral LV or basal septal Sm velocities but a reduction in 
both basal septal and basal lateral LV segment Em, indicating that LV compliance was 
reduced in ERK3+/- compared to ERK3+/+ mice. 
 
3.8. Hypertrophic response in ERK3 haploinsufficient mice following TAC 
ERK3+/+ and ERK3+/- mice [28] underwent TAC and were sacrificed 3 wk post-
surgery.  Direct assessment of hemodynamic function using a Millar catheter revealed 
that systolic and mean aortic BP as well as peak LV pressure increased similarly in 
banded ERK3+/+ and ERK3+/- mice (Fig. 5A, Table 4). Following TAC, HW/BW 
increased by 44% (from 4.7±0.1 mg/gm to 6.7±0.4 mg/gm, p<0.001) in ERK3+/+ mice 
and by 34% (from 4.6±0.1 mg/g to 6.2±0.2 mg/g, p<0.001) in ERK3+/- mice (Fig. 5B). 
Hence, pressure overload induced LV hypertrophy in both ERK3+/+ and ERK3+/- mice. 
Moreover, the HW/BW was the same in both sham-operated groups. Newborn ERK3-/- 
and ERK3+/- mice have significantly lower body weight as compared to their wild type 
littermates. Newborn ERK3-/- mice also exhibit a reduction in absolute heart weight in 
comparison with ERK3+/+ litter mates [28]. Adult (12-13 wks) ERK3+/+ and ERK3+/- 
mice did not differ in heart or body weight (Fig. 5C,D). Hence, the effects of ERK3 
haploinsufficiency on growth normalized with age. Furthermore, ANP, BNP, and -
MHC mRNA levels were assessed in RNA isolated from ERK3+/+ and ERK3+/- hearts. 
Following TAC, BNP and -MHC mRNA levels increased significantly in ERK3+/+ and 
ERK3+/- hearts. Interestingly, while ANP increased significantly in ERK3+/+ hearts, 
pressure overload did not induce an increase in ANP mRNA in ERK3+/- hearts (Fig. 5E). 
In conclusion, ERK3 haploinsufficiency did not prevent the development of left 
ventricular hypertrophy or the increase in BNP and -MHC mRNA in response to 
chronic pressure-overload. 
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3.9. Echocardiographic assessment of ERK3+/- mice after 3 weeks of pressure 
overload 
Echocardiographic imaging of the ascending aorta was performed to assess cross-
TAC aortic flow and revealed comparable changes in hemodynamics although the cross-
TAC peak velocity and peak gradients were lower in banded ERK3+/- than ERK3+/+ 
mice. Echocardiography confirmed that both ERK3+/+ and ERK+/- hearts hypertrophied 
in response to pressure overload. However, surprisingly, although pressure overload 
induced hypertrophy in both ERK3+/+ and ERK3+/- mice, none of the functional 
parameters assessed by echo were altered (Table 5). As the MK5 and ERK3 mice were 
in different background strain, this strain difference might underlie that ability of TAC 
to alter cardiac function in the MK5 mice but not the ERK3 mice. A comparison of 
these 2 strains by echocardiography revealed numerous differences (Supplemental Table 
4). 
 
3.10. ERK3+/- hearts are resistant to fibrosis following TAC  
 Masson trichrome staining revealed that pressure overload increased collagen 
deposition (stained blue) in ERK3+/+ hearts but not in ERK3+/- hearts (Figure 6A). No 
collagen deposition was observed in sham hearts. Similarly, COL1A1 mRNA levels 
were significantly increased in ERK3+/+, but not ERK3+/- hearts, in response to TAC 
(Fig. 6B). These results suggest a role for ERK3 in the development of cardiac fibrosis 
in response to chronic pressure-overload. 
 
3.11. Assessment of TGF- expression in ERK3 and MK5 mice post-TAC 
TGF-1 controls the development of cardiac fibrosis through the activation of its 
receptor (TGF- receptor type 1 and type 2), which phosphorylates Smads 2 and 3 
(reviewed in [39]). Therefore, we assessed TGF-1 and TGF-3 mRNA levels by qPCR 
in total RNA from sham and banded hearts. TGF-1 and TGF-3 mRNA levels were 
increased significantly in both MK5+/+ and MK5+/- hearts both 2- and 3-wks post-TAC 
(Fig. 7A). Similarly, pressure overload increased TGF-1 mRNA levels both ERK3+/+ 
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and ERK3+/- hearts (Fig. 7B). In contrast, whereas TGF-3 mRNA content was 
significantly increased in ERK3+/+ hearts in response to TAC, the increase observed in 
ERK3+/- hearts did not reach significance. Interestingly, the relative abundance of both 
TGF-1 and TGF-3 mRNA was lower in ERK3+/- hearts than in there respective 
ERK3+/+ counterparts. In summary, MK5 and ERK3 haploinsufficiency did not prevent 
the pressure-overload-induced increase in TGF1 mRNA. 
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4. Discussion 
The physiological function of MK5 and atypical MAPKs ERK3/ERK4 are 
currently unknown. We show that, in response to chronic pressure overload, hearts from 
MK5+/- mice reexpressed fetal genes (e.g., ANP, BNP, -MHC) and hypertrophied but 
were resistant to myocardial interstitial fibrosis. Although MK5 has been shown to be 
activated both by p38/ [17] and ERK3/4 [15, 19, 20, 27], in the mouse heart, MK5 is 
bound to ERK3 but not ERK4 or p38 [14]. In addition, although pressure overload 
elevated phospho p38 levels in comparison to sham-operated mice, MK5 immune 
complexes contained ERK3, but not p38 or ERK4 immunoreactivity. Similar to 
MK5+/- hearts, ERK3+/- hearts underwent molecular remodeling and hypertrophied in 
response the pressure overload, but fibrosis was not detected. These results imply a role 
for ERK3-MK5 signalling in pressure overload-induced myocardial interstitial fibrosis. 
Pressure overload induced activation of p38 and p38 and translocation of p38  
into the nucleus [40, 41]. Transfecting neonatal myocytes with activated mutants of 
MAP kinase kinase 6b (MKK6b) or MKK3b, upstream activators of p38 and p38, 
evokes changes characteristic of the hypertrophic phenotype and apoptosis, respectively 
[40].  In the intact heart, the situation appears more complicated. Chronic inhibition of 
p38 signaling, using cardiac-directed expression of DN-p38, DN-p38, DN-MKK3, or 
DN-MKK6, facilitates cardiac hypertrophy, expression of fetal genes (ANP and BNP), 
but not fibrosis, in response to pressure overload [35, 42] or infusion of Ang II, 
isoproterenol, or phenylephrine (PE) [42]. In addition, cardiac-specific expression of 
constitutively active MKK3bE or MKK6bE results in cardiac fibrosis and systolic and 
diastolic dysfunction, but not hypertrophy [43] in some cases, but hypertrophy in others 
[44]. Expression of an activated form of TAK1, an MKKK, in heart resulted in p38 
activation associated with hypertrophy [45]. Cardiac-specific p38-/- mice exhibit 
hypertrophy in response to aortic banding, but also show cardiac dysfunction and 
dilation accompanied by massive fibrosis and myocyte apoptosis [46]. One explanation 
for the differences observed using in vivo models is that the chronic nature of the 
modification in p38 signaling employed in these models may interfere with other aspects 
of intracellular signalling or induce compensatory mechanisms. The role of p38 in 
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hypertrophy may depend upon the nature and duration of the hypertrophic stimulus [46-
48] as the nature and intensity of the stimuli can alter which p38 isoforms become 
activated [49]. In fact, mice having life-long changes in p38 signaling may have 
developed compensatory mechanism. Consistent with this, a recent report showed that 
the acute activation of p38, induced by the conditional and myocyte-specific 
expression of MKK3bE, in the adult mouse heart resulted in the rapid onset of a severe 
cardiomyopathy involving impaired cardiac function, hypertrophy, and interstitial 
fibrosis [36]. Hence, it would appear that inhibition of p38 would be a desirable 
pharmacological intervention in the treatment of cardiovascular disease. However, no 
inhibitors have progressed to phase III clinical trials due, in part, to adverse effects 
including hepatotoxicity, skin rash, and dizziness [50]. In addition, as the means 
whereby p38 mediates deleterious effects upon cardiac structure and function remains 
unknown, a better understanding of the roles and regulation of downstream targets of 
p38 is important. In vitro and in vivo studies have suggested the involvement of MK5 
downstream of p38 MAPK [16-18, 37, 51]. The biological role of MK5 remains 
unknown; however, MK5+/- mice underwent hypertrophy and molecular remodeling in 
response to chronic pressure overload, they were resistant to cardiac interstitial fibrosis. 
These results suggest that MK5 may mediate the pro-fibrotic effects of p38 activation in 
the heart. However, MK5 is also regulated by atypical MAPKs ERK3/ERK4 [15, 19, 
20] and in the heart MK5 appears to associate with ERK3, but not ERK4 or p38 [14]. 
Similarly, following 3 wks of pressure overload ERK3, but not p38 or ERK4, co-
immunoprecipitated with MK5. In fact, it has been controversial whether or not MK5 
and p38 for a complex in vivo. Tandem affinity purification studies did not detect p38-
MK5 complexes in HEK293 cells [29] whereas MK5 and p38 co-immunoprecipitate 
when over expressed in NIH3T3 cells [52, 53]. Alternatively, activation of p38 causes 
relocalization of MK5 from the nucleus to the cytosol and this relocalization is blocked 
upon mutating the putative p38-docking motif in MK5 [14, 37, 51, 52]. Consistent with 
a functional role for ERK3-MK5 signalling in the myocardium, ERK3+/- mice 
underwent hypertrophy and molecular remodeling, but not fibrosis, in response to 
chronic pressure overload, in a manner similar to MK5+/- mice. Taken together, these 
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results indicate that the increased myocardial interstitial fibrosis induced by pressure 
overload involves ERK3-MK5 signalling. 
Chronic pressure overload induces cardiac fibroblast proliferation, increased 
interstitial fibrosis, and remodeling of the extracellular matrix. Cardiac interstitial 
fibrosis can result from either enhanced collagen deposition or reduced degradation. 
Collagen type I and type III are the major components of the cardiac ECM with collagen 
type 1 comprising approximately 85% of total collagen in the heart and hence 
representing a major determinant for myocardial stiffness [54, 55].  In both MK5+/- and 
ERK3+/- hearts, pressure overload failed to induce a noticeable increase in collagen 
accumulation within 3 weeks. This was accompanied by a significant reduction in the 
ability of pressure overload to increase COL11 mRNA synthesis and/or stability. TGF 
is a growth factor expressed in both myocytes and fibroblasts that acts upon receptors 
that are also expressed in both cell types. In ventricular myocytes TGF induces 
molecular remodeling and hypertrophy [56] whereas in fibroblasts, it induces 
proliferation, differentiation to myofibroblasts, and production of ECM proteins 
including collagen, fibronectin, and proteoglycans [39]. TGF also reduces ECM 
breakdown by both inhibiting matrix metalloproteinase (MMP) expression and by 
inducing the synthesis of MMP inhibitors, such as plasminogen activator inhibitor-1 
(PAI-1) and tissue inhibitors of metalloproteinases (TIMPs) [57]. As shown previously 
[58, 59], pressure overload increased myocardial TGF1 and TGF3 mRNA and this 
increase was unaffected by MK5 haploinsufficiency. A similar expression pattern for 
TGF1 was observed in ERK3+/- hearts. In contrast, pressure overload failed to induce 
an increase in TGF3 mRNA in ERK3+/- hearts. Very little is curently know regarding 
the role of TGF3 in cardiac remodeling; however,  a polymorphism of TGF3 is 
associated with changes in LV geometry in hypertensive patients [60]. -AR signaling 
has been implicated downstream of TGF1 and the catalytic subunit of protein kinase A 
(PKA) was recently shown to phosphorylate MK5, resulting in its activation and 
translocation out of the nucleus [61, 62]. However, as 1-AR blockade in mice 
overexpressing TGF1 is antihypertrophic but not antifibrotic [63] whereas MK5 
haploinsufficiency prevented fibrosis, it is unlikely that MK5 haploinsufficiency is 
158

    Article-3  
preventing fibrosis by attenuating TGF1/AR signalling in the heart. In summary, 
MK5+/- or ERK3+/- prevented pressure-overload induced fibrosis and attenuated 
increases in COL11 expression without blocking increased TGF expression or 
preventing LV hypertrophy, implicating MK5-ERK3 post-TGF receptor signalling in 
cardiac fibroblasts. 
Although MK5+/- and ERK3+/- mice showed similar reductions in the ability of 
pressure overload to induce myocardial interstitial fibrosis, MK5- and ERK3-deficient 
mice show markedly different phenotypes. In fact, MK5-/- mice either show no obvious 
phenotype or embryonic lethality with incomplete penetrance, resulting in 50% of the 
predicted MK5-/- offspring, depending upon the genetic background of the mice [64]. 
ERK3-/- mice do not show embryonic lethality but die within 24 hours of birth [28]. 
Around 40% of ERK3-/- neonates show severe respiratory distress and die within 15 min 
of delivery. In addition, ERK3-deficient mice show evidence of intrauterine growth 
restriction (IUGR) [28]. Heart, lung and liver weights are 25-40% lower in E18.5 ERK3-
/- embryos than their ERK3+/+ litter mates. At birth, ERK3-/- and ERK3+/- mice are of 
significantly lower body weight than wild type mice [28]. In humans, IUGR affects 5-
10% of all newborns and is defined as having a birth weight below the 10th percentile 
for gestational age [65]. Fetal growth restriction (birth weight adjusted for gestational 
age) is associated with an increased incidence of hypertension, diabetes mellitus, and 
cardiovascular mortality in adulthood [66, 67]. Crispi et al recently demonstrated that 
IUGR induced adaptive cardiovascular changes that persist in childhood [68]. 
Specifically, children having undergone IUGR have hearts that are larger in diameter, 
with normal wall thickness, resulting in dilated ventricular chambers. Reduced stroke 
volume was compensated for by increased heart rate and vascular assessment revealed 
increased systolic and diastolic blood pressure. Although ejection fraction remained 
unchanged, assessment of cardiac function by echocardiography revealed significant 
reduction in both septal and lateral S and E velocities, indicating changes in both 
systolic and diastolic function. Follow studies also revealed the children with IUGR 
remained of lower body weight and size in comparison with control children (age range 
2-6 yr). In contrast, by the age of 15 weeks, ERK3+/- mice did not differ significantly 
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from wild type in terms of body weight, heart weight or LV diameter. Hence these mice 
had recovered from IUGR in terms of growth and the shape of the heart remained 
unaffected. Whereas early S wave velocity was reduced in IUGR children, in ERK3+/- 
mice systolic function was unaffected. However, in both IUGR children and ERK3+/- 
mice septal and LV lateral E wave velocity was reduced, resulting in an elevation in 
E/Em ratios. In contrast, MK5+/- mice showed normal cardiac structure and function at a 
comparable age. Hence, ERK3+/- mice recapitulated some but not all of the effects of 
IUGR observed in humans, which may be attributed to differences in age or species 
differences in the response to fetal growth restriction. 
 
Study Limitations 
We were unable to determine if ERK3+/- altered the changes in cardiac functional 
evoked by pressure overload as in this particular strain of mice 3 weeks of pressure 
overload evoked morphological and molecular changes but no functional changes.  
The mouse models employed herein were not equivalent. In the case of the MK5+/- 
mouse, the mice express one wild-type copy of MK5 and one copy that is non-
functional due to a deletion within the catalytic domain. In contrast, the ERK3+/- mice 
contain one null allel and hence express half the normal amount of ERK3 protein. 
Hence, if ERK3 plays a structural role in addition to is role as a protein kinase, functions 
related to this interaction will also be affected.  
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5. Conclusions 
MK5 and ERK3 form a complex in the mouse heart. In the present study, we 
shown that although MK5+/- and ERK3+/- hearts hypertrophied in response to chronic 
pressure overload they were resistant to fibrosis and less prone to diastolic dysfunction. 
Furthermore, MK5 and ERK3 remained associated after 3 wks of pressure overload. The 
lack of collagen accumulation in response to pressure-overload in ERK3+/- or MK5+/- 
hearts was not the result of reduced TGF- synthesis. Here, for the first time we show a 
role for MK5/ERK3 during the pathological cardiac remodeling induced by pressure-
overload. Further studies will address the mechanism by which MK5/ERK3 signaling 
regulates fibrosis.  
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Figure Legends 
Figure 1. Hypertrophic response of MK5+/- hearts to pressure overload. 
Pressure overload was induced in MK5+/- and wild type litter mate controls (MK5+/+) 
mice by transverse aortic constriction (TAC) and mice were sacrificed 2 wks post-
surgery. Sham animals underwent the identical surgical procedure, however the aorta 
was not constricted. (A) Left ventricular maximum developed pressure was measured 
using by a Millar micro-tip catheter pressure transducer. (B) Mice were sacrificed, heart 
weight/body weight ratio of MK5+/- and MK5+/+ measured. (C) HW/BW ratio versus left 
ventricular maximum developed pressure. Shown are the mean ± S.E. (n= 6-9). ***, p < 
0.001: **, p < 0.01: *, p < 0.05:  one-way ANOVA with Newman-Keuls post-hoc 
analysis.  
Figure 2. Expression of molecular markers of hypertrophy in the ventricular 
myocardium of MK5+/+ and MK5+/- mice after 2 weeks of pressure overload. Total 
RNA was isolated from 14 μm transverse cryosections of the ventricular myocardium. 
mRNA levels were quantified by qPCR. The relative abundance of (A) atrial natriuretic 
peptide (ANP), (B) B-type natriuretic peptide (BNP), (C) and beta-myosin heavy chain 
(-MHC) was normalized to GAPDH mRNA levels. Shown are the mean ± S.E. (n= 6-
9). ***, p < 0.001: **, p < 0.01: *, p < 0.05:  one-way ANOVA with Newman-Keuls 
post-hoc analysis.  
Figure 3. Assessment of cardiac fibrosis in MK5+/+ and MK5+/- mice after 
pressure overload. Transverse cryocections (8 m) of the ventricular myocardium were 
stained with Masson’s trichrome (A) 2 wks and (C) 3 wks post-TAC. Note the increased 
extracellular matrix content (stained blue). 3 sections for each heart were stained and 
shown are the representative images.  The original magnification was 10X. Total RNA 
was isolated from 14 μm transverse cryosections of the ventricular myocardium. 
Collagen alpha 1 type 1 (COL1A1) mRNA levels were measured in MK5+/+ and MK5+/- 
2 (B) and 3 wks (D) post-TAC by qPCR and were normalized to the amount of  
GAPDH mRNA. Shown are the mean ± S.E. (n= 6-9). ***, p < 0.001: **, p < 0.01: *, p 
< 0.05:  one-way ANOVA with Newman-Keuls post-hoc analysis.  
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Figure 4. ERK3 co-immunoprecipitates with MK5. (A) Mice were sacrificed 
after 3 wk of pressure overload, the ventricular myocardium isolated, lysates prepared, 
and MK5 immunoprecipitated with ab anti-MK5 antibody. Purified rabbit IgG was 
employed in control immunoprecipitations. Immunoprecipitate were separated on SDS-
PAGE and transferred to nitrocellulose membrane. Co-immunoprecipitated ERK3, 
ERK4, p38, phospho p38, and GAPDH were detected by immunoblotting. Aliquots (50 
g) of lysate from TAC and sham hearts were included as controls (Input). Results 
shown are representative of 3 animals in each group. (B) Lysates (50 g) from 3 TAC 
and sham hearts were analyzed by SDS-PAGE and immunoblotting using an anti-ERK3, 
anti-p38, or anti-ERK4 antibodies. Shown are the mean ± S.E. (n=3). 
Figure 5. Hypertrophic response of ERK3+/- mice to pressure overload. 
Pressure overload was induced in ERK3+/- and wild type litter mate controls (ERK3+/+) 
mice by transverse aortic constriction (TAC) and mice were sacrificed 3 wks post-
surgery. Sham animals underwent the identical surgical procedure, however the aorta 
was not constricted. (A) Left ventricular maximum developed pressure was measured 
using by a Millar micro-tip catheter pressure transducer. (B) Mice were sacrificed and 
heart weight/body weight ratio measured. (C) HW/BW ratio versus left ventricular 
maximum developed pressure. (D) Body weight (n=17) of ERK3+/+ and ERK3+/- mice. 
(E) Heart weight (n=7) of ERK3+/+ and ERK3+/- mice. (F) Total RNA was isolated from 
14 μm transverse cryosections of the ventricular myocardium. mRNA levels were 
quantified by qPCR. The relative abundance of atrial natriuretic peptide (ANP), B-type 
natriuretic peptide (BNP), and beta-myosin heavy chain (-MHC) was normalized to the 
amount of  GAPDH mRNA. (n= 7-8). Shown are the mean ± S.E. ***, p < 0.001: **, p 
< 0.01: *, p < 0.05:  one-way ANOVA with Newman-Keuls post-hoc analysis except for 
(C-D) where Students t-Test was performed.  
Figure 6. Assessment of cardiac fibrosis in ERK3+/+ and ERK3+/- mice after 3 
weeks of pressure overload. (A) Transverse cryocections (8 m) of the ventricular 
myocardium were stained with Masson’s trichrome in ERK3+/+ and ERK3+/- hearts 3 
wks post-TAC. Note the increased extracellular matrix content (stained blue). For each 
heart, 3 sections were stained: and representative images are shown. The original 
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magnification was 10X. (B) Total RNA was isolated from 14 μm transverse 
cryosections of the ventricular myocardium. Collagen alpha 1 type 1 (COL1A1) mRNA 
levels were measured by qPCR and normalized to the amount of  GAPDH mRNA. 
Shown are the mean ± S.E. (n= 7-8). ***, p < 0.001: **, p < 0.01: *, p < 0.05:  one-way 
ANOVA with Newman-Keuls post-hoc analysis.  
Figure 7. Quantification of TGF1 and TGF3 mRNA. Total RNA was 
isolated from 14 μm transverse cryosections of the ventricular myocardium. 
Transforming growth factor-beta 1 (TGF-1) and transforming growth factor-beta 3 
(TGF-3) mRNA was quantified by qPCR and normalized to the amount of GAPDH 
mRNA in: (A) MK5+/+ and MK5+/- hearts 2 and 3 wks post TAC hearts and (B) ERK3+/+ 
and ERK3+/- hearts 3 wks post-TAC. Shown are the mean ± S.E. (n= 6-9). ***, p < 
0.001: **, p < 0.01: *, p < 0.05:  one-way ANOVA with Newman-Keuls post-hoc 
analysis. 
Supplementary Figure 1. Response of MK5+/- hearts to 3 weeks of pressure 
overload. Pressure overload was induced in MK5+/- and wild type litter mate controls 
(MK5+/+) mice by transverse aortic constriction (TAC) for 3 wks. Sham animals 
underwent the identical surgical procedure, however the aorta was not constricted. (A) 2 
wk post-surgery, left ventricular maximum pressure was measured following catheter 
insertion in LV. (B) Mice were sacrificed, heart weight/body weight ratio of MK5+/- and 
MK5+/+ measured. Total RNA was isolated from 14 μm ventricle sections. The relative 
abundance of (C) atrial natriuretic peptide (ANP), (D) B-type natriuretic peptide (BNP), 
(E) and b-myosin heavy chain (-MHC) was quantified by qPCR and normalized to 
GAPDH mRNA levels. Shown are the mean ± S.E. (n= 6-9). ***, p < 0.001: **, p < 
0.01: *, p < 0.05:  one-way ANOVA with Newman-Keuls post-hoc analysis.  
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  Tables 
Table 1. Hemodynamic parameters for MK5+/+ and MK5+/- mice after 2 wk of pressure 
overload. 
                 Sham TAC 
MK5+/+  
(n=7) 
MK5+/-  
(n=6) 
MK5+/+ 
(n=9) 
MK5+/-  
(n=6) 
P max (mmHg) 99.6±3.5 94.8±4.3 144.8±9.8 130.7±15.2 
P min (mmHg) 64.0±2.8 61.5±3.0 65.3±4.9 67.1±5.1 
P mean (mmHg) 75.8±2.9 72.6±3.2 91.8±5.1 88.3±7.5 
LVP max (mmHg) 100±4.1 97.0±3.7 160.5±10.3 146.2±16.7 
LVP min (mmHg) 1.8±1.2 2.6±0.6 1.3±0.9 2.1±1.2 
LVP dPmax (mmHg/s) 6598±540.0 6145±382.0 5993±792.4 5982±515.7 
LVP dPmin (mmHg/s) -5774±437.1 -5586±407.8 -6269±822.7 -6545±648.1 
Ped (mmHg) 8.4±1.4 8.3±1.2 8.3±1.9 9.4±2.7 
CT (msec) 13.4±0.6 13.2±0.4 15.4±3.1 13.8±0.5 
RT (msec) 46.7±0.9 45.8±1.1 41.7±5.2 47.3±1.5 
Tau (msec) 9.1±0.4 8.9±0.5 8.2±0.9 9.2±0.5 
HR (bpm) 354.0±17.9 356.3±19.3 304.8±40.5 333.5±17.9 
Data reported as mean ± SEM. For statistical comparisons One-way ANOVA followed 
by Newman-Keuls test was performed. Shown are the values of mean and SEM. : 
p<0.05 vs Sham; †: p<0.05 for MK5+/- vs MK5+/+. 
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Table 2. Echocardiographic parameters of MK5+/+ and MK5+/- mice after 2 wk of 
pressure overload. 
  Sham TAC 
MK5+/+ 
(n=6) 
MK5+/-  
(n=7) 
MK5+/+ 
(n=6) 
MK5+/-  
(n=8) 
Aortic Peak Velocity (cm/s) 119.1±11.2 117.3±4.3 381.5±36.58 332.2±63.7
R-R interval (msec) 136.8±6.7 136.0±5.1 164.2±10.5 148.0±11.0 
Left ventricular dimensions 
and mass 
    
LVAWd (mm) 0.8±0.02  0.8±0.03 1.0±0.08  0.9±0.06 
LVPWd (mm) 0.7±0.03  0.8±0.04 0.9±0.05  0.8±0.05 
LVEDD (mm) 4.3±0.1  4.1±0.1 4.2±0.1   4.2±0.2  
LVESD (mm) 2.5±0.1  2.3±0.1 2.8±0.2 2.8±0.2 
LV mass (mg) 233.4±6.2  236.4±8.0 267.7±12.5 250.8±6.0 
LV mass / LVDd (mg/mm) 54.5±0.8 57.5±0.9† 63.7±2.7 59.8±2.5 
LV mass/BW (mg/g) 7.8±0.4 8.0±0.2 10.1±0.3 9.8±0.5 
Systolic Function     
FS (%) 40.5±2.0 43.0±1.4 32.5±2.7 34.5±1.2 
LVEF (%) 77.3±2.2 80.1±1.4 66.9±3.6 70.2±1.6 
Lateral Sm (cm/s) 2.9±0.1  3.0±0.2 2.0±0.2 2.5±0.1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Septal Sm (cm/s) 3.2±0.4 2.6±0.2 1.9±0.1 3.1±0.4† 
Diastolic function     
E velocity (cm/s) 72.1±5.1 63.9±5.9 82.6±5.5 87.0±8.7 
E DT (msec) 37.4±4.2 42.4±4.5 38.7±5.1 36.6±3.1 
E D rate (m/s2) 20.2±2.0 15.3±0.7† 25.0±4.8 24.3±2.5 
Septal Em 3.0±0.2 2.7±0.2 2.9±0.2 3.9±0.4† 
Septal E/Em 24.7±2.7 24.1±1.7 28.7±1.4 23.1±2.0† 
Lateral Em 2.9±0.1 3.0±0.3 2.8±0.3 3.4±0.1†  
Lateral E/Em 24.8±1.8 21.8±2.4 30.7±2.1 25.2±2.3  
LV isovolumetric relaxation 
time 
    
IVRT (msec) 13.8±1.0 13.2±1.3 22.5±2.7 15.1±1.8† 
IVRTc 1.18±0.1 1.13±0.1 1.74±0.2 1.23±0.1† 
Myocardial performance index     
Septal MPI (%) 82.7±8.8 84.4±10.0 111.5±14.0* 68.3±10.5† 
Lateral MPI (%) 81.2±6.7 96.1±5.9 112.8±14.5 76.1±13.7† 
Global MPI (%) 22.4±2.4 31.4±6.7 53.1±4.6 31.1±3.2† 
LVAWd, LV anterior wall end-diastolic thickness; LVPWd, LV posterior wall end-
diastolic thickness; LVEDD, Left ventricular end-diastolic diameter; LVESD, Left 
ventricular end-systolic diameter; FS, Fractional shortening, LVEF, Left ventricular 
ejection fraction; E, early diastolic transmitral filling velocity; IVRT, isovolumic 
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relaxation time; IVRTc, rate-corrected isovolumic relaxation time; EDT, early diastolic 
transmitral filling deceleration time; ED rate, early diastolic transmitral filling 
deceleration rate; Em, peak early diastolic tissue velocity; Sm, peak systolic tissue 
velocity.  
Data reported as mean ± SEM. : p<0.05 vs Sham; †: p<0.05 for MK5+/- vs MK5+/+. 
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Table 3. Structural and functional assessment of ERK3+/+ and ERK3+/- mice by 
echocardiography. 
  ERK3+/+       
(n=14) 
ERK3+/- 
(n=15) 
Aortic Peak Velocity (cm/s) 58.4±2.5 63.4±2.4 
Aortic Peak Gradient (mmHg)  1.4±0.1 1.7±0.1 
Aortic Mean Gradient (mmHg) 0.7±0.1 0.9±0.1† 
R-R interval (msec) 181.5±8.5 198.9±10.3 
Left ventricular dimensions and mass   
LVAWd (mm) 0.8±0.02 0.8±0.01 
LVPWd (mm) 0.8±0.03 0.8±0.01 
LVEDD (mm) 4.2±0.1 4.2±0.1 
LVESD (mm) 2.9±0.1 2.9±0.1 
LV mass (mg) 238.6±5.9 237.6±3.7 
LV mass / LVDd (mg/mm) 57.4±0.9 57.0±0.4 
LV mass/BW (mg/g) 8.0±0.2 8.0±0.2 
Systolic Function   
FS (%) 31.1±1.3 31.3±1.5 
LVEF (%) 65.3±1.8 65.4±2.4 
Lateral Sm (cm/s) 2.0±0.1 1.9±0.1 
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Septal Sm (cm/s) 2.1±0.1 2.1±0.1 
Diastolic function   
E velocity (cm/s) 87.4±4.3 82.3±5.4 
E DT (msec) 49.3±3.0 43.7±3.1 
E D rate (m/s2) 19.0±1.9 20.0±1.8 
Septal Em 4.2±0.3 2.9±0.3† 
Septal E/Em 21.5±0.8 29.4±1.8† 
Lateral Em 3.7±0.3 2.6±0.3† 
Lateral E/Em 24.7±1.6 34.1±2.2† 
Left ventricular isovolumetric relaxation 
time 
  
IVRT (msec) 21.6±2.0 23.9±3.2 
IVRTc 1.6±0.1 1.7±0.2 
Myocardial performance index   
Septal MPI (%) 59.2±2.3 62.8±2.6 
Lateral MPI (%) 62.6±1.7 64.2±2.0 
Global MPI (%) 44.0±3.9 44.6±4.5 
LVAWd, LV anterior wall end-diastolic thickness; LVPWd, LV posterior wall end-
diastolic thickness; LVEDD, Left ventricular end-diastolic diameter; LVESD, Left 
ventricular end-systolic diameter; FS, Fractional shortening, LVEF, Left ventricular 
ejection fraction; E, early diastolic transmitral filling velocity; IVRT, isovolumic 
relaxation time; IVRTc, rate-corrected isovolumic relaxation time; EDT, early diastolic 
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transmitral filling deceleration time; ED rate, early diastolic transmitral filling 
deceleration rate; Em, peak early diastolic tissue velocity; Sm, peak systolic tissue 
velocity.  
Data reported as mean ± SEM. †, p < 0.05 versus ERK3+/+. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
186

                                                               Article-3                           
  
Table 4. Hemodynamic parameters for ERK3+/+ and ERK3+/- mice after 3 wk of 
pressure overload. 
                 Sham TAC 
ERK3+/+  
(n=6) 
ERK3+/-  
(n=7) 
ERK3+/+ 
(n=6) 
ERK3+/-  
(n=8) 
P max (mmHg) 106.0±4.6 101.0±1.4 156.2±10.7  155.0±7.4  
P min (mmHg) 74.4±3.6 71.4±1.2 75.2±4.4 80.3±2.8 
P mean 85.0±3.8 74.5±7.0 102.2±6.3 105.2±3.7  
LVP max (mmHg) 106.3±4.4 101.4±2.0 167.7±11.6 172.4±12.0  
LVP min (mmHg) 4.0±1.6 1.2±0.6 5.4±1.0 3.2±1.3 
LVP dPmax 
(mmHg/s) 
6480±361.9 6515±360.6 6882±529.2 8110±616.2 
LVP dPmin 
(mmHg/s) 
-5831±446.7 -5833±338.7 -7035±324.6 -8273±671.7  
Ped (mmHg) 8.7±1.8 5.2±0.9 9.6±1.6 7.7±2.0 
CT (msec) 14.3±0.6 15.1±0.5 14.5±0.7 14.2±0.9 
RT (msec) 48.4±1.9 48.7±1.4 47.7±1.0 45.4±1.3 
Tau (msec) 3.3±2.0 3.1±1.7 0.1±0.1 2.4±1.4 
HR (bpm) 345.8±19.0 344.0±21.0 346.7±12.1 388.9±9.9 
Data reported as mean ± SEM. For statistical comparisons One-way ANOVA followed 
by Newman-Keuls test was performed. Shown are the values of mean and SEM. : 
p<0.05 vs Sham; †: p<0.05 for ERK3+/- vs ERK3+/+. 
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Table 5. Echocardiographic paramerters of ERK3+/+ and ERK3+/- mice after 3 wk of 
pressure overload. 
  Sham TAC 
ERK3+/+ 
(n=7) 
ERK3+/-  
(n=7) 
ERK3+/+ 
(n=7) 
ERK3+/-  
(n=8) 
Aortic Peak Velocity (cm/s) 73.7±8.5 78.5±5.4 287.7±15.7 235.3±13.1†
R-R interval (msec) 164.5±7.2 188.0±6.1† 158.9±9.9 192.7±9.8† 
Left ventricular dimensions 
and mass 
    
LVAWd (mm) 0.82±0.01 0.8±0.02 1.1±0.04  1.0±0.02† 
LVPWd (mm) 0.8±0.04 0.7±0.02 1.0±0.04  0.9±0.04  
LVEDD (mm) 4.0±0.1  4.0±0.1 4.4±0.1   4.2±0.1  
LVESD (mm) 2.5±0.1  2.6±0.1 3.0±0.2 2.7±0.2  
LV mass (mg) 234.3±3.8  231.0±3.6 298.7±13.2  261.6±6.0† 
LV mass / LVDd (mg/mm) 59.2±0.9 57.4±0.9 67.7±1.7 63.1±1.5 
LV mass/BW (mg/g) 8.4±0.3 8.0±0.2 9.7±0.4 9.3±0.2 
Systolic Function     
FS (%) 37.5±1.9 34.5±1.5 32.5±2.9 35.4±2.7 
LVEF (%) 73.9±2.3 70.2±1.9 66.6±4.8 70.5±3.6 
Lateral Sm (cm/s) 2.2±0.1  2.1±0.1 2.1±0.3  2.0±0.1  
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Septal Sm (cm/s) 2.5±0.1 2.5±0.1 2.6±0.2 2.7±0.1 
Diastolic function     
E velocity (cm/s) 85.2±4.4 79.9±2.5 92.2±6.0 90.6±5.5 
E DT (msec) 34.6±2.1 41.3±1.2† 34.8±3.0 38.8±3.0 
E D rate (m/s2) 25.1±2.0 19.5±1.1† 28.3±3.8 24.5±2.7 
Septal Em Nd nd nd nd 
Septal E/Em Nd nd nd nd 
Lateral Em Nd nd nd nd 
Lateral E/Em Nd nd nd nd 
LV isovolumetric relaxation 
time 
    
IVRT (msec) 19.8±1.4 22.6±1.1 21.4±1.7 22.7±2.0 
IVRTc 1.55±0.1 1.65±0.1 1.69±0.1 1.63±0.1 
Myocardial performance index     
Septal MPI (%) 63.7±4.7 71.3±4.6 64.0±6.6 61.6±2.4 
Lateral MPI (%) 68.3±3.5 76.2±2.7 70.4±4.2  64.2±2.4 
Global MPI (%) 42.0±3.8 51.2±3.6 48.7±2.8 41.0±4.3 
LVAWd, LV anterior wall end-diastolic thickness; LVPWd, LV posterior wall end-
diastolic thickness; LVEDD, Left ventricular end-diastolic diameter; LVESD, Left 
ventricular end-systolic diameter; FS, Fractional shortening, LVEF, Left ventricular 
ejection fraction; E, early diastolic transmitral filling velocity; IVRT, isovolumic 
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relaxation time; IVRTc, rate-corrected isovolumic relaxation time; EDT, early diastolic 
transmitral filling deceleration time; ED rate, early diastolic transmitral filling 
deceleration rate; Em, peak early diastolic tissue velocity; Sm, peak systolic tissue 
velocity.  
Data reported as mean ± SEM. : p<0.05 vs Sham; †: p<0.05 for ERK3+/- vs ERK3+/+. 
nd, not determined 
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Supplemental Table 1.  The primers used for qPCR 
Target Primers 
ANP S 
ANP AS 
5’-GTG CGG TGT CCA ACA CAG A-3’ 
5’-TTC TAC CGG CAT CTT CTC CTC-3’ 
BNP S 
BNP AS 
5’-GTT TGG GCT GTA ACG CAC TGA-3’ 
5’-GAA AGA GAC CCA GGC AGA GTC A-3’ 
-MHC S 
-MHC AS 
5’-AGG GTG GCA AAG TCA CTG CT-3’ 
5’-CAT CAC CTG GTC CTC CTT CA-3’ 
TGF-1 S 
TGF-1 AS 
5’-TGC TAA TGG TGG ACC GCA A-3’ 
5’-AGA TGT CTT TGG TTT TCT CAT AGA TGG-3’ 
TGF-3 S 
TGF-3 AS 
5’-AGA GAT CCA TAA ATT CGA CAT-3’ 
5’-ACA CAT TGA AAC GAA AAA CCT-3’ 
COL11 S 
COL11 AS 
5’-CTG ACG CAT GGC CAA GAA GAC A-3’ 
5’- CGT GCC ATT GTG GCA GAT ACA GAT -3’ 
GAPDH S 
GAPDH AS 
5’-CTG CAC CAC CAA CTG CTT AGC-3’ 
5’-ACT GTG GTC ATG AGC CCT TCC A-3’ 
S, sense; AS, anti-sense; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; qPCR, 
quantitative polymerase chain reaction; ANP, atrial natriuretic peptide; BNP, B-type 
natriuretic peptides; -MHC, -myosin heavy chain; TGF-1, transforming growth 
factor beta 1; TGF-3, transforming growth factor beta 3; COL11, collagen type 1 
alpha 1. 
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Supplemental Table 2. Structural and functional assessment of MK5+/+ and MK5+/- 
mice by echocardiography. 
  MK5+/+    
(n=13) 
MK5+/- 
(n=12) 
Aortic Peak Velocity (cm/s) 87.2±8.4 94.6±6.7 
Aortic Peak Gradient (mmHg) 3.4±0.6 3.7±0.5 
Aortic Mean Gradient (mmHg) 1.9±0.4 2.1±0.3 
R-R interval (msec) 147.5±5.5 150.3±5.4 
Left ventricular dimensions and mass   
LVAWd (mm) 0.7±0.02 0.7±0.04 
LVPWd (mm) 0.7±0.02 0.6±0.03 
LVEDD (mm) 4.1±0.1 4.1+0.2 
LVESD (mm) 2.6±0.2 2.5±0.2 
LV mass (mg) 217.1±4.1 211.5±7.8 
LV mass / LVDd (mg/mm) 53.5±1.1 52.3±1.3 
LV mass/BW (mg/g) 8.5±0.5 8.0±0.3 
Systolic Function   
FS (%) 38.3±2.3 38.4±2.3 
LVEF (%) 74.1±2.6 74.5±2.6 
Lateral Sm (cm/s) 3.0±0.1 2.9±0.2 
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Septal Sm (cm/s) 2.9±0.2 2.9±0.2 
Diastolic function   
E velocity (cm/s) 60.0±3.7 62.2±2.5 
E DT (msec) 40.0±2.6 40.8±2.7 
E D rate (m/s2) 15.7±1.3 15.8±1.3 
Septal Em 3.3±0.2 3.4±0.2 
Septal E/Em 18.2±1.0 18.8±1.0 
Lateral Em 3.0±0.3 3.3±0.2 
Lateral E/Em 15.6±1.6 19.2±1.3 
Left ventricular isovolumetric relaxation 
time 
  
IVRT (msec) 15.2±1.6 15.6±1.6 
IVRTc 1.2±0.1 1.3±0.1 
Myocardial performance index   
Septal MPI (%) 79.2±8.4 69.9±7.6 
Lateral MPI (%) 81.0±6.1 91.7±12.6 
Global MPI (%) 36.8±5.0 46.3±5.5 
LVAWd, LV anterior wall end-diastolic thickness; LVPWd, LV posterior wall end-
diastolic thickness; LVEDD, Left ventricular end-diastolic diameter; LVESD, Left 
ventricular end-systolic diameter; FS, Fractional shortening, LVEF, Left ventricular 
ejection fraction; E, early diastolic transmitral filling velocity; IVRT, isovolumic 
relaxation time; IVRTc, rate-corrected isovolumic relaxation time; EDT, early diastolic 
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transmitral filling deceleration time; ED rate, early diastolic transmitral filling 
deceleration rate; Em, peak early diastolic tissue velocity; Sm, peak systolic tissue 
velocity.  
Data reported as mean ± SEM. †, p < 0.05 versus ERK3+/+. 
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Supplemental Table 3. Hemodynamic parameters for MK5+/+ and MK5+/- mice after 3 
wk of pressure overload. 
               Sham TAC 
MK5+/+  
(n=9) 
MK5+/-  
(n=8) 
MK5+/+  
(n=8) 
MK5+/-  
(n=8) 
P max (mmHg) 89.9±2.0 89.9±3.1 143.7±5.6  142.3±10.8  
P min (mmHg) 57.4±2.6 58.7±3.1 64.8±2.9 65.1±3.6 
P mean 69.7±2.7 71.3±3.3 90.7±2.9 93.9±6.1 
LVP max (mmHg) 90.6±1.3 92.6±2.7 155.1±10.4  144.4±11.8  
LVP min (mmHg) 2.3±1.0 3.3±1.5 2.7±0.5 8.0±2.7 
LVP dPmax 
(mmHg/s) 
4872±145.1 5176±234.7 6308±630.6  5047±362.8 
LVP dPmin 
(mmHg/s) 
-4794±216.7 -4865±168.3 -6542±567.1  -5589±417.9 
Ped (mmHg) 6.9±1.2 7.6±2.3 6.33±0.3 16.6±3.1 † 
CT (msec) 14.3±0.5 14.0±0.5 15.1±0.6 13.7±0.6 
RT (msec) 48.4±0.8 49.0±1.4 46.7±1.6 47.7±0.6 
Tau (msec) 9.4±0.5 9.3±0.4 8.7±0.5 9.4±0.5 
HR (bpm) 327.4±15.1 329.8±15.4 387.7±20.2 328.5±15.9 
Data reported as mean ± SEM. For statistical comparisons One-way ANOVA followed 
by Newman-Keuls test was performed. Shown are the values of mean and SEM. : 
p<0.05 vs Sham; †: p<0.05 for MK5+/- vs MK5+/+. 
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Supplemental Table 4. Structural and functional assessment of ERK3 and MK5 mice 
by echocardiography. 
  ERK3+/+  
(n=14) 
MK5+/+ 
(n=13) 
Aortic Peak Velocity (cm/s) 58.4±2.5* 87.2±8.4 
Aortic Peak Gradient (mmHg) 1.4±0.1* 3.4±0.6 
Aortic Mean Gradient (mmHg) 0.7±0.1* 1.9±0.4 
R-R interval (msec) 181.5±8.5* 147.5±5.5 
Left ventricular dimensions and mass   
LVAWd (mm) 0.8±0.02* 0.7±0.02 
LVPWd (mm) 0.8±0.03* 0.7±0.02 
LVEDD (mm) 4.2±0.1 4.1±0.1 
LVESD (mm) 2.9±0.1 2.6±0.2 
LV mass (mg) 238.6±5.9* 217.1±4.1 
LV mass / LVDd (mg/mm) 57.4±0.9* 53.5±1.1 
LV mass/BW (mg/g) 8.0±0.2 8.5±0.5 
BW (g) 29.8±0.8* 26.2±1.3 
Systolic Function   
FS (%) 31.1±1.3* 38.3±2.3 
LVEF (%) 65.3±1.8* 74.1±2.6 
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Lateral Sm (cm/s) 2.0±0.1* 3.0±0.1 
Septal Sm (cm/s) 2.1±0.1* 2.9±0.2 
Diastolic function   
E velocity (cm/s) 87.4±4.3* 60.0±3.7 
E DT (msec) 49.3±3.0* 40.0±2.6 
E D rate (m/s2) 19.0±1.9 15.7±1.3 
Septal Em 4.2±0.3* 3.3±0.2 
Septal E/Em 21.5±0.8* 18.2±1.0 
Lateral Em 3.7±0.3 3.0±0.3 
Lateral E/Em 24.7±1.6 21.9±2.1 
Left ventricular isovolumetric relaxation 
time 
  
IVRT (msec) 21.6±2.0* 15.2±1.6 
IVRTc 1.6±0.1* 1.2±0.1 
Myocardial performance index   
Septal MPI (%) 59.2±2.3* 79.2±8.4 
Lateral MPI (%) 62.6±1.7* 81.0±6.1 
Global MPI (%) 44.0±3.9 36.8±5.0 
LVAWd, LV anterior wall end-diastolic thickness; LVPWd, LV posterior wall end-
diastolic thickness; LVEDD, Left ventricular end-diastolic diameter; LVESD, Left 
ventricular end-systolic diameter; FS, Fractional shortening, LVEF, Left ventricular 
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ejection fraction; E, early diastolic transmitral filling velocity; IVRT, isovolumic 
relaxation time; IVRTc, rate-corrected isovolumic relaxation time; EDT, early diastolic 
transmitral filling deceleration time; ED rate, early diastolic transmitral filling 
deceleration rate; Em, peak early diastolic tissue velocity; Sm, peak systolic tissue 
velocity.  
Data reported as mean ± SEM. *, p < 0.05 versus MK5+/+. 
             
UNPUBLISHED RESULTS 

Screening for MK5 substrates in the heart
 There is still a lack of knowledge about the upstream signaling and regulatory 
inputs that control the expression and/or activity of ERK3 and ERK4. In fact, MK5 is 
currently the only known target downstream of ERK3/ERK4 [63, 107, 108]. In vitro, 
MK5 phosphorylates Hsp27, however studies in MK5 knock-out MEFs raised serious 
concerns about in vivo HSP25 (mouse homologue of HSP27) as a substrate of MK5 
[106]. Therefore, given the involvement of MK5 in pathological fibrosis and to gain a 
further understanding of MK5 downstream signaling, we sought to identify its substrates 
in the heart. Rat heart cytosol was incubated with activated GST-MK5 (phosphorylated 
in vitro with p38) in the presence of [32P]ATP and protein phosphorylation was 
assessed by autoradiography following SDS-PAGE (1D) or IPG-PAGE (2D). Two low 
molecular weight proteins were labeled with 32PO4 in 1D as well as 2D gels (Fig. 7A).  
In both cases, regions of the gel containing the phosphorylated protein were excised and 
the protein was identified by liquid chromatography-tandem mass spectrometry (LC-
MSMS). The high molecular weight band corresponded to Hsp25 and the lower MWt 
band corresponded to alpha-B crystalline (BC). We confirmed these observations by 
showing that activated GST-MK5 was able to phosphorylate purified recombinant His-
HSP27 and bovine BC. Activated GST-MK2 was employed as a positive control. 
GST-MK5 incorporated more phosphate in Hsp27 than GST-MK2, but in the case of 
BC both enzymes incorporated same amount of phosphate (Fig. 7B). MK2 is known to 
phosphorylate HSP27 and BC in vitro and in vivo [161]. Phosphorylation of cytosolic 
and purified bovine BC by activated GST-MK5 may indicate BC as a novel substrate 
for MK5, although phosphorylation of BC in vivo by MK5 remains to be determined. 
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Fig. 7.  Screening for MK5 substrates in heart (A) GST-MK5 (1 mU) was incubated 
with 50 µg cytosol and 10 µM [γ32P]ATP (10 µCi) for 60 min at 30°C. Reactions were 
terminated using 4x SDS-PAGE sample buffer. Proteins were separated on 10-20% 
SDS-PAGE. Gels were stained with Coomassie blue, dried and exposed to x-ray film. 
For 2D gels, reactions were stopped by addition of TCA, the protein pellet dissolved in 
rehydration buffer, and protein resolved on 7 cm pH 3-10 IPG strips. For the second 
dimension, proteins were resolved on 10-20% SDS page as discussed above. Shown are 
representative images of two independent experiments.  (B) 0.1 µg of phosphorylated 
GST-MK5 or  GST-MK2 was incubated with 1.0 µg of purified recombinant His6-
Hsp27 (left) or bovine αB-crystallin (right) and 10 µM [γ32P]ATP (1 µCi). Solid arrow 
shows point  of 32PO4 incorporation in 1D and 2D gel. 
-αBC 
             
DISCUSSION 
 
MK5 is phosphorylated both by p38 and atypical MAPKs, ERK3 and ERK4. 
Recently PKA has also been shown to be involved. Despite this, the physiological role 
of MK5 and ERK3/ERK4 remain unknown. Moreover, p38 is considered to be the 
dominant p38 isoform in heart. Little is known about p38 and p38. Here we show that 
following 2- and 3-wks of pressure overload, hearts from MK5+/- mice developed 
hypertrophy but were resistant to myocardial interstitial fibrosis. In lysates prepared 
from normal hearts, where p38 would not be activated, ERK3, but not ERK4 or p38, 
co-immunoprecipitated with MK5. After acute or chronic pressure overload, MK5 
remained bound to ERK3 while no interaction with ERK4 or p38 was detected. Similar 
to MK5+/- hearts, following 3 wks of pressure overload, ERK3+/- mice developed 
hypertrophy whereas cardiac interstitial fibrosis was not detected. Thus ERK3-MK5 
signaling plays a role in pressure overload-induced myocardial interstitial fibrosis. 
Furthermore, in the heart, mRNA for 5 splice variants of MK5 (MK5.1-5.5) including 
the original form (MK5: referred to herein as MK5.1), was detected. One of the variant 
(MK5.3) lacked binding sites for ERK3/ERK4, while two others (MK5.4-5.5) lacked 
part of kinase domain and hence were catalytically inactive. The relative abundance of 
variant mRNA was changed in response to chronic pressure overload and during 
postnatal heart development. Hence, distinct effects may be mediated by these MK5 
variants which would increase the functional diversity of ERK3-MK5 signaling. To date 
all p38 isoforms except p38 have been reported in the heart. p38 is considered to be 
the dominant isoform. Here we show that p38 is expressed in the mouse heart at 
protein levels which are comparable to p38, and at both mRNA and protein levels 
p38 and p38 expressions levels were similar. Moreover, p38 but not p38 
accumulated in the nucleus in hearts in response to chronic pressure overload, which 
suggests that p38 may play a distinct role during pressure overload-induced cardiac 
remodelling. In summary, we have now shown 1) ERK3-MK5 signaling plays an 
important role in pressure overload-induced cardiac interstitial fibrosis and 2) p38 may 
play an important role in the heart.  
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Due to the availability of pharmacological inhibitors, such as SB203580, p38 
and p38 have been studied extensively in the heart, and have been shown to be 
activated in response to various stimuli such as ischemia and reperfusion, pressure 
overload, pro-hypertrophic agonists, and mechanical stretch [162-165]. During 
ischemia, inhibition of p38 is protective and p38+/- mice are resistant to infarction 
[166-168]. In neonatal myocytes, p38 has been shown to be involved in the MKK6-
mediated hypertrophic response and p38 in the MKK3-mediated apoptosis [33]. Our 
results showed that p38 was expressed at protein levels similar to p38, and its mRNA 
levels increased in the hypertrophying mouse heart. Despite lower expression of p38 
relative to p38/, it has been shown to mediate specific signaling in the heart [33]. 
Therefore, further study may also reveal a unique role for p38 in the heart.  
Until now p38 has been considered to be the predominant isoform in the heart: 
however, this has not been studied systematically. We therefore studied the p38 isoform 
expression profile and subcellular distribution in both the normal mouse heart as well as 
those subjected to pressure overload. p38 mRNA and protein was expressed at levels 
similar to p38. Moreover, in response to pressure overload, p38// mRNA levels 
were increased. However, no corresponding changes were observed at the protein level. 
In response to pressure overload, p38, but not p38, accumulated in the nucleus. p38 
is the only member of the p38 family to have a KETXL sequence in its C-terminus. This 
sequence can interact with PDZ domains [169], which may allow p38 to diversify its 
signaling. One would ask, why p38 and not p38 accumulates in nucleus following 
pressure overload. The answer could be in p38’s ability to interact with proteins 
containing a PDZ domain. For example, the PDZ-binding motif FLTWL in YES kinase-
associated protein (YAP) is essential for its nuclear import and ability to promotes 
apoptosis in HEK293 cells in response to low serum [170]. p38 has been shown to 
interact with number of PDZ-containing proteins such as 1-syntrophin, SAP90/PSD95, 
and SAP97/hDlg [169, 171] as well as several transcription factors, including MEF2A, 
AP-1, p53, ATF2, Elk-1, SAP1, and SAP2 [172-174]. Under pathological conditions, 
p38 has been shown to regulate myocardial fibrosis and apoptosis [33, 51, 175]. As 
p38 was expressed at protein equivalent levels to p38, and accumulates in the nucleus 
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when the heart is chronically exposed to pressure overload, it is highly likely that p38 
plays a role in the changes in gene expression associated with cardiac remodeling. In 
order to begin to understand the consequences of the nuclear localization of p38, we 
sought to identify proteins in cytosolic and nuclear fractions isolated from rat heart that 
became phosphorylated while incubated in the presence of [32P]ATP plus 
phosphorylated, activated GST-p38, GST-p38, GST-p38, or GST-p38. However, 
no p38-specific  phosphorylation was observed in either subcellular fraction. The failure 
to detect p38-dependent incorporation of 32P into proteins in the cytosolic or nuclear 
fraction may reflect low copy number or phosphorylation status of target proteins in 
these fractions or localization or, perhaps, the absence of a suitable scaffolding protein.  
MK2, MK3, and MK5 lie downstream of p38. The physiological roles of MK3 
and MK5 remain unknown. Herein we determined if MK5 is involved in pathological 
remodeling of the heart. In response to chronic pressure overloads, mice heterozygous  
for a functional knockout of MK5 underwent molecular remodeling and hypertrophy but 
were resistant to fibrosis in response to chronic pressure overload induced by TAC. In 
vitro and in cells studies have shown the involvement of MK5 downstream of p38 and 
atypical MAPKs ERK3 and ERK4 [63, 87-90, 94, 108]. Of the four p38 isoforms, MK5 
is regulated by p38 and p38. In HeLa cells, in response to stress or constitutively 
activated form of MKK6, p38 and p38 activate MK5 [88]. Additinally, in vitro 
kinetic studies also demonstrate MK5 to be a better substrate for p38 and p38 than 
p38 and p38 [176]. MK5 interacts physically with all of its known upstream kinases. 
MK5 and p38 co-immunoprecipitate when over expressed in NIH3T3 cells [91, 177]. 
Over-expressed ERK4 forms a complex with ERK3 and in HEK cells, endogenous (i.e., 
not heterologously expressed) ERK3 and ERK4 both interact with MK5. Moreover, 
deletion of either ERK3 or ERK4 does not affect the ability of the other ERK to interact 
with MK5: in an ERK3-deficient background ERK4 is still able to interact with MK5 
and vice versa [62, 63]. This suggests that the interaction of MK5 with ERK4 or ERK3 
is independent of the presence of the other atypical MAPK. Similarly, at endogenous 
levels, both ERK3 and ERK4 are physiological regulators of MK5 activity. MK5 
activity is reduced by 50% in ERK3-/- cells or following siRNA-mediated knock down 
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of either ERK3 or ERK4. Combined siRNA mediated knock down of ERK3 plus ERK4 
reduces MK5 activity by 80% [63, 108]. Therefore, in the heart we sought to determine 
which of these kinases (e.g., p38, p38, ERK3, ERK4) interact with MK5. 
Immunoprecipitation of MK5 from whole mouse heart lysates resulted in co-
immunoprecipitation of ERK3 but not ERK4 or p38. Under these conditions p38 
activity was minimal. We then determined if MK5 interacts with p38 under conditions 
where the p38 pathway was activated. We have shown a peak in phospho p38 levels 
occurs 3 d post-TAC. In hearts exposed to either acute (3 days) or chronic (3 weeks) 
pressure overload, immunoprecipitation of MK5 resulted in co-immunoprecipitation of 
ERK3, but not ERK4 or p38. Hence, in the heart, activation of the p38 pathway does 
not appear to induce the formation of a stable p38-MK5 complex or alter the stability of 
MK5-ERK3 complexes. These observations suggesting that the pro-fibrotic signaling of 
MK5 is regulated by ERK3. Consistently, similar to MK5+/- mice, ERK3+/- mice 
underwent hypertrophy and molecular remodeling, but not fibrosis in response to 3 
weeks of pressure overload. Taken together, these results show that MK5-ERK3 
signaling plays an important role in remodeling of the myocardial extracellular matrix 
and resulting increase in wall stress induced by chronic pressure overload. 
During fibrosis, both the synthesis and degradation of collagen are altered, the net 
result of with is collagen accumulation. Collagen type I and type III are the major 
components of the cardiac ECM. Approximately 85% of total collagen in the heart is 
collagen type 1, and hence it is a major determinant of myocardial stiffness [178, 179]. 
In both MK5+/- and ERK3+/- hearts, TAC induced less collagen accumulation, as 
detected by Masson trichrome staining, and this reduction appears to be a consequence 
of hampered COL11 mRNA synthesis and/or stability. In both MK5+/- and ERK3+/- 
hearts, the ability of pressure overload to induce an increase in COL11 mRNA levels 
was reduced compared to wild type littermates. In the heart, TGF-1 is a locally 
generated cytokine that induces fibroblast proliferation, fibroblast differentiation into 
myofibroblasts, and increased production of ECM proteins, including collagens, 
fibronectin, and proteoglycans [141]. On the other hand, to maintain the increase in 
fibrosis, TGF- also reduces the degradation of ECM by inhibiting the expression of 
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matrix metalloproteinases (MMP), and by inducing the expression of protease inhibitors, 
such as plasminogen activator inhibitor-1 (PAI-1) and tissue inhibitors of 
metalloproteinases (TIMPs) [142]. There was no difference in TGF-1 and TGF-3 
mRNA levels in MK5+/- hearts following 2 and 3 wks TAC compared to hearts from 
wild type littermates. A similar TGF-1 pattern was observed in ERK3+/- TAC hearts. In 
conclusion, although chronic pressure overload failed to induce fibrosis in MK5+/- and 
ERK3+/- hearts, the increase in TGF mRNA, was maintained, suggesting the 
involvement of ERK3-MK5 in the fibrotic response to pressure overload lies 
downstream of TGF transcription. 
The results presented herein indicate that MK5 and ERK3 are involved in the 
increase in interstitial fibrosis induced by chronic pressure overload, the main 
determinant of diastolic dysfunction in heart disease. These results may be interpreted as 
suggesting that MK5 or ERK3 activities may represent potential targets for the treatment 
of fibrosis induced by pressure overload. However, this study was based on genetic 
models wherein the actual level of expression of MK5 or ERK3 was reduced. It remains 
to be determined if the antifibrotic effects were due to the reduction in MK5 or ERK3 
activity or due to a decrease in the cellular content of these proteins. Both MK5 and 
ERK can physically interact with other proteins within the cell and it may be the loss of 
these physical interactions, rather than a reduction in kinase activity, that has resulted in 
reduced fibrosis. For example, in the absence of a binding partner such as MK5, ERK3 
is rapidly broken down. Hence, reductions in MK5 expression results in reduced in 
ERK3 content as well and thus the protective effects observed in the MK5+/- mouse may 
have resulted from a reduction in ERK3 protein levels or activity. Future studies will be 
required to address the involvement of the catalytic activity of MK5 and ERK3 in the 
development of interstitial fibrosis using mice engineered to express inactive mutants of 
MK5 or ERK3 in order to resolve this issue.  
An analysis of cDNA prepared from the mouse ventricular myocardium 
demonstrated 5 splice variants of MK5 (MK5.1-5), including the originally published 
form (MK5.1). The putative amino acid sequences indicated that all variants retain the 
activating phosphorylation site (Thr-182) plus both the NES and NLS within the C-
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terminus. MK5.2 lacks 2 amino acids, MK5.3 lacks C-terminal amino acids 370 through 
473, and MK5.4 and MK5.5 lack kinase subdomains I-VIb. In full-length MK5, C-
terminal amino acid residues 383-393 and 460-465 are required for its interaction with 
ERK3/ERK4 [110]. Hence, with the exception of MK5.3, all other variants retain the 
binding sites for ERK3/ERK4. Moreover, the relative abundance of MK5.3 mRNA was 
reduced following 1 wk of pressure overload. At this point, the role played by each 
variant in MK5 mediated myocardial fibrosis remains unclear, as the deletion of exon 6 
in the MK5 knockout mice used in this study [106] affects all 5 variants. In the future, 
gain of function studies wherein the introduction of MK5.1-3 variant into isolated MK5-
/- cardiac fibroblast or loss of function studies wherein the introduction of MK5.4-5 in to 
wild type cardiac fibroblast, should reveal if these variants play a similar role in the 
regulation of collagen expression. 
MK5 is located within the nucleus when inactive and translocates to the cytosol 
upon over-expression or activation of p38 [89-91]. Similarly, in HEK293 cells, 
exogenously expressed MK5.1-V5, MK5.2-V5 or MK5.3-V5 localized to the nucleus. 
Incubation with anisomycin, which activates p38, resulted in the translocation of all 3 
variants to the cytosol. The nuclear export was blocked by SB203580, an inhibitor of 
p38/ activity. Therefore, the lack of 2 amino acid residues on MK5.2 and 103 amino 
acid residues in the C-terminal of MK5.3 had no effect on p38-mediated subcellular 
relocalization. Surprisingly, exogenously expressed MK5.4-V5 and MK5.5-V5 localized 
to the cytoplasm and p38 activation induced a small increase in 
immunocytofluorescence within the nucleus. The nuclear import of MK5.4 and MK5.5 
was not blocked by SB203580. Hence, the absence of kinase subdomains I-VIb in 
MK5.4 and MK5.5 affected its ability to translocate into, or be retained within, the 
nucleus. One possible explanation for the small amount of MK5.4 and MK5.5 in nucleus 
following p38 activation is that it interacts with p38 within the cytosol and enters the 
nucleus as heterodimer with activated p38. 
In MK5 signaling, the regulation of its activity by upstream kinases and its 
downstream effectors are currently controversial. The activation and subcellular 
localization of MK5 is regulated by both p38 and ERK3/ERK4. Recently, PKA was also 
206

Discussion 
  
shown to be involved. When originally identified, MK5 was described as a p38 
substrate, as its activation and cellular localization depended on p38 activity [88]. 
Additionally, in the cellular localization of MK5 was altered by just over-expression of 
kinase-dead p38 or p38 as well as non-activatable p38 [89, 90], suggesting that the 
binding of p38 to MK5 may be sufficient to induce translocation. However, these 
studies may also reflect an inappropriate localization or translocation of p38 when 
overexpressed. More recent studies suggest that the regulation of MK5 activity may be 
more complicated. While both the stability of p38 and stress induced Hsp25 (mouse 
homologue of Hsp27) phosphorylation are reduced in cells isolated from MK2-deficient 
mice, no such effects are observed in cells from MK5-deficient mice [106, 132]. These 
observations raised serious concerns about the role of MK5 as an Hsp25-kinase and 
substrate for p38 in vivo. On the other hand, in a different line of MK5 knockout mice, 
MK5 has been shown to mediate senescence in response to the induction of oncogenic 
ras through activation of p38 [94]. These differences in in vivo observations remain 
unexplained. Both lines of mice are in a similar genetic background: however, one line 
expressed non-functional MK5 [106] whereas the other does not express MK5 [94]. It is 
possible that deletion of the kinase domain within MK5 might not be enough to 
eliminate all of MK5’s functions: MK5 may also serve as a scaffold to recruit other 
proteins.  
Atypical MAPKs ERK3 and ERK4 regulate both the activity and cellular 
localization of MK5 [63, 108]. Although inactive MK5 primarily located within the 
nucleus, it constantly shuttles between nucleus and cytoplasm [90]. Over-expressing 
ERK3 retains MK5 in the cytoplasm [107]. The phosphorylation of ERK3 and ERK4 
within the activating S-E-G motif does not change in response extracellular mitogenic or 
stress stimuli [65, 109]. However, both ERK3 and ERK4 directly phosphorylate MK5 
and phosphorylation of ERK3 and ERK4 within their S-E-G motif is indispensable for 
their ability to form a stable interaction with MK5 and thus regulate its activation and 
subcellular localization [65]. During embryogenesis ERK3 and MK5 mRNA expression 
peaks at day E11 [107]. ERK3 accumulates during cell differentiation, inducing G1 
arrest, and thus inhibiting cell proliferation [59]. Hence, it is conceivable that both 
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ERK3/ERK4 and p38 regulate MK5 activity and cellular localization, depending upon 
the differentiation status and nature of the cell system being studied. Given the p38’s 
ability to regulates ERK3 transcription and translation [61], and the dependence of MK5 
activation and interactions on ERK3/ERK4 phosphorylation [65], it is also possible that 
a kinase that phosphorylates ERK3/ERK4 is under indirect control of p38 activity. In the 
heart, MK5 co-immunoprecipitated ERK3 but not ERK4 or p38, and this ERK3-MK5 
complex was stable irrespective of p38 activity. Moreover, exogenously added GST-
MK5 in the heart lysate was able to pull down ERK4 and p38 immunoreactivity but not 
ERK3. These observations suggest that there is no free ERK3 in the heart: all the ERK3 
is bound to the endogenous proteins, including, but not limited to, MK5. Conversely, 
exogenously added GST-ERK3 or GST-p38 were not able to pull down endogenous 
MK5 from mouse heart lysates. These results suggest that although MK5 can interact 
with p38 and ERK4 in cultured cells at the levels expressed in the heart, MK5 and 
ERK3 are in complexes and neither is in an unbound form. These results do not, 
however, indicate 1) if MK5 and ERK3 are present only as an ERK3-MK5 complex 
versus complexes with other endogenous proteins, and 2) if ERK3-MK5 complexes also 
include other proteins. 
Little is known about the substrate specificity of MK5. In vitro, MK5 
phosphorylates Hsp27, but studies in MK5 knockout MEF cell raised some concerns 
about Hsp25 being a MK5 substrate in vivo [106]. In our in vitro kinase assay screening 
for MK5 substrates, activated GST-MK5 incorporated 32PO4 into B-crystallin. B-
crystallin belongs to the family of small heat shock proteins (sHsps) and is 
phosphorylated at three serine sites corresponding to residues 19, 45, and 59. Serine 59 
gets phosphorylated by MK2, serine 45 appears under the control of p42/p44 MAPK, 
and the kinase responsible for the phosphorylation of ser 19 remains unknown [161]. In 
U373 MG human glioma cells, Kato et al. showed that these three serine residues are 
phosphorylated by three different protein kinases, and the kinase responsible for 
phosphorylating ser 19 eluted from a Superdex 200 gel filtration column with an 
apparent molecular mass of around 60 kDa: however, they were not able to identify the 
kinase. Moreover, mitotic cells and cells treated with phorbol 12-myristate 13-acetate 
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(PMA) increased the phosphorylation at ser 19 [180]. The molecular mass of MK5 is 54 
kDa, close to the unidentified 60 kDa kinase that phosphorylated BC on ser 19. 
Additionally, in the isolated perfused heart, ischemic stress induces B-crystallin 
translocation from a diffuse, cytosolic localization to the sarcomeres [181]. This 
translocation was shown to be temporally coordinated with increased B-crystallin 
phosphorylation, although the identities of the phosphorylated residues have yet to be 
established [182]. Moreover, in PC12 cells PKA activated MK5, which was required for 
PKA induced microfilament rearrangement [98]. Altogether it appears that B-crystallin 
may be a novel MK5 substrate, however this requires further characterization. 
             
CONCLUSIONS 
 
This study shows a novel role for ERK3-MK5 in the heart during pathological 
remodelling induced by pressure overload. We have shown that MK5+/- and ERK3+/- 
hearts hypertrophy but are resistant to fibrosis and show preserved diastolic function 
following pressure overload. The reduced collagen expression in MK5+/- or ERK3+/- was 
not due to reduction in TGF mRNA synthesis. Additionally, ERK3+/- hearts showed 
diastolic dysfunction. Moreover, MK5 and ERK3 are in a complex in control hearts, and 
the stability of this complex was not altered by 3-d or 3-wk of pressure overload. No 
unbound MK5 or ERK3 was detected in heart lysates.  
We also have shown the existence of 5 splice variants (MK5.1-5.5) of MK5. One 
of the variant (MK5.3) lacked binding sites for ERK3/ERK4, while two others (MK5.4-
5.5) lacked a complete kinase domain and hence were catalytically inactive. The relative 
abundance of variant mRNA was changed both in response to pressure overload and 
during postnatal heart development. Hence, distinct effects may be mediated by these 
MK5 variants which would increase the functional diversity of ERK3-MK5 signaling.  
Furthermore, we have shown that p38 is expressed in the mouse heart at protein 
levels which were comparable to p38, and at both mRNA and protein levels p38 and 
p38 expression levels were similar. Moreover, p38 but not p38 accumulated in the 
nucleus in response to chronic pressure overload, which may suggest distinct role played 
by p38 during hypertrophy. 
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ORIGINAL CONTRIBUTION TO THE LITERATURE 

1. MK5 is involved in cardiac interstitial fibrosis induced by chronic pressure 
overload. 
2. MK5 forms complex with ERK3 and not with ERK4 and/or p38 in control and 
hypertrophic heart, and the pro-fibrotic signaling mediated by MK5 may involve 
ERK3 activation. 
3. In heart, both MK5 and ERK3 are bound to each other, or other proteins, hence 
there is no pool of uncomplexed MK5 or ERK3. 
4. Like MK5, ERK3 is involved in cardiac interstitial fibrosis induced by chronic 
pressure overload. 
5. A deficiency in ERK3 in heart results in diastolic dysfunction.   
6. Demonstration of 5 splice variants of MK5 in the heart and its expression is 
regulated during post-natal heart development and pressure-overload induced 
hypertrophy. 
7. The abundance of p38 is equal to that of p38 at both mRNA and protein 
levels. It was previously thought that p38 was the dominant isoform in the 
heart. 
8. Demonstrated the presence of p38 in the heart at mRNA and protein levels, and 
its increase in mRNA levels with hypertrophy. 
9. Following exposure to chronic pressure overload, p38 accumulates in nucleus, 
suggesting p38 may be involved in regulating in gene expression during 
pathologic remodelling of the heart. 
 
 
 
 
 
 
          
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